INDICATOR_LABEL	INDICATOR_ID	INDICATOR_DESC	MINSET_SERIES	MINSET_SERIES_DESC	REF_AREA	REF_AREA_DESC	ISO3	X	Y	SDG_REGION	TIME_PERIOD	SEX	SEX_DESC	OBS_VALUE_MODIFIER	OBS_VALUE	UNIT_MEASURE	UNIT_MEASURE_DESC	LOWER_BOUND_MODIFIER	LOWER_BOUND	UPPER_BOUND_MODIFIER	UPPER_BOUND	NATURE	NATURE_DESC	REPORTING_TYPE	REPORTING_TYPE_DESC	SOURCE_YEAR	sort_order	SDG_SeriesID	ILO_SeriesID	UNESCO_SeriesID	TSK_sub_dims	TSK_sub_id	TSK_sub_desc	isLatestValue
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2007	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2008	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2009	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2010	F	Female		1.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2011	F	Female		2.0	PT	Percent		1.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2012	F	Female		2.0	PT	Percent		1.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2013	F	Female		3.0	PT	Percent		2.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2014	F	Female		4.0	PT	Percent		2.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2015	F	Female		5.0	PT	Percent		2.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2016	F	Female		10.0	PT	Percent		4.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2017	F	Female		9.0	PT	Percent		4.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2018	F	Female		9.0	PT	Percent		4.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2019	F	Female		10.0	PT	Percent		4.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2020	F	Female		9.0	PT	Percent		4.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2004	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2005	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2006	F	Female		14.000000000000002	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2007	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2008	F	Female		18.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2009	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2010	F	Female		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2011	F	Female		23.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2012	F	Female		30.0	PT	Percent		27.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2013	F	Female		41.0	PT	Percent		37.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2014	F	Female		41.0	PT	Percent		36.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2015	F	Female		45.0	PT	Percent		40.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2016	F	Female		46.0	PT	Percent		41.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2017	F	Female		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2018	F	Female		47.0	PT	Percent		42.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2019	F	Female		48.0	PT	Percent		42.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2020	F	Female		53.0	PT	Percent		46.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1998	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1999	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2000	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2001	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2002	F	Female		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2003	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2004	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2005	F	Female		9.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2006	F	Female		11.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2007	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2008	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2009	F	Female		29.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2010	F	Female		42.0	PT	Percent		39.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2011	F	Female		44.0	PT	Percent		41.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2012	F	Female		48.0	PT	Percent		44.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2013	F	Female		60.0	PT	Percent		56.00000000000001		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2014	F	Female		70.0	PT	Percent		65.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2015	F	Female		75.0	PT	Percent		70.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2016	F	Female		81.0	PT	Percent		75.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2017	F	Female		83.0	PT	Percent		77.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2018	F	Female		87.0	PT	Percent		81.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2019	F	Female		88.0	PT	Percent		82.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2020	F	Female		87.0	PT	Percent		80.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2006	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2007	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2008	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2009	F	Female		8.0	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2010	F	Female		10.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2011	F	Female		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2012	F	Female		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2013	F	Female		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2014	F	Female		27.0	PT	Percent		23.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2015	F	Female		28.000000000000004	PT	Percent		24.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2016	F	Female		26.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2017	F	Female		27.0	PT	Percent		23.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2018	F	Female		30.0	PT	Percent		25.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2019	F	Female		33.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2020	F	Female		39.0	PT	Percent		33.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1998	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1999	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2000	F	Female		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2001	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2002	F	Female		29.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2003	F	Female		32.0	PT	Percent		30.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2004	F	Female		36.0	PT	Percent		34.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2005	F	Female		36.0	PT	Percent		34.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2006	F	Female		38.0	PT	Percent		36.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2007	F	Female		43.0	PT	Percent		40.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2008	F	Female		45.0	PT	Percent		42.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2009	F	Female		48.0	PT	Percent		45.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2010	F	Female		51.0	PT	Percent		48.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2011	F	Female		54.0	PT	Percent		50.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2012	F	Female		56.99999999999999	PT	Percent		53.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2013	F	Female		59.0	PT	Percent		55.00000000000001		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2014	F	Female		62.0	PT	Percent		56.99999999999999		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2015	F	Female		64.0	PT	Percent		59.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2016	F	Female		66.0	PT	Percent		60.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2017	F	Female		68.0	PT	Percent		62.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2018	F	Female		70.0	PT	Percent		64.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2019	F	Female		72.0	PT	Percent		66.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2020	F	Female		72.0	PT	Percent		65.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2006	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2007	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2008	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2009	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2010	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2011	F	Female		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2012	F	Female		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2013	F	Female		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2014	F	Female		19.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2015	F	Female		24.0	PT	Percent		20.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2016	F	Female		30.0	PT	Percent		26.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2017	F	Female		38.0	PT	Percent		33.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2018	F	Female		44.0	PT	Percent		38.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2019	F	Female		48.0	PT	Percent		42.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2020	F	Female		48.0	PT	Percent		42.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1996	F	Female		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1997	F	Female		23.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1998	F	Female		32.0	PT	Percent		27.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1999	F	Female		41.0	PT	Percent		34.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2000	F	Female		50.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2001	F	Female		52.0	PT	Percent		44.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2002	F	Female		50.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2003	F	Female		50.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2004	F	Female		50.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2005	F	Female		53.0	PT	Percent		45.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2006	F	Female		56.00000000000001	PT	Percent		47.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2007	F	Female		55.00000000000001	PT	Percent		47.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2008	F	Female		53.0	PT	Percent		45.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2009	F	Female		53.0	PT	Percent		46.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2010	F	Female		56.99999999999999	PT	Percent		49.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2011	F	Female		59.0	PT	Percent		50.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2012	F	Female		61.0	PT	Percent		52.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2013	F	Female		60.0	PT	Percent		51.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2014	F	Female		64.0	PT	Percent		55.00000000000001		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2015	F	Female		68.0	PT	Percent		57.99999999999999		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2016	F	Female		70.0	PT	Percent		61.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2017	F	Female		72.0	PT	Percent		62.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2018	F	Female		76.0	PT	Percent		65.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2019	F	Female		77.0	PT	Percent		67.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2020	F	Female		81.0	PT	Percent		69.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2007	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2008	F	Female		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2009	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2010	F	Female		4.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2011	F	Female		6.0	PT	Percent		4.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2012	F	Female		9.0	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2013	F	Female		13.0	PT	Percent		9.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2014	F	Female		16.0	PT	Percent		11.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2015	F	Female		21.0	PT	Percent		15.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2016	F	Female		26.0	PT	Percent		19.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2017	F	Female		33.0	PT	Percent		24.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2018	F	Female		40.0	PT	Percent		29.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2019	F	Female		46.0	PT	Percent		33.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2020	F	Female		50.0	PT	Percent		36.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2003	F	Female		17.0	PT	Percent		14.000000000000002		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2004	F	Female		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2005	F	Female		25.0	PT	Percent		21.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2006	F	Female		37.0	PT	Percent		32.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2007	F	Female		33.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2008	F	Female		46.0	PT	Percent		40.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2009	F	Female		41.0	PT	Percent		36.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2010	F	Female		32.0	PT	Percent		28.000000000000004		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2011	F	Female		31.0	PT	Percent		27.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2012	F	Female		38.0	PT	Percent		33.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2013	F	Female		45.0	PT	Percent		40.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2014	F	Female		53.0	PT	Percent		47.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2015	F	Female		52.0	PT	Percent		46.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2016	F	Female		49.0	PT	Percent		44.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2017	F	Female		65.0	PT	Percent		57.99999999999999		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2018	F	Female		66.0	PT	Percent		57.99999999999999		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2019	F	Female		65.0	PT	Percent		56.99999999999999		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2020	F	Female		69.0	PT	Percent		61.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2005	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2006	F	Female		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2007	F	Female		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2008	F	Female		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2009	F	Female		14.000000000000002	PT	Percent		11.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2010	F	Female		25.0	PT	Percent		20.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2011	F	Female		28.000000000000004	PT	Percent		22.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2012	F	Female		34.0	PT	Percent		26.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2013	F	Female		32.0	PT	Percent		25.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2014	F	Female		39.0	PT	Percent		31.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2015	F	Female		47.0	PT	Percent		37.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2016	F	Female		53.0	PT	Percent		42.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2017	F	Female		61.0	PT	Percent		47.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2018	F	Female		78.0	PT	Percent		60.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2019	F	Female		85.0	PT	Percent		65.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2020	F	Female		81.0	PT	Percent		62.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2002	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2003	F	Female		5.0	PT	Percent		3.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2004	F	Female		5.0	PT	Percent		3.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2005	F	Female		8.0	PT	Percent		5.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2006	F	Female		10.0	PT	Percent		6.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2007	F	Female		13.0	PT	Percent		8.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2008	F	Female		17.0	PT	Percent		11.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2009	F	Female		24.0	PT	Percent		15.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2010	F	Female		26.0	PT	Percent		16.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2011	F	Female		28.000000000000004	PT	Percent		18.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2012	F	Female		27.0	PT	Percent		17.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2013	F	Female		29.0	PT	Percent		19.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2014	F	Female		32.0	PT	Percent		21.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2015	F	Female		33.0	PT	Percent		22.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2016	F	Female		36.0	PT	Percent		24.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2017	F	Female		36.0	PT	Percent		25.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2018	F	Female		37.0	PT	Percent		26.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2019	F	Female		41.0	PT	Percent		28.000000000000004		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2020	F	Female		39.0	PT	Percent		27.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2007	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2008	F	Female		25.0	PT	Percent		22.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2009	F	Female		33.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2010	F	Female		39.0	PT	Percent		34.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2011	F	Female		48.0	PT	Percent		41.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2012	F	Female		51.0	PT	Percent		44.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2013	F	Female		45.0	PT	Percent		38.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2014	F	Female		50.0	PT	Percent		43.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2015	F	Female		56.99999999999999	PT	Percent		49.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2016	F	Female		63.0	PT	Percent		55.00000000000001		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2017	F	Female		63.0	PT	Percent		55.00000000000001		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2018	F	Female		77.0	PT	Percent		66.0		93.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2019	F	Female		79.0	PT	Percent		68.0		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2020	F	Female		86.0	PT	Percent		74.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2005	F	Female		1.0	PT	Percent	<	1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2006	F	Female		2.0	PT	Percent		1.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2007	F	Female		3.0	PT	Percent		1.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2008	F	Female		5.0	PT	Percent		1.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2009	F	Female		7.000000000000001	PT	Percent		2.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2010	F	Female		10.0	PT	Percent		3.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2011	F	Female		13.0	PT	Percent		4.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2012	F	Female		18.0	PT	Percent		6.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2013	F	Female		23.0	PT	Percent		8.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2014	F	Female		27.0	PT	Percent		9.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2015	F	Female		35.0	PT	Percent		12.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2016	F	Female		40.0	PT	Percent		14.000000000000002		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2017	F	Female		50.0	PT	Percent		18.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2018	F	Female		56.00000000000001	PT	Percent		20.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2019	F	Female		61.0	PT	Percent		22.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2020	F	Female		66.0	PT	Percent		24.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2003	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2005	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2006	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2007	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2008	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2009	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2010	F	Female		8.0	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2011	F	Female		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2012	F	Female		16.0	PT	Percent		13.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2013	F	Female		19.0	PT	Percent		16.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2014	F	Female		23.0	PT	Percent		20.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2015	F	Female		30.0	PT	Percent		26.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2016	F	Female		35.0	PT	Percent		30.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2017	F	Female		39.0	PT	Percent		33.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2018	F	Female		44.0	PT	Percent		37.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2019	F	Female		50.0	PT	Percent		43.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2020	F	Female		45.0	PT	Percent		37.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2001	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2002	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2003	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2004	F	Female		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2005	F	Female		18.0	PT	Percent		17.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2006	F	Female		24.0	PT	Percent		23.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2007	F	Female		29.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2008	F	Female		36.0	PT	Percent		34.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2009	F	Female		47.0	PT	Percent		45.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2010	F	Female		53.0	PT	Percent		50.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2011	F	Female		56.99999999999999	PT	Percent		53.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2012	F	Female		66.0	PT	Percent		62.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2013	F	Female		69.0	PT	Percent		65.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2014	F	Female		72.0	PT	Percent		67.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2015	F	Female		78.0	PT	Percent		73.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2016	F	Female		83.0	PT	Percent		78.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2017	F	Female		86.0	PT	Percent		80.0		92.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2018	F	Female		93.0	PT	Percent		87.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2019	F	Female		93.0	PT	Percent		87.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2020	F	Female		95.0	PT	Percent		88.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2003	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2004	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2005	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2006	F	Female		15.0	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2007	F	Female		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2008	F	Female		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2009	F	Female		31.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2010	F	Female		37.0	PT	Percent		32.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2011	F	Female		51.0	PT	Percent		44.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2012	F	Female		54.0	PT	Percent		46.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2013	F	Female		59.0	PT	Percent		51.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2014	F	Female		66.0	PT	Percent		56.00000000000001		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2015	F	Female		73.0	PT	Percent		62.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2016	F	Female		81.0	PT	Percent		68.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2017	F	Female		93.0	PT	Percent		78.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2018	F	Female		87.0	PT	Percent		72.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2019	F	Female	>	98.0	PT	Percent		82.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2020	F	Female		98.0	PT	Percent		81.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2001	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2002	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2004	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2005	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2006	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2007	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2008	F	Female		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2009	F	Female		22.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2010	F	Female		30.0	PT	Percent		27.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2011	F	Female		35.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2012	F	Female		43.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2013	F	Female		49.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2014	F	Female		55.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2015	F	Female		62.0	PT	Percent		56.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2016	F	Female		76.0	PT	Percent		69.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2017	F	Female		88.0	PT	Percent		79.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2018	F	Female		94.0	PT	Percent		85.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2019	F	Female	>	98.0	PT	Percent		92.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2020	F	Female	>	98.0	PT	Percent		94.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2002	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2003	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2004	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2005	F	Female		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2006	F	Female		22.0	PT	Percent		19.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2007	F	Female		29.0	PT	Percent		26.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2008	F	Female		36.0	PT	Percent		32.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2009	F	Female		44.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2010	F	Female		50.0	PT	Percent		45.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2011	F	Female		55.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2012	F	Female		57.99999999999999	PT	Percent		52.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2013	F	Female		61.0	PT	Percent		54.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2014	F	Female		65.0	PT	Percent		57.99999999999999		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2015	F	Female		69.0	PT	Percent		62.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2016	F	Female		72.0	PT	Percent		65.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2017	F	Female		76.0	PT	Percent		68.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2018	F	Female		78.0	PT	Percent		70.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2019	F	Female		81.0	PT	Percent		72.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2020	F	Female		82.0	PT	Percent		73.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2004	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2005	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2006	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2007	F	Female		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2008	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2009	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2010	F	Female		16.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2011	F	Female		19.0	PT	Percent		18.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2012	F	Female		27.0	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2013	F	Female		29.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2014	F	Female		32.0	PT	Percent		30.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2015	F	Female		37.0	PT	Percent		35.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2016	F	Female		45.0	PT	Percent		42.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2017	F	Female		56.00000000000001	PT	Percent		53.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2018	F	Female		62.0	PT	Percent		57.99999999999999		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2019	F	Female		68.0	PT	Percent		64.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2020	F	Female		80.0	PT	Percent		75.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2005	F	Female		10.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2006	F	Female		16.0	PT	Percent		13.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2007	F	Female		23.0	PT	Percent		19.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2008	F	Female		29.0	PT	Percent		24.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2009	F	Female		31.0	PT	Percent		25.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2010	F	Female		35.0	PT	Percent		29.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2011	F	Female		43.0	PT	Percent		36.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2012	F	Female		49.0	PT	Percent		42.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2013	F	Female		55.00000000000001	PT	Percent		48.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2014	F	Female		64.0	PT	Percent		55.00000000000001		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2015	F	Female		70.0	PT	Percent		61.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2016	F	Female		83.0	PT	Percent		71.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2017	F	Female		95.0	PT	Percent		82.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2018	F	Female	>	98.0	PT	Percent		92.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2019	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2020	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2006	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2007	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2008	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2009	F	Female		11.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2010	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2011	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2012	F	Female		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2013	F	Female		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2014	F	Female		23.0	PT	Percent		20.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2015	F	Female		27.0	PT	Percent		23.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2016	F	Female		41.0	PT	Percent		35.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2017	F	Female		47.0	PT	Percent		39.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2018	F	Female		50.0	PT	Percent		42.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2019	F	Female		61.0	PT	Percent		50.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2020	F	Female		64.0	PT	Percent		53.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2006	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2007	F	Female		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2008	F	Female		19.0	PT	Percent		15.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2009	F	Female		28.000000000000004	PT	Percent		22.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2010	F	Female		36.0	PT	Percent		29.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2011	F	Female		35.0	PT	Percent		28.000000000000004		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2012	F	Female		39.0	PT	Percent		32.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2013	F	Female		41.0	PT	Percent		34.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2014	F	Female		49.0	PT	Percent		41.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2015	F	Female		60.0	PT	Percent		49.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2016	F	Female		50.0	PT	Percent		41.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2017	F	Female		56.00000000000001	PT	Percent		47.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2018	F	Female		65.0	PT	Percent		53.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2019	F	Female		71.0	PT	Percent		57.99999999999999		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2020	F	Female		78.0	PT	Percent		64.0		93.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2001	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2002	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2003	F	Female		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2004	F	Female		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2005	F	Female		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2006	F	Female		16.0	PT	Percent		13.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2007	F	Female		14.000000000000002	PT	Percent		11.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2008	F	Female		14.000000000000002	PT	Percent		11.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2009	F	Female		16.0	PT	Percent		13.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2010	F	Female		24.0	PT	Percent		20.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2011	F	Female		33.0	PT	Percent		28.000000000000004		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2012	F	Female		40.0	PT	Percent		33.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2013	F	Female		48.0	PT	Percent		40.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2014	F	Female		56.99999999999999	PT	Percent		47.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2015	F	Female		64.0	PT	Percent		53.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2016	F	Female		70.0	PT	Percent		56.99999999999999		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2017	F	Female		67.0	PT	Percent		55.00000000000001		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2018	F	Female		70.0	PT	Percent		56.00000000000001		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2019	F	Female		72.0	PT	Percent		57.99999999999999		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2020	F	Female		90.0	PT	Percent		72.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2007	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2008	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2009	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2010	F	Female		20.0	PT	Percent		10.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2011	F	Female		20.0	PT	Percent		10.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2012	F	Female		25.0	PT	Percent		12.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2013	F	Female		25.0	PT	Percent		13.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2014	F	Female		28.000000000000004	PT	Percent		14.000000000000002		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2015	F	Female		32.0	PT	Percent		17.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2016	F	Female		43.0	PT	Percent		23.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2017	F	Female		45.0	PT	Percent		24.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2018	F	Female		48.0	PT	Percent		26.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2019	F	Female		60.0	PT	Percent		32.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2020	F	Female		63.0	PT	Percent		34.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2005	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2006	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2007	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2008	F	Female		10.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2009	F	Female		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2010	F	Female		15.0	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2011	F	Female		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2012	F	Female		20.0	PT	Percent		16.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2013	F	Female		22.0	PT	Percent		18.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2014	F	Female		21.0	PT	Percent		17.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2015	F	Female		27.0	PT	Percent		21.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2016	F	Female		29.0	PT	Percent		22.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2017	F	Female		29.0	PT	Percent		22.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2018	F	Female		30.0	PT	Percent		21.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2019	F	Female		25.0	PT	Percent		18.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2020	F	Female		25.0	PT	Percent		18.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2000	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2001	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2002	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2003	F	Female		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2004	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2005	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2006	F	Female		17.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2007	F	Female		18.0	PT	Percent		17.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2008	F	Female		20.0	PT	Percent		18.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2009	F	Female		21.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2010	F	Female		23.0	PT	Percent		21.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2011	F	Female		23.0	PT	Percent		22.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2012	F	Female		23.0	PT	Percent		21.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2013	F	Female		24.0	PT	Percent		22.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2014	F	Female		21.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2015	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2016	F	Female		26.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2017	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2018	F	Female		26.0	PT	Percent		24.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2019	F	Female		21.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2020	F	Female		36.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2005	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2006	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2007	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2008	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2009	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2010	F	Female		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2011	F	Female		25.0	PT	Percent		22.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2012	F	Female		28.000000000000004	PT	Percent		25.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2013	F	Female		32.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2014	F	Female		38.0	PT	Percent		35.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2015	F	Female		44.0	PT	Percent		40.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2016	F	Female		55.00000000000001	PT	Percent		49.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2017	F	Female		66.0	PT	Percent		60.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2018	F	Female		73.0	PT	Percent		66.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2019	F	Female		78.0	PT	Percent		70.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2020	F	Female		83.0	PT	Percent		74.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1996	F	Female		21.0	PT	Percent		18.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1997	F	Female		33.0	PT	Percent		28.000000000000004		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1998	F	Female		46.0	PT	Percent		40.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1999	F	Female		52.0	PT	Percent		45.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2000	F	Female		60.0	PT	Percent		51.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2001	F	Female		64.0	PT	Percent		54.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2002	F	Female		66.0	PT	Percent		56.99999999999999		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2003	F	Female		69.0	PT	Percent		60.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2004	F	Female		69.0	PT	Percent		59.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2005	F	Female		70.0	PT	Percent		60.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2006	F	Female		72.0	PT	Percent		62.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2007	F	Female		74.0	PT	Percent		64.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2008	F	Female		70.0	PT	Percent		61.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2009	F	Female		67.0	PT	Percent		59.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2010	F	Female		66.0	PT	Percent		57.99999999999999		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2011	F	Female		69.0	PT	Percent		61.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2012	F	Female		69.0	PT	Percent		61.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2013	F	Female		73.0	PT	Percent		63.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2014	F	Female		74.0	PT	Percent		65.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2015	F	Female		74.0	PT	Percent		64.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2016	F	Female		73.0	PT	Percent		63.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2017	F	Female		71.0	PT	Percent		61.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2018	F	Female		73.0	PT	Percent		63.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2019	F	Female		70.0	PT	Percent		60.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2020	F	Female		73.0	PT	Percent		63.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2000	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2001	F	Female		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2002	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2003	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2004	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2005	F	Female		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2006	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2007	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2008	F	Female		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2009	F	Female		13.0	PT	Percent		12.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2010	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2011	F	Female		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2012	F	Female		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2013	F	Female		22.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2014	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2015	F	Female		29.0	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2016	F	Female		31.0	PT	Percent		29.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2017	F	Female		34.0	PT	Percent		30.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2018	F	Female		36.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2019	F	Female		39.0	PT	Percent		35.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2020	F	Female		40.0	PT	Percent		36.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2006	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2007	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2008	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2009	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2010	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2011	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2012	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2013	F	Female		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2014	F	Female		22.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2015	F	Female		26.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2016	F	Female		31.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2017	F	Female		45.0	PT	Percent		38.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2018	F	Female		53.0	PT	Percent		46.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2019	F	Female		63.0	PT	Percent		54.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2020	F	Female		74.0	PT	Percent		64.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1997	F	Female		42.0	PT	Percent		36.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1998	F	Female		44.0	PT	Percent		38.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1999	F	Female		48.0	PT	Percent		41.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2000	F	Female		47.0	PT	Percent		40.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2001	F	Female		49.0	PT	Percent		42.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2002	F	Female		49.0	PT	Percent		42.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2003	F	Female		51.0	PT	Percent		43.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2004	F	Female		52.0	PT	Percent		43.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2005	F	Female		52.0	PT	Percent		43.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2006	F	Female		54.0	PT	Percent		45.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2007	F	Female		55.00000000000001	PT	Percent		45.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2008	F	Female		59.0	PT	Percent		48.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2009	F	Female		63.0	PT	Percent		51.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2010	F	Female		67.0	PT	Percent		54.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2011	F	Female		70.0	PT	Percent		56.00000000000001		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2012	F	Female		74.0	PT	Percent		59.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2013	F	Female		71.0	PT	Percent		56.99999999999999		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2014	F	Female		82.0	PT	Percent		65.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2015	F	Female		85.0	PT	Percent		67.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2016	F	Female		88.0	PT	Percent		69.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2017	F	Female		89.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2018	F	Female		89.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2019	F	Female		91.0	PT	Percent		72.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2020	F	Female		92.0	PT	Percent		72.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2003	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2006	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2007	F	Female		6.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2008	F	Female		7.000000000000001	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2009	F	Female		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2010	F	Female		10.0	PT	Percent		7.000000000000001		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2011	F	Female		11.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2012	F	Female		15.0	PT	Percent		11.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2013	F	Female		17.0	PT	Percent		12.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2014	F	Female		22.0	PT	Percent		16.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2015	F	Female		25.0	PT	Percent		18.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2016	F	Female		30.0	PT	Percent		22.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2017	F	Female		38.0	PT	Percent		28.000000000000004		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2018	F	Female		43.0	PT	Percent		32.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2019	F	Female		28.000000000000004	PT	Percent		21.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2020	F	Female		31.0	PT	Percent		23.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2004	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2005	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2006	F	Female		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2007	F	Female		10.0	PT	Percent		7.000000000000001		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2008	F	Female		13.0	PT	Percent		10.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2009	F	Female		17.0	PT	Percent		13.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2010	F	Female		22.0	PT	Percent		17.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2011	F	Female		26.0	PT	Percent		20.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2012	F	Female		29.0	PT	Percent		23.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2013	F	Female		31.0	PT	Percent		25.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2014	F	Female		35.0	PT	Percent		28.000000000000004		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2015	F	Female		37.0	PT	Percent		30.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2016	F	Female		40.0	PT	Percent		33.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2017	F	Female		43.0	PT	Percent		35.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2018	F	Female		45.0	PT	Percent		37.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2019	F	Female		48.0	PT	Percent		40.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2020	F	Female		52.0	PT	Percent		43.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1995	F	Female		4.0	PT	Percent		1.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1996	F	Female		3.0	PT	Percent		1.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1997	F	Female		3.0	PT	Percent		1.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1998	F	Female		3.0	PT	Percent		2.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1999	F	Female		3.0	PT	Percent		2.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2000	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2001	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2002	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2003	F	Female		2.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2004	F	Female		4.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2005	F	Female		6.0	PT	Percent		4.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2006	F	Female		7.000000000000001	PT	Percent		5.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2007	F	Female		10.0	PT	Percent		7.000000000000001		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2008	F	Female		14.000000000000002	PT	Percent		10.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2009	F	Female		18.0	PT	Percent		13.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2010	F	Female		22.0	PT	Percent		15.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2011	F	Female		26.0	PT	Percent		18.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2012	F	Female		30.0	PT	Percent		21.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2013	F	Female		42.0	PT	Percent		29.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2014	F	Female		49.0	PT	Percent		34.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2015	F	Female		55.00000000000001	PT	Percent		37.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2016	F	Female		52.0	PT	Percent		35.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2017	F	Female		57.99999999999999	PT	Percent		39.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2018	F	Female		64.0	PT	Percent		43.0		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2019	F	Female		75.0	PT	Percent		49.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2020	F	Female		81.0	PT	Percent		53.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2006	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2007	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2008	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2009	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2010	F	Female		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2011	F	Female		15.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2012	F	Female		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2013	F	Female		18.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2014	F	Female		22.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2015	F	Female		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2016	F	Female		28.000000000000004	PT	Percent		26.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2017	F	Female		36.0	PT	Percent		34.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2018	F	Female		43.0	PT	Percent		40.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2019	F	Female		41.0	PT	Percent		39.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2020	F	Female		38.0	PT	Percent		36.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2002	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2003	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2004	F	Female		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2005	F	Female		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2006	F	Female		12.0	PT	Percent		12.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2007	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2008	F	Female		20.0	PT	Percent		18.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2009	F	Female		24.0	PT	Percent		22.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2010	F	Female		28.000000000000004	PT	Percent		26.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2011	F	Female		29.0	PT	Percent		27.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2012	F	Female		35.0	PT	Percent		32.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2013	F	Female		37.0	PT	Percent		35.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2014	F	Female		38.0	PT	Percent		35.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2015	F	Female		36.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2016	F	Female		39.0	PT	Percent		36.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2017	F	Female		41.0	PT	Percent		38.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2018	F	Female		41.0	PT	Percent		38.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2019	F	Female		42.0	PT	Percent		38.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2020	F	Female		43.0	PT	Percent		39.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2005	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2006	F	Female		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2007	F	Female		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2008	F	Female		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2009	F	Female		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2010	F	Female		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2011	F	Female		13.0	PT	Percent		11.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2012	F	Female		18.0	PT	Percent		15.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2013	F	Female		36.0	PT	Percent		31.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2014	F	Female		33.0	PT	Percent		28.000000000000004		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2015	F	Female		33.0	PT	Percent		27.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2016	F	Female		40.0	PT	Percent		33.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2017	F	Female		52.0	PT	Percent		42.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2018	F	Female		51.0	PT	Percent		40.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2019	F	Female		49.0	PT	Percent		39.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2020	F	Female		53.0	PT	Percent		40.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2006	F	Female		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2007	F	Female		11.0	PT	Percent		9.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2008	F	Female		16.0	PT	Percent		13.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2009	F	Female		21.0	PT	Percent		16.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2010	F	Female		28.000000000000004	PT	Percent		22.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2011	F	Female		36.0	PT	Percent		28.000000000000004		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2012	F	Female		41.0	PT	Percent		32.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2013	F	Female		47.0	PT	Percent		36.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2014	F	Female		54.0	PT	Percent		42.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2015	F	Female		60.0	PT	Percent		46.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2016	F	Female		61.0	PT	Percent		47.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2017	F	Female		70.0	PT	Percent		53.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2018	F	Female		72.0	PT	Percent		55.00000000000001		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2019	F	Female		73.0	PT	Percent		56.00000000000001		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2020	F	Female		75.0	PT	Percent		57.99999999999999		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2000	F	Female		7.000000000000001	PT	Percent		3.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2001	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2002	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2003	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2004	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2005	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2006	F	Female		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2007	F	Female		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2008	F	Female		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2009	F	Female		25.0	PT	Percent		22.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2010	F	Female		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2011	F	Female		38.0	PT	Percent		34.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2012	F	Female		43.0	PT	Percent		38.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2013	F	Female		45.0	PT	Percent		40.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2014	F	Female		49.0	PT	Percent		44.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2015	F	Female		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2016	F	Female		60.0	PT	Percent		54.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2017	F	Female		63.0	PT	Percent		56.00000000000001		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2018	F	Female		65.0	PT	Percent		56.99999999999999		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2019	F	Female		66.0	PT	Percent		57.99999999999999		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2020	F	Female		67.0	PT	Percent		59.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2002	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2003	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2004	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2005	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2006	F	Female		10.0	PT	Percent		10.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2007	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2008	F	Female		20.0	PT	Percent		19.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2009	F	Female		25.0	PT	Percent		24.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2010	F	Female		36.0	PT	Percent		34.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2011	F	Female		39.0	PT	Percent		37.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2012	F	Female		44.0	PT	Percent		41.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2013	F	Female		49.0	PT	Percent		46.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2014	F	Female		61.0	PT	Percent		56.99999999999999		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2015	F	Female		72.0	PT	Percent		67.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2016	F	Female		83.0	PT	Percent		77.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2017	F	Female		93.0	PT	Percent		87.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2018	F	Female		95.0	PT	Percent		88.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2019	F	Female	>	98.0	PT	Percent		94.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2020	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2005	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2006	F	Female		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2007	F	Female		15.0	PT	Percent		13.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2008	F	Female		23.0	PT	Percent		18.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2009	F	Female		30.0	PT	Percent		25.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2010	F	Female		38.0	PT	Percent		31.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2011	F	Female		45.0	PT	Percent		37.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2012	F	Female		46.0	PT	Percent		37.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2013	F	Female		52.0	PT	Percent		42.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2014	F	Female		57.99999999999999	PT	Percent		48.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2015	F	Female		64.0	PT	Percent		52.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2016	F	Female		69.0	PT	Percent		56.00000000000001		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2017	F	Female		72.0	PT	Percent		57.99999999999999		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2018	F	Female		74.0	PT	Percent		60.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2019	F	Female		77.0	PT	Percent		63.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2020	F	Female		80.0	PT	Percent		65.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2004	F	Female		8.0	PT	Percent		5.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2005	F	Female		8.0	PT	Percent		6.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2006	F	Female		11.0	PT	Percent		8.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2007	F	Female		11.0	PT	Percent		8.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2008	F	Female		16.0	PT	Percent		11.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2009	F	Female		17.0	PT	Percent		13.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2010	F	Female		21.0	PT	Percent		15.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2011	F	Female		22.0	PT	Percent		16.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2012	F	Female		32.0	PT	Percent		24.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2013	F	Female		29.0	PT	Percent		22.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2014	F	Female		31.0	PT	Percent		23.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2015	F	Female		29.0	PT	Percent		21.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2016	F	Female		30.0	PT	Percent		21.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2017	F	Female		34.0	PT	Percent		23.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2018	F	Female		39.0	PT	Percent		25.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2019	F	Female		42.0	PT	Percent		27.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2020	F	Female		42.0	PT	Percent		26.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2002	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2004	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2005	F	Female		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2006	F	Female		10.0	PT	Percent		8.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2007	F	Female		12.0	PT	Percent		10.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2008	F	Female		15.0	PT	Percent		12.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2009	F	Female		19.0	PT	Percent		15.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2010	F	Female		21.0	PT	Percent		17.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2011	F	Female		24.0	PT	Percent		20.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2012	F	Female		33.0	PT	Percent		27.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2013	F	Female		43.0	PT	Percent		36.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2014	F	Female		45.0	PT	Percent		38.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2015	F	Female		56.00000000000001	PT	Percent		47.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2016	F	Female		66.0	PT	Percent		55.00000000000001		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2017	F	Female		70.0	PT	Percent		57.99999999999999		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2018	F	Female		74.0	PT	Percent		61.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2019	F	Female		56.99999999999999	PT	Percent		47.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2020	F	Female		53.0	PT	Percent		44.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2006	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2007	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2008	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2009	F	Female		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2010	F	Female		10.0	PT	Percent		8.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2011	F	Female		18.0	PT	Percent		14.000000000000002		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2012	F	Female		21.0	PT	Percent		18.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2013	F	Female		21.0	PT	Percent		18.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2014	F	Female		24.0	PT	Percent		19.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2015	F	Female		26.0	PT	Percent		21.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2016	F	Female		30.0	PT	Percent		25.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2017	F	Female		35.0	PT	Percent		28.000000000000004		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2018	F	Female		37.0	PT	Percent		30.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2019	F	Female		40.0	PT	Percent		32.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2020	F	Female		38.0	PT	Percent		31.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2004	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2005	F	Female		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2006	F	Female		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2007	F	Female		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2008	F	Female		19.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2009	F	Female		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2010	F	Female		25.0	PT	Percent		22.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2011	F	Female		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2012	F	Female		39.0	PT	Percent		36.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2013	F	Female		43.0	PT	Percent		40.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2014	F	Female		51.0	PT	Percent		47.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2015	F	Female		54.0	PT	Percent		50.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2016	F	Female		59.0	PT	Percent		55.00000000000001		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2017	F	Female		61.0	PT	Percent		56.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2018	F	Female		62.0	PT	Percent		56.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2019	F	Female		63.0	PT	Percent		56.99999999999999		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2020	F	Female		62.0	PT	Percent		55.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1995	F	Female		13.0	PT	Percent		11.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1996	F	Female		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1997	F	Female		23.0	PT	Percent		19.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1998	F	Female		29.0	PT	Percent		24.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1999	F	Female		34.0	PT	Percent		29.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2000	F	Female		39.0	PT	Percent		33.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2001	F	Female		43.0	PT	Percent		36.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2002	F	Female		47.0	PT	Percent		39.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2003	F	Female		50.0	PT	Percent		41.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2004	F	Female		53.0	PT	Percent		44.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2005	F	Female		55.00000000000001	PT	Percent		46.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2006	F	Female		55.00000000000001	PT	Percent		45.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2007	F	Female		56.99999999999999	PT	Percent		47.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2008	F	Female		60.0	PT	Percent		49.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2009	F	Female		62.0	PT	Percent		51.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2010	F	Female		65.0	PT	Percent		53.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2011	F	Female		67.0	PT	Percent		55.00000000000001		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2012	F	Female		70.0	PT	Percent		56.99999999999999		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2013	F	Female		72.0	PT	Percent		59.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2014	F	Female		74.0	PT	Percent		61.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2015	F	Female		76.0	PT	Percent		63.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2016	F	Female		79.0	PT	Percent		64.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2017	F	Female		81.0	PT	Percent		67.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2018	F	Female		80.0	PT	Percent		66.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2019	F	Female		84.0	PT	Percent		69.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2020	F	Female		85.0	PT	Percent		70.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2006	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2007	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2008	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2009	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2010	F	Female		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2011	F	Female		20.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2012	F	Female		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2013	F	Female		26.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2014	F	Female		28.000000000000004	PT	Percent		25.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2015	F	Female		32.0	PT	Percent		28.000000000000004		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2016	F	Female		35.0	PT	Percent		30.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2017	F	Female		37.0	PT	Percent		33.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2018	F	Female		40.0	PT	Percent		35.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2019	F	Female		53.0	PT	Percent		46.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2020	F	Female		69.0	PT	Percent		60.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1995	F	Female		22.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1996	F	Female		31.0	PT	Percent		27.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1997	F	Female		39.0	PT	Percent		34.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1998	F	Female		45.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1999	F	Female		50.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2000	F	Female		53.0	PT	Percent		46.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2001	F	Female		56.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2002	F	Female		55.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2003	F	Female		55.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2004	F	Female		55.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2005	F	Female		56.00000000000001	PT	Percent		50.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2006	F	Female		56.00000000000001	PT	Percent		50.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2007	F	Female		54.0	PT	Percent		48.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2008	F	Female		53.0	PT	Percent		48.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2009	F	Female		51.0	PT	Percent		46.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2010	F	Female		48.0	PT	Percent		43.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2011	F	Female		47.0	PT	Percent		42.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2012	F	Female		48.0	PT	Percent		44.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2013	F	Female		49.0	PT	Percent		45.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2014	F	Female		51.0	PT	Percent		47.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2015	F	Female		54.0	PT	Percent		50.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2016	F	Female		56.99999999999999	PT	Percent		52.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2017	F	Female		60.0	PT	Percent		55.00000000000001		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2018	F	Female		63.0	PT	Percent		57.99999999999999		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2019	F	Female		64.0	PT	Percent		59.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2020	F	Female		63.0	PT	Percent		57.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2003	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2004	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2005	F	Female		6.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2006	F	Female		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2007	F	Female		16.0	PT	Percent		12.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2008	F	Female		24.0	PT	Percent		19.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2009	F	Female		27.0	PT	Percent		22.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2010	F	Female		31.0	PT	Percent		24.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2011	F	Female		41.0	PT	Percent		32.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2012	F	Female		43.0	PT	Percent		34.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2013	F	Female		50.0	PT	Percent		39.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2014	F	Female		54.0	PT	Percent		42.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2015	F	Female		51.0	PT	Percent		40.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2016	F	Female		51.0	PT	Percent		40.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2017	F	Female		54.0	PT	Percent		43.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2018	F	Female		56.99999999999999	PT	Percent		46.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2019	F	Female		60.0	PT	Percent		49.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2020	F	Female		60.0	PT	Percent		49.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2006	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2007	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2008	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2009	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2010	F	Female		21.0	PT	Percent		20.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2011	F	Female		24.0	PT	Percent		22.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2012	F	Female		32.0	PT	Percent		31.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2013	F	Female		31.0	PT	Percent		29.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2014	F	Female		36.0	PT	Percent		34.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2015	F	Female		37.0	PT	Percent		35.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2016	F	Female		41.0	PT	Percent		39.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2017	F	Female		39.0	PT	Percent		37.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2018	F	Female		52.0	PT	Percent		49.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2019	F	Female		62.0	PT	Percent		59.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2020	F	Female		54.0	PT	Percent		51.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2006	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2007	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2008	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2009	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2010	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2011	F	Female		14.000000000000002	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2012	F	Female		22.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2013	F	Female		24.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2014	F	Female		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2015	F	Female		32.0	PT	Percent		28.000000000000004		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2016	F	Female		39.0	PT	Percent		35.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2017	F	Female		40.0	PT	Percent		36.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2018	F	Female		54.0	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2019	F	Female		55.00000000000001	PT	Percent		50.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2020	F	Female		73.0	PT	Percent		65.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2003	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2004	F	Female		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2005	F	Female		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2006	F	Female		30.0	PT	Percent		26.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2007	F	Female		34.0	PT	Percent		30.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2008	F	Female		39.0	PT	Percent		34.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2009	F	Female		43.0	PT	Percent		38.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2010	F	Female		45.0	PT	Percent		40.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2011	F	Female		49.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2012	F	Female		53.0	PT	Percent		47.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2013	F	Female		56.99999999999999	PT	Percent		51.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2014	F	Female		59.0	PT	Percent		54.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2015	F	Female		62.0	PT	Percent		56.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2016	F	Female		65.0	PT	Percent		60.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2017	F	Female		67.0	PT	Percent		62.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2018	F	Female		70.0	PT	Percent		64.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2019	F	Female		75.0	PT	Percent		68.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2020	F	Female		73.0	PT	Percent		67.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2003	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2005	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2006	F	Female		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2007	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2008	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2009	F	Female		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2010	F	Female		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2011	F	Female		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2012	F	Female		35.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2013	F	Female		45.0	PT	Percent		41.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2014	F	Female		50.0	PT	Percent		45.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2015	F	Female		54.0	PT	Percent		49.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2016	F	Female		64.0	PT	Percent		57.99999999999999		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2017	F	Female		71.0	PT	Percent		64.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2018	F	Female		67.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2019	F	Female		79.0	PT	Percent		70.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2020	F	Female		87.0	PT	Percent		76.0		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2002	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2003	F	Female		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2004	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2005	F	Female		14.000000000000002	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2006	F	Female		20.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2007	F	Female		25.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2008	F	Female		29.0	PT	Percent		25.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2009	F	Female		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2010	F	Female		36.0	PT	Percent		31.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2011	F	Female		41.0	PT	Percent		36.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2012	F	Female		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2013	F	Female		49.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2014	F	Female		51.0	PT	Percent		45.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2015	F	Female		54.0	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2016	F	Female		56.00000000000001	PT	Percent		51.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2017	F	Female		59.0	PT	Percent		53.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2018	F	Female		60.0	PT	Percent		54.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2019	F	Female		60.0	PT	Percent		53.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2020	F	Female		60.0	PT	Percent		53.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1998	F	Female		25.0	PT	Percent		16.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1999	F	Female		39.0	PT	Percent		26.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2000	F	Female		52.0	PT	Percent		35.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2001	F	Female		61.0	PT	Percent		42.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2002	F	Female		67.0	PT	Percent		47.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2003	F	Female		70.0	PT	Percent		49.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2004	F	Female		76.0	PT	Percent		56.99999999999999		92.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2005	F	Female		76.0	PT	Percent		55.00000000000001		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2006	F	Female		80.0	PT	Percent		62.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2007	F	Female		82.0	PT	Percent		65.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2008	F	Female		83.0	PT	Percent		67.0		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2009	F	Female		84.0	PT	Percent		69.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2010	F	Female		85.0	PT	Percent		71.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2011	F	Female		86.0	PT	Percent		74.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2012	F	Female		87.0	PT	Percent		74.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2013	F	Female		88.0	PT	Percent		77.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2014	F	Female		88.0	PT	Percent		77.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2015	F	Female		89.0	PT	Percent		77.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2016	F	Female		91.0	PT	Percent		79.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2017	F	Female		84.0	PT	Percent		72.0		96.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2018	F	Female		98.0	PT	Percent		84.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2019	F	Female		94.0	PT	Percent		80.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2020	F	Female		92.0	PT	Percent		79.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2006	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2007	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2008	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2009	F	Female		5.0	PT	Percent		5.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2010	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2011	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2012	F	Female		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2013	F	Female		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2014	F	Female		11.0	PT	Percent		11.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2015	F	Female		13.0	PT	Percent		13.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2016	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2017	F	Female		17.0	PT	Percent		16.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2018	F	Female		20.0	PT	Percent		19.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2019	F	Female		22.0	PT	Percent		21.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2020	F	Female		24.0	PT	Percent		23.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2005	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2006	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2007	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2008	F	Female		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2009	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2010	F	Female		4.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2011	F	Female		5.0	PT	Percent		4.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2012	F	Female		7.000000000000001	PT	Percent		5.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2013	F	Female		10.0	PT	Percent		7.000000000000001		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2014	F	Female		13.0	PT	Percent		9.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2015	F	Female		17.0	PT	Percent		12.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2016	F	Female		21.0	PT	Percent		14.000000000000002		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2017	F	Female		26.0	PT	Percent		17.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2018	F	Female		30.0	PT	Percent		20.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2019	F	Female		33.0	PT	Percent		22.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2020	F	Female		33.0	PT	Percent		22.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1996	F	Female		10.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1997	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1998	F	Female		28.000000000000004	PT	Percent		24.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1999	F	Female		37.0	PT	Percent		32.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2000	F	Female		43.0	PT	Percent		38.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2001	F	Female		49.0	PT	Percent		43.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2002	F	Female		53.0	PT	Percent		47.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2003	F	Female		56.99999999999999	PT	Percent		50.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2004	F	Female		60.0	PT	Percent		53.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2005	F	Female		63.0	PT	Percent		56.00000000000001		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2006	F	Female		65.0	PT	Percent		57.99999999999999		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2007	F	Female		67.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2008	F	Female		68.0	PT	Percent		61.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2009	F	Female		70.0	PT	Percent		62.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2010	F	Female		71.0	PT	Percent		64.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2011	F	Female		73.0	PT	Percent		65.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2012	F	Female		75.0	PT	Percent		67.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2013	F	Female		77.0	PT	Percent		69.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2014	F	Female		79.0	PT	Percent		70.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2015	F	Female		80.0	PT	Percent		70.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2016	F	Female		74.0	PT	Percent		64.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2017	F	Female		76.0	PT	Percent		66.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2018	F	Female		81.0	PT	Percent		70.0		92.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2019	F	Female		84.0	PT	Percent		72.0		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2020	F	Female		85.0	PT	Percent		73.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1996	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1997	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1998	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1999	F	Female		27.0	PT	Percent		24.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2000	F	Female		33.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2001	F	Female		39.0	PT	Percent		36.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2002	F	Female		44.0	PT	Percent		40.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2003	F	Female		49.0	PT	Percent		44.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2004	F	Female		53.0	PT	Percent		47.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2005	F	Female		56.00000000000001	PT	Percent		50.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2006	F	Female		59.0	PT	Percent		53.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2007	F	Female		62.0	PT	Percent		56.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2008	F	Female		65.0	PT	Percent		57.99999999999999		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2009	F	Female		68.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2010	F	Female		70.0	PT	Percent		62.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2011	F	Female		72.0	PT	Percent		64.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2012	F	Female		79.0	PT	Percent		70.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2013	F	Female		77.0	PT	Percent		68.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2014	F	Female		76.0	PT	Percent		66.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2015	F	Female		77.0	PT	Percent		67.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2016	F	Female		79.0	PT	Percent		68.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2017	F	Female		85.0	PT	Percent		73.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2018	F	Female		91.0	PT	Percent		78.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2019	F	Female		91.0	PT	Percent		77.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2020	F	Female		94.0	PT	Percent		80.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2004	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2005	F	Female		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2006	F	Female		7.000000000000001	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2007	F	Female		11.0	PT	Percent		9.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2008	F	Female		13.0	PT	Percent		11.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2009	F	Female		18.0	PT	Percent		15.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2010	F	Female		19.0	PT	Percent		15.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2011	F	Female		21.0	PT	Percent		17.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2012	F	Female		24.0	PT	Percent		20.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2013	F	Female		32.0	PT	Percent		26.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2014	F	Female		33.0	PT	Percent		27.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2015	F	Female		35.0	PT	Percent		28.000000000000004		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2016	F	Female		37.0	PT	Percent		31.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2017	F	Female		41.0	PT	Percent		34.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2018	F	Female		43.0	PT	Percent		36.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2019	F	Female		48.0	PT	Percent		40.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2020	F	Female		44.0	PT	Percent		36.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2000	F	Female		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2001	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2002	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2003	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2004	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2005	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2006	F	Female		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2007	F	Female		13.0	PT	Percent		12.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2008	F	Female		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2009	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2010	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2011	F	Female		17.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2012	F	Female		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2013	F	Female		17.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2014	F	Female		17.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2015	F	Female		17.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2016	F	Female		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2017	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2018	F	Female		21.0	PT	Percent		19.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2019	F	Female		22.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2020	F	Female		23.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2005	F	Female		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2006	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2007	F	Female		4.0	PT	Percent		2.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2008	F	Female		4.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2009	F	Female		7.000000000000001	PT	Percent		4.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2010	F	Female		8.0	PT	Percent		5.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2011	F	Female		12.0	PT	Percent		8.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2012	F	Female		17.0	PT	Percent		11.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2013	F	Female		23.0	PT	Percent		15.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2014	F	Female		29.0	PT	Percent		19.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2015	F	Female		37.0	PT	Percent		24.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2016	F	Female		44.0	PT	Percent		29.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2017	F	Female		56.99999999999999	PT	Percent		37.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2018	F	Female		69.0	PT	Percent		45.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2019	F	Female		73.0	PT	Percent		47.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2020	F	Female		75.0	PT	Percent		49.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2004	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2005	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2006	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2007	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2008	F	Female		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2009	F	Female		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2010	F	Female		30.0	PT	Percent		26.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2011	F	Female		43.0	PT	Percent		37.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2012	F	Female		47.0	PT	Percent		41.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2013	F	Female		51.0	PT	Percent		44.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2014	F	Female		59.0	PT	Percent		51.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2015	F	Female		69.0	PT	Percent		60.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2016	F	Female		79.0	PT	Percent		68.0		93.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2017	F	Female		84.0	PT	Percent		73.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2018	F	Female		82.0	PT	Percent		71.0		96.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2019	F	Female		86.0	PT	Percent		75.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2020	F	Female		91.0	PT	Percent		79.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2006	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2007	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2008	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2009	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2010	F	Female		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2011	F	Female		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2012	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2013	F	Female		25.0	PT	Percent		24.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2014	F	Female		35.0	PT	Percent		32.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2015	F	Female		41.0	PT	Percent		38.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2016	F	Female		49.0	PT	Percent		45.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2017	F	Female		56.99999999999999	PT	Percent		52.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2018	F	Female		60.0	PT	Percent		55.00000000000001		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2019	F	Female		63.0	PT	Percent		57.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2020	F	Female		67.0	PT	Percent		61.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2002	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2003	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2004	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2005	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2006	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2007	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2008	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2009	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2010	F	Female		21.0	PT	Percent		19.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2011	F	Female		23.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2012	F	Female		26.0	PT	Percent		23.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2013	F	Female		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2014	F	Female		33.0	PT	Percent		30.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2015	F	Female		36.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2016	F	Female		41.0	PT	Percent		38.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2017	F	Female		46.0	PT	Percent		42.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2018	F	Female		50.0	PT	Percent		46.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2019	F	Female		53.0	PT	Percent		48.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2020	F	Female		56.00000000000001	PT	Percent		51.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2000	F	Female		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2001	F	Female		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2002	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2003	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2004	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2005	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2006	F	Female		17.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2007	F	Female		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2008	F	Female		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2009	F	Female		22.0	PT	Percent		21.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2010	F	Female		24.0	PT	Percent		23.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2011	F	Female		27.0	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2012	F	Female		28.000000000000004	PT	Percent		26.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2013	F	Female		27.0	PT	Percent		26.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2014	F	Female		29.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2015	F	Female		30.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2016	F	Female		35.0	PT	Percent		32.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2017	F	Female		35.0	PT	Percent		32.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2018	F	Female		39.0	PT	Percent		36.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2019	F	Female		42.0	PT	Percent		39.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2020	F	Female		46.0	PT	Percent		42.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2005	F	Female		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2006	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2007	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2008	F	Female		20.0	PT	Percent		19.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2009	F	Female		31.0	PT	Percent		29.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2010	F	Female		38.0	PT	Percent		35.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2011	F	Female		37.0	PT	Percent		34.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2012	F	Female		42.0	PT	Percent		38.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2013	F	Female		46.0	PT	Percent		42.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2014	F	Female		50.0	PT	Percent		46.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2015	F	Female		55.00000000000001	PT	Percent		51.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2016	F	Female		64.0	PT	Percent		59.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2017	F	Female		74.0	PT	Percent		68.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2018	F	Female		74.0	PT	Percent		68.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2019	F	Female		80.0	PT	Percent		74.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2020	F	Female		87.0	PT	Percent		80.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2006	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2007	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2008	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2009	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2010	F	Female		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2011	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2012	F	Female		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2013	F	Female		22.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2014	F	Female		24.0	PT	Percent		20.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2015	F	Female		25.0	PT	Percent		21.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2016	F	Female		29.0	PT	Percent		25.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2017	F	Female		45.0	PT	Percent		38.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2018	F	Female		50.0	PT	Percent		41.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2019	F	Female		55.00000000000001	PT	Percent		46.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2020	F	Female		65.0	PT	Percent		54.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2000	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2001	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2002	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2003	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2004	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2005	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2006	F	Female		9.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2007	F	Female		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2008	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2009	F	Female		21.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2010	F	Female		28.000000000000004	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2011	F	Female		31.0	PT	Percent		29.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2012	F	Female		37.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2013	F	Female		40.0	PT	Percent		36.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2014	F	Female		46.0	PT	Percent		43.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2015	F	Female		55.00000000000001	PT	Percent		51.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2016	F	Female		60.0	PT	Percent		56.00000000000001		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2017	F	Female		63.0	PT	Percent		57.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2018	F	Female		72.0	PT	Percent		66.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2019	F	Female		72.0	PT	Percent		66.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2020	F	Female		67.0	PT	Percent		61.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2006	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2007	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2008	F	Female		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2009	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2010	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2011	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2012	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2013	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2014	F	Female		4.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2015	F	Female		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2016	F	Female		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2017	F	Female		8.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2018	F	Female		12.0	PT	Percent		10.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2019	F	Female		16.0	PT	Percent		13.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2020	F	Female		16.0	PT	Percent		13.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2005	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2006	F	Female		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2007	F	Female		12.0	PT	Percent		12.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2008	F	Female		19.0	PT	Percent		18.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2009	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2010	F	Female		30.0	PT	Percent		29.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2011	F	Female		39.0	PT	Percent		37.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2012	F	Female		49.0	PT	Percent		46.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2013	F	Female		56.00000000000001	PT	Percent		53.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2014	F	Female		63.0	PT	Percent		59.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2015	F	Female		68.0	PT	Percent		64.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2016	F	Female		75.0	PT	Percent		71.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2017	F	Female		81.0	PT	Percent		76.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2018	F	Female		87.0	PT	Percent		81.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2019	F	Female		88.0	PT	Percent		82.0		96.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2020	F	Female		89.0	PT	Percent		83.0		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1998	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1999	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2000	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2001	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2002	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2003	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2004	F	Female		18.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2005	F	Female		21.0	PT	Percent		19.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2006	F	Female		25.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2007	F	Female		27.0	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2008	F	Female		30.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2009	F	Female		32.0	PT	Percent		28.000000000000004		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2010	F	Female		34.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2011	F	Female		35.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2012	F	Female		35.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2013	F	Female		39.0	PT	Percent		36.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2014	F	Female		48.0	PT	Percent		43.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2015	F	Female		49.0	PT	Percent		44.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2016	F	Female		62.0	PT	Percent		56.00000000000001		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2017	F	Female		65.0	PT	Percent		59.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2018	F	Female		64.0	PT	Percent		57.99999999999999		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2019	F	Female		64.0	PT	Percent		57.99999999999999		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2020	F	Female		63.0	PT	Percent		56.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2004	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2005	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2006	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2007	F	Female		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2008	F	Female		17.0	PT	Percent		14.000000000000002		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2009	F	Female		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2010	F	Female		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2011	F	Female		33.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2012	F	Female		32.0	PT	Percent		27.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2013	F	Female		32.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2014	F	Female		35.0	PT	Percent		30.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2015	F	Female		39.0	PT	Percent		33.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2016	F	Female		41.0	PT	Percent		35.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2017	F	Female		46.0	PT	Percent		38.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2018	F	Female		51.0	PT	Percent		43.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2019	F	Female		56.99999999999999	PT	Percent		47.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2020	F	Female		62.0	PT	Percent		51.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2005	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2006	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2007	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2008	F	Female		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2009	F	Female		22.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2010	F	Female		25.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2011	F	Female		23.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2012	F	Female		26.0	PT	Percent		23.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2013	F	Female		31.0	PT	Percent		26.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2014	F	Female		32.0	PT	Percent		27.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2015	F	Female		34.0	PT	Percent		29.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2016	F	Female		35.0	PT	Percent		29.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2017	F	Female		42.0	PT	Percent		36.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2018	F	Female		42.0	PT	Percent		35.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2019	F	Female		45.0	PT	Percent		37.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2020	F	Female		45.0	PT	Percent		37.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2002	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2006	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2007	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2008	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2009	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2010	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2011	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2012	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2013	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2014	F	Female		12.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2015	F	Female		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2016	F	Female		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2017	F	Female		17.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2018	F	Female		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2019	F	Female		20.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2020	F	Female		21.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1995	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1996	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1997	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1998	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1999	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2000	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2001	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2002	F	Female		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2003	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2004	F	Female		14.000000000000002	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2005	F	Female		16.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2006	F	Female		19.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2007	F	Female		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2008	F	Female		24.0	PT	Percent		20.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2009	F	Female		25.0	PT	Percent		22.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2010	F	Female		27.0	PT	Percent		23.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2011	F	Female		29.0	PT	Percent		25.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2012	F	Female		41.0	PT	Percent		35.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2013	F	Female		39.0	PT	Percent		34.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2014	F	Female		40.0	PT	Percent		34.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2015	F	Female		45.0	PT	Percent		39.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2016	F	Female		46.0	PT	Percent		40.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2017	F	Female		46.0	PT	Percent		40.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2018	F	Female		49.0	PT	Percent		42.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2019	F	Female		52.0	PT	Percent		45.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2020	F	Female		56.99999999999999	PT	Percent		48.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2003	F	Female		10.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2004	F	Female		7.000000000000001	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2007	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2008	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2009	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2010	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2011	F	Female		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2012	F	Female		11.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2013	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2014	F	Female		21.0	PT	Percent		19.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2015	F	Female		28.000000000000004	PT	Percent		25.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2016	F	Female		25.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2017	F	Female		27.0	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2018	F	Female		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2019	F	Female		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2020	F	Female		30.0	PT	Percent		27.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2000	F	Female		14.000000000000002	PT	Percent		6.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2001	F	Female		13.0	PT	Percent		5.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2002	F	Female		11.0	PT	Percent		5.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2003	F	Female		9.0	PT	Percent		3.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2004	F	Female		25.0	PT	Percent		10.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2005	F	Female		21.0	PT	Percent		9.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2006	F	Female		19.0	PT	Percent		7.000000000000001		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2007	F	Female		22.0	PT	Percent		9.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2008	F	Female		25.0	PT	Percent		9.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2009	F	Female		23.0	PT	Percent		8.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2010	F	Female		20.0	PT	Percent		7.000000000000001		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2011	F	Female		19.0	PT	Percent		6.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2012	F	Female		21.0	PT	Percent		6.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2013	F	Female		23.0	PT	Percent		7.000000000000001		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2014	F	Female		30.0	PT	Percent		10.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2015	F	Female		31.0	PT	Percent		10.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2016	F	Female		35.0	PT	Percent		11.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2017	F	Female		38.0	PT	Percent		12.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2018	F	Female		43.0	PT	Percent		14.000000000000002		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2019	F	Female		48.0	PT	Percent		15.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2020	F	Female		43.0	PT	Percent		14.000000000000002		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2003	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2004	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2005	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2006	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2007	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2008	F	Female		12.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2009	F	Female		14.000000000000002	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2010	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2011	F	Female		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2012	F	Female		28.000000000000004	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2013	F	Female		33.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2014	F	Female		38.0	PT	Percent		34.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2015	F	Female		51.0	PT	Percent		46.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2016	F	Female		60.0	PT	Percent		55.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2017	F	Female		61.0	PT	Percent		56.00000000000001		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2018	F	Female		70.0	PT	Percent		64.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2019	F	Female		76.0	PT	Percent		70.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2020	F	Female		83.0	PT	Percent		75.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2006	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2007	F	Female		8.0	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2008	F	Female		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2009	F	Female		13.0	PT	Percent		10.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2010	F	Female		16.0	PT	Percent		13.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2011	F	Female		19.0	PT	Percent		15.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2012	F	Female		21.0	PT	Percent		17.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2013	F	Female		31.0	PT	Percent		25.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2014	F	Female		40.0	PT	Percent		32.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2015	F	Female		48.0	PT	Percent		39.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2016	F	Female		57.99999999999999	PT	Percent		47.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2017	F	Female		64.0	PT	Percent		52.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2018	F	Female		69.0	PT	Percent		56.00000000000001		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2019	F	Female		74.0	PT	Percent		60.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2020	F	Female		73.0	PT	Percent		59.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2004	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2005	F	Female		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2006	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2007	F	Female		27.0	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2008	F	Female		33.0	PT	Percent		30.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2009	F	Female		36.0	PT	Percent		34.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2010	F	Female		44.0	PT	Percent		41.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2011	F	Female		52.0	PT	Percent		49.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2012	F	Female		57.99999999999999	PT	Percent		54.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2013	F	Female		62.0	PT	Percent		56.99999999999999		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2014	F	Female		60.0	PT	Percent		56.00000000000001		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2015	F	Female		66.0	PT	Percent		62.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2016	F	Female		71.0	PT	Percent		66.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2017	F	Female		79.0	PT	Percent		74.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2018	F	Female		82.0	PT	Percent		77.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2019	F	Female		90.0	PT	Percent		84.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2020	F	Female		92.0	PT	Percent		86.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2006	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2007	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2008	F	Female		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2009	F	Female		14.000000000000002	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2010	F	Female		18.0	PT	Percent		17.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2011	F	Female		24.0	PT	Percent		22.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2012	F	Female		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2013	F	Female		33.0	PT	Percent		30.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2014	F	Female		37.0	PT	Percent		34.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2015	F	Female		42.0	PT	Percent		38.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2016	F	Female		45.0	PT	Percent		42.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2017	F	Female		53.0	PT	Percent		48.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2018	F	Female		57.99999999999999	PT	Percent		53.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2019	F	Female		62.0	PT	Percent		56.99999999999999		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2020	F	Female		66.0	PT	Percent		61.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1996	F	Female		27.0	PT	Percent		23.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1997	F	Female		37.0	PT	Percent		31.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1998	F	Female		40.0	PT	Percent		34.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1999	F	Female		43.0	PT	Percent		37.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2000	F	Female		49.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2001	F	Female		56.00000000000001	PT	Percent		48.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2002	F	Female		62.0	PT	Percent		54.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2003	F	Female		66.0	PT	Percent		57.99999999999999		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2004	F	Female		70.0	PT	Percent		61.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2005	F	Female		71.0	PT	Percent		63.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2006	F	Female		71.0	PT	Percent		63.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2007	F	Female		73.0	PT	Percent		65.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2008	F	Female		74.0	PT	Percent		66.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2009	F	Female		75.0	PT	Percent		67.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2010	F	Female		77.0	PT	Percent		69.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2011	F	Female		77.0	PT	Percent		69.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2012	F	Female		79.0	PT	Percent		70.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2013	F	Female		79.0	PT	Percent		71.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2014	F	Female		80.0	PT	Percent		72.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2015	F	Female		81.0	PT	Percent		73.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2016	F	Female		82.0	PT	Percent		73.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2017	F	Female		82.0	PT	Percent		74.0		92.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2018	F	Female		83.0	PT	Percent		74.0		93.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2019	F	Female		85.0	PT	Percent		75.0		96.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2020	F	Female		88.0	PT	Percent		77.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1995	F	Female		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1996	F	Female		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1997	F	Female		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1998	F	Female		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1999	F	Female		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2000	F	Female		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2001	F	Female		32.0	PT	Percent		30.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2002	F	Female		37.0	PT	Percent		34.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2003	F	Female		41.0	PT	Percent		38.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2004	F	Female		45.0	PT	Percent		42.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2005	F	Female		55.00000000000001	PT	Percent		51.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2006	F	Female		51.0	PT	Percent		47.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2007	F	Female		52.0	PT	Percent		48.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2008	F	Female		52.0	PT	Percent		48.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2009	F	Female		54.0	PT	Percent		49.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2010	F	Female		56.00000000000001	PT	Percent		52.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2011	F	Female		62.0	PT	Percent		56.00000000000001		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2012	F	Female		60.0	PT	Percent		55.00000000000001		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2013	F	Female		61.0	PT	Percent		56.00000000000001		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2014	F	Female		64.0	PT	Percent		57.99999999999999		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2015	F	Female		66.0	PT	Percent		60.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2016	F	Female		69.0	PT	Percent		62.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2017	F	Female		70.0	PT	Percent		64.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2018	F	Female		74.0	PT	Percent		67.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2019	F	Female		77.0	PT	Percent		70.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2020	F	Female		79.0	PT	Percent		71.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2003	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2005	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2006	F	Female		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2007	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2008	F	Female		10.0	PT	Percent		8.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2009	F	Female		14.000000000000002	PT	Percent		10.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2010	F	Female		21.0	PT	Percent		16.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2011	F	Female		25.0	PT	Percent		19.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2012	F	Female		29.0	PT	Percent		22.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2013	F	Female		31.0	PT	Percent		23.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2014	F	Female		38.0	PT	Percent		29.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2015	F	Female		39.0	PT	Percent		31.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2016	F	Female		42.0	PT	Percent		32.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2017	F	Female		43.0	PT	Percent		33.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2018	F	Female		50.0	PT	Percent		39.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2019	F	Female		51.0	PT	Percent		39.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2020	F	Female		48.0	PT	Percent		36.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2006	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2007	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2008	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2009	F	Female		22.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2010	F	Female		26.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2011	F	Female		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2012	F	Female		39.0	PT	Percent		35.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2013	F	Female		46.0	PT	Percent		41.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2014	F	Female		42.0	PT	Percent		37.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2015	F	Female		48.0	PT	Percent		43.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2016	F	Female		56.99999999999999	PT	Percent		52.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2017	F	Female		67.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2018	F	Female		73.0	PT	Percent		66.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2019	F	Female		76.0	PT	Percent		68.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2020	F	Female		81.0	PT	Percent		72.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2003	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2004	F	Female		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2005	F	Female		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2006	F	Female		13.0	PT	Percent		10.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2007	F	Female		15.0	PT	Percent		11.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2008	F	Female		22.0	PT	Percent		16.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2009	F	Female		26.0	PT	Percent		20.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2010	F	Female		30.0	PT	Percent		22.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2011	F	Female		33.0	PT	Percent		25.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2012	F	Female		46.0	PT	Percent		35.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2013	F	Female		53.0	PT	Percent		40.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2014	F	Female		57.99999999999999	PT	Percent		44.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2015	F	Female		62.0	PT	Percent		47.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2016	F	Female		69.0	PT	Percent		51.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2017	F	Female		71.0	PT	Percent		53.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2018	F	Female		73.0	PT	Percent		55.00000000000001		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2019	F	Female		81.0	PT	Percent		61.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2020	F	Female	>	98.0	PT	Percent		75.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1996	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1997	F	Female		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1998	F	Female		22.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1999	F	Female		26.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2000	F	Female		34.0	PT	Percent		31.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2001	F	Female		40.0	PT	Percent		36.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2002	F	Female		46.0	PT	Percent		41.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2003	F	Female		50.0	PT	Percent		45.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2004	F	Female		53.0	PT	Percent		49.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2005	F	Female		56.00000000000001	PT	Percent		51.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2006	F	Female		60.0	PT	Percent		55.00000000000001		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2007	F	Female		64.0	PT	Percent		57.99999999999999		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2008	F	Female		64.0	PT	Percent		59.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2009	F	Female		65.0	PT	Percent		59.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2010	F	Female		66.0	PT	Percent		60.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2011	F	Female		67.0	PT	Percent		61.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2012	F	Female		68.0	PT	Percent		62.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2013	F	Female		69.0	PT	Percent		63.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2014	F	Female		71.0	PT	Percent		64.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2015	F	Female		73.0	PT	Percent		66.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2016	F	Female		73.0	PT	Percent		66.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2017	F	Female		74.0	PT	Percent		67.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2018	F	Female		76.0	PT	Percent		67.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2019	F	Female		77.0	PT	Percent		67.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2020	F	Female		79.0	PT	Percent		68.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2002	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2003	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2004	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2005	F	Female		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2006	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2007	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2008	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2009	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2010	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2011	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2012	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2013	F	Female		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2014	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2015	F	Female		7.000000000000001	PT	Percent		7.000000000000001		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2016	F	Female		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2017	F	Female		9.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2018	F	Female		11.0	PT	Percent		10.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2019	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2020	F	Female		15.0	PT	Percent		14.000000000000002		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1999	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2000	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2001	F	Female		11.0	PT	Percent		10.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2002	F	Female		13.0	PT	Percent		13.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2003	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2004	F	Female		17.0	PT	Percent		16.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2005	F	Female		19.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2006	F	Female		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2007	F	Female		22.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2008	F	Female		23.0	PT	Percent		21.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2009	F	Female		28.000000000000004	PT	Percent		26.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2010	F	Female		27.0	PT	Percent		26.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2011	F	Female		33.0	PT	Percent		31.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2012	F	Female		25.0	PT	Percent		24.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2013	F	Female		37.0	PT	Percent		35.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2014	F	Female		35.0	PT	Percent		33.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2015	F	Female		39.0	PT	Percent		37.0		42.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2016	F	Female		45.0	PT	Percent		42.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2017	F	Female		49.0	PT	Percent		45.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2018	F	Female		41.0	PT	Percent		38.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2019	F	Female		43.0	PT	Percent		40.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2020	F	Female		41.0	PT	Percent		37.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2005	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2006	F	Female		5.0	PT	Percent		3.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2007	F	Female		13.0	PT	Percent		8.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2008	F	Female		16.0	PT	Percent		10.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2009	F	Female		20.0	PT	Percent		13.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2010	F	Female		24.0	PT	Percent		16.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2011	F	Female		30.0	PT	Percent		20.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2012	F	Female		35.0	PT	Percent		23.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2013	F	Female		42.0	PT	Percent		28.000000000000004		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2014	F	Female		49.0	PT	Percent		33.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2015	F	Female		53.0	PT	Percent		36.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2016	F	Female		56.00000000000001	PT	Percent		38.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2017	F	Female		59.0	PT	Percent		40.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2018	F	Female		63.0	PT	Percent		42.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2019	F	Female		64.0	PT	Percent		43.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2020	F	Female		69.0	PT	Percent		46.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2005	F	Female		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2006	F	Female		3.0	PT	Percent		2.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2007	F	Female		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2008	F	Female		8.0	PT	Percent		6.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2009	F	Female		11.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2010	F	Female		15.0	PT	Percent		11.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2011	F	Female		15.0	PT	Percent		12.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2012	F	Female		20.0	PT	Percent		15.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2013	F	Female		22.0	PT	Percent		17.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2014	F	Female		26.0	PT	Percent		20.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2015	F	Female		28.000000000000004	PT	Percent		22.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2016	F	Female		33.0	PT	Percent		26.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2017	F	Female		37.0	PT	Percent		29.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2018	F	Female		39.0	PT	Percent		30.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2019	F	Female		42.0	PT	Percent		33.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2020	F	Female		41.0	PT	Percent		32.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2002	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2003	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2004	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2005	F	Female		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2006	F	Female		13.0	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2007	F	Female		29.0	PT	Percent		26.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2008	F	Female		33.0	PT	Percent		30.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2009	F	Female		46.0	PT	Percent		43.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2010	F	Female		52.0	PT	Percent		49.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2011	F	Female		54.0	PT	Percent		50.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2012	F	Female		66.0	PT	Percent		62.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2013	F	Female		65.0	PT	Percent		61.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2014	F	Female		72.0	PT	Percent		68.0		92.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2015	F	Female		96.0	PT	Percent		91.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2016	F	Female		87.0	PT	Percent		83.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2017	F	Female		83.0	PT	Percent		79.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2018	F	Female		86.0	PT	Percent		83.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2019	F	Female		91.0	PT	Percent		88.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2020	F	Female		89.0	PT	Percent		86.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2005	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2006	F	Female		10.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2007	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2008	F	Female		18.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2009	F	Female		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2010	F	Female		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2011	F	Female		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2012	F	Female		18.0	PT	Percent		17.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2013	F	Female		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2014	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2015	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2016	F	Female		18.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2017	F	Female		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2018	F	Female		24.0	PT	Percent		22.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2019	F	Female		22.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2020	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1997	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1998	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1999	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2000	F	Female		19.0	PT	Percent		18.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2001	F	Female		24.0	PT	Percent		22.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2002	F	Female		29.0	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2003	F	Female		33.0	PT	Percent		30.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2004	F	Female		37.0	PT	Percent		34.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2005	F	Female		40.0	PT	Percent		37.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2006	F	Female		43.0	PT	Percent		40.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2007	F	Female		46.0	PT	Percent		42.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2008	F	Female		49.0	PT	Percent		45.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2009	F	Female		51.0	PT	Percent		47.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2010	F	Female		56.00000000000001	PT	Percent		51.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2011	F	Female		60.0	PT	Percent		55.00000000000001		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2012	F	Female		65.0	PT	Percent		59.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2013	F	Female		69.0	PT	Percent		63.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2014	F	Female		73.0	PT	Percent		67.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2015	F	Female		76.0	PT	Percent		69.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2016	F	Female		79.0	PT	Percent		72.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2017	F	Female		87.0	PT	Percent		78.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2018	F	Female		90.0	PT	Percent		81.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2019	F	Female		91.0	PT	Percent		82.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2020	F	Female		92.0	PT	Percent		82.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2007	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2008	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2009	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2010	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2011	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2012	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2013	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2014	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2015	F	Female		29.0	PT	Percent		14.000000000000002		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2016	F	Female		53.0	PT	Percent		25.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2017	F	Female		76.0	PT	Percent		40.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2018	F	Female		88.0	PT	Percent		47.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2019	F	Female		96.0	PT	Percent		61.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2020	F	Female	>	98.0	PT	Percent		68.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2005	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2006	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2007	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2008	F	Female		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2009	F	Female		8.0	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2010	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2011	F	Female		17.0	PT	Percent		14.000000000000002		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2012	F	Female		21.0	PT	Percent		17.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2013	F	Female		25.0	PT	Percent		20.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2014	F	Female		32.0	PT	Percent		27.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2015	F	Female		38.0	PT	Percent		32.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2016	F	Female		44.0	PT	Percent		37.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2017	F	Female		50.0	PT	Percent		41.0		59.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2018	F	Female		55.00000000000001	PT	Percent		46.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2019	F	Female		60.0	PT	Percent		50.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2020	F	Female		60.0	PT	Percent		50.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1998	F	Female		29.0	PT	Percent		16.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1999	F	Female		38.0	PT	Percent		21.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2000	F	Female		44.0	PT	Percent		25.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2001	F	Female		49.0	PT	Percent		28.000000000000004		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2002	F	Female		54.0	PT	Percent		31.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2003	F	Female		53.0	PT	Percent		30.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2004	F	Female		52.0	PT	Percent		30.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2005	F	Female		51.0	PT	Percent		30.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2006	F	Female		50.0	PT	Percent		30.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2007	F	Female		50.0	PT	Percent		30.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2008	F	Female		50.0	PT	Percent		30.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2009	F	Female		50.0	PT	Percent		30.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2010	F	Female		50.0	PT	Percent		30.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2011	F	Female		49.0	PT	Percent		30.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2012	F	Female		48.0	PT	Percent		29.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2013	F	Female		46.0	PT	Percent		29.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2014	F	Female		50.0	PT	Percent		32.0		64.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2015	F	Female		55.00000000000001	PT	Percent		35.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2016	F	Female		60.0	PT	Percent		38.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2017	F	Female		61.0	PT	Percent		40.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2018	F	Female		63.0	PT	Percent		41.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2019	F	Female		65.0	PT	Percent		43.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2020	F	Female		64.0	PT	Percent		43.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2004	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2005	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2006	F	Female		19.0	PT	Percent		18.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2007	F	Female		25.0	PT	Percent		23.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2008	F	Female		34.0	PT	Percent		32.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2009	F	Female		41.0	PT	Percent		38.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2010	F	Female		47.0	PT	Percent		44.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2011	F	Female		51.0	PT	Percent		48.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2012	F	Female		60.0	PT	Percent		56.00000000000001		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2013	F	Female		67.0	PT	Percent		62.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2014	F	Female		74.0	PT	Percent		69.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2015	F	Female		80.0	PT	Percent		74.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2016	F	Female		87.0	PT	Percent		81.0		97.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2017	F	Female		90.0	PT	Percent		83.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2018	F	Female		92.0	PT	Percent		86.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2019	F	Female		93.0	PT	Percent		87.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2020	F	Female		96.0	PT	Percent		88.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1995	F	Female		26.0	PT	Percent		12.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1996	F	Female		42.0	PT	Percent		22.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1997	F	Female		53.0	PT	Percent		30.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1998	F	Female		60.0	PT	Percent		36.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1999	F	Female		65.0	PT	Percent		42.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2000	F	Female		68.0	PT	Percent		47.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2001	F	Female		69.0	PT	Percent		50.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2002	F	Female		70.0	PT	Percent		54.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2003	F	Female		69.0	PT	Percent		56.00000000000001		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2004	F	Female		68.0	PT	Percent		56.99999999999999		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2005	F	Female		68.0	PT	Percent		59.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2006	F	Female		69.0	PT	Percent		61.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2007	F	Female		69.0	PT	Percent		62.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2008	F	Female		69.0	PT	Percent		63.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2009	F	Female		69.0	PT	Percent		63.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2010	F	Female		69.0	PT	Percent		62.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2011	F	Female		68.0	PT	Percent		61.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2012	F	Female		67.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2013	F	Female		65.0	PT	Percent		59.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2014	F	Female		63.0	PT	Percent		56.99999999999999		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2015	F	Female		61.0	PT	Percent		55.00000000000001		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2016	F	Female		63.0	PT	Percent		56.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2017	F	Female		68.0	PT	Percent		60.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2018	F	Female		60.0	PT	Percent		53.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2019	F	Female		45.0	PT	Percent		39.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2020	F	Female		41.0	PT	Percent		36.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2006	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2007	F	Female		26.0	PT	Percent		22.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2008	F	Female		31.0	PT	Percent		26.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2009	F	Female		35.0	PT	Percent		30.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2010	F	Female		40.0	PT	Percent		34.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2011	F	Female		43.0	PT	Percent		37.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2012	F	Female		40.0	PT	Percent		35.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2013	F	Female		44.0	PT	Percent		39.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2014	F	Female		52.0	PT	Percent		46.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2015	F	Female		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2016	F	Female		69.0	PT	Percent		62.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2017	F	Female		75.0	PT	Percent		67.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2018	F	Female		86.0	PT	Percent		77.0		96.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2019	F	Female		92.0	PT	Percent		83.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2020	F	Female		95.0	PT	Percent		85.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2003	F	Female		27.0	PT	Percent		21.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2004	F	Female		34.0	PT	Percent		28.000000000000004		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2005	F	Female		41.0	PT	Percent		33.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2006	F	Female		41.0	PT	Percent		34.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2007	F	Female		42.0	PT	Percent		35.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2008	F	Female		43.0	PT	Percent		36.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2009	F	Female		43.0	PT	Percent		37.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2010	F	Female		46.0	PT	Percent		40.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2011	F	Female		48.0	PT	Percent		41.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2012	F	Female		49.0	PT	Percent		42.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2013	F	Female		52.0	PT	Percent		44.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2014	F	Female		55.00000000000001	PT	Percent		47.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2015	F	Female		59.0	PT	Percent		50.0		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2016	F	Female		64.0	PT	Percent		55.00000000000001		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2017	F	Female		71.0	PT	Percent		60.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2018	F	Female		65.0	PT	Percent		54.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2019	F	Female		68.0	PT	Percent		56.00000000000001		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2020	F	Female		64.0	PT	Percent		53.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2006	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2007	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2008	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2009	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2010	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2011	F	Female		14.000000000000002	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2012	F	Female		17.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2013	F	Female		19.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2014	F	Female		23.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2015	F	Female		27.0	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2016	F	Female		35.0	PT	Percent		31.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2017	F	Female		44.0	PT	Percent		40.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2018	F	Female		51.0	PT	Percent		46.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2019	F	Female		57.99999999999999	PT	Percent		51.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2020	F	Female		65.0	PT	Percent		56.99999999999999		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2006	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2007	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2008	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2009	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2010	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2011	F	Female		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2012	F	Female		14.000000000000002	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2013	F	Female		19.0	PT	Percent		17.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2014	F	Female		24.0	PT	Percent		21.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2015	F	Female		30.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2016	F	Female		35.0	PT	Percent		31.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2017	F	Female		41.0	PT	Percent		36.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2018	F	Female		45.0	PT	Percent		39.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2019	F	Female		49.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2020	F	Female		53.0	PT	Percent		47.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2002	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2004	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2005	F	Female		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2006	F	Female		5.0	PT	Percent		3.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2007	F	Female		9.0	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2008	F	Female		14.000000000000002	PT	Percent		9.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2009	F	Female		20.0	PT	Percent		12.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2010	F	Female		26.0	PT	Percent		17.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2011	F	Female		34.0	PT	Percent		22.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2012	F	Female		42.0	PT	Percent		27.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2013	F	Female		48.0	PT	Percent		31.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2014	F	Female		53.0	PT	Percent		34.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2015	F	Female		57.99999999999999	PT	Percent		38.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2016	F	Female		63.0	PT	Percent		41.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2017	F	Female		68.0	PT	Percent		44.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2018	F	Female		71.0	PT	Percent		47.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2019	F	Female		75.0	PT	Percent		49.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2020	F	Female		78.0	PT	Percent		51.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2007	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2008	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2009	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2010	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2011	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2012	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2013	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2014	F	Female		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2015	F	Female		15.0	PT	Percent		12.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2016	F	Female		15.0	PT	Percent		12.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2017	F	Female		17.0	PT	Percent		13.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2018	F	Female		21.0	PT	Percent		16.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2019	F	Female		22.0	PT	Percent		17.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2020	F	Female		25.0	PT	Percent		19.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1996	F	Female		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1997	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1998	F	Female		21.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1999	F	Female		27.0	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2000	F	Female		34.0	PT	Percent		32.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2001	F	Female		40.0	PT	Percent		38.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2002	F	Female		46.0	PT	Percent		43.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2003	F	Female		52.0	PT	Percent		48.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2004	F	Female		56.99999999999999	PT	Percent		53.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2005	F	Female		62.0	PT	Percent		57.99999999999999		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2006	F	Female		67.0	PT	Percent		62.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2007	F	Female		72.0	PT	Percent		65.0		77.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2008	F	Female		76.0	PT	Percent		69.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2009	F	Female		80.0	PT	Percent		72.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2010	F	Female		81.0	PT	Percent		72.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2011	F	Female		82.0	PT	Percent		73.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2012	F	Female		83.0	PT	Percent		74.0		90.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2013	F	Female		84.0	PT	Percent		74.0		92.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2014	F	Female		85.0	PT	Percent		75.0		93.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2015	F	Female		85.0	PT	Percent		75.0		94.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2016	F	Female		86.0	PT	Percent		76.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2017	F	Female		88.0	PT	Percent		77.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2018	F	Female		88.0	PT	Percent		77.0		98.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2019	F	Female		88.0	PT	Percent		76.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2020	F	Female		88.0	PT	Percent		76.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2005	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2006	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2007	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2008	F	Female		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2009	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2010	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2011	F	Female		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2012	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2013	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2014	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2015	F	Female		24.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2016	F	Female		31.0	PT	Percent		28.000000000000004		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2017	F	Female		36.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2018	F	Female		41.0	PT	Percent		37.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2019	F	Female		46.0	PT	Percent		41.0		50.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2020	F	Female		52.0	PT	Percent		47.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2007	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2008	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2009	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2010	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2011	F	Female		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2012	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2013	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2014	F	Female		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2015	F	Female		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2016	F	Female		12.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2017	F	Female		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2018	F	Female		19.0	PT	Percent		16.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2019	F	Female		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2020	F	Female		23.0	PT	Percent		20.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2002	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2003	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2004	F	Female		7.000000000000001	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2005	F	Female		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2006	F	Female		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2007	F	Female		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2008	F	Female		22.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2009	F	Female		24.0	PT	Percent		21.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2010	F	Female		27.0	PT	Percent		24.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2011	F	Female		32.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2012	F	Female		44.0	PT	Percent		38.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2013	F	Female		52.0	PT	Percent		45.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2014	F	Female		56.00000000000001	PT	Percent		48.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2015	F	Female		56.99999999999999	PT	Percent		48.0		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2016	F	Female		61.0	PT	Percent		51.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2017	F	Female		62.0	PT	Percent		51.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2018	F	Female		64.0	PT	Percent		53.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2019	F	Female		63.0	PT	Percent		52.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2020	F	Female		39.0	PT	Percent		32.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2003	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2004	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2005	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2006	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2007	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2008	F	Female		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2009	F	Female		12.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2010	F	Female		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2011	F	Female		14.000000000000002	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2012	F	Female		17.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2013	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2014	F	Female		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2015	F	Female		17.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2016	F	Female		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2017	F	Female		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2018	F	Female		25.0	PT	Percent		22.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2019	F	Female		30.0	PT	Percent		25.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2020	F	Female		30.0	PT	Percent		25.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2006	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2007	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2008	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2009	F	Female		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2010	F	Female		9.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2011	F	Female		10.0	PT	Percent		10.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2012	F	Female		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2013	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2014	F	Female		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2015	F	Female		29.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2016	F	Female		36.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2017	F	Female		42.0	PT	Percent		39.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2018	F	Female		48.0	PT	Percent		44.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2019	F	Female		56.00000000000001	PT	Percent		51.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2020	F	Female		62.0	PT	Percent		55.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2001	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2002	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2003	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2004	F	Female		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2005	F	Female		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2006	F	Female		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2007	F	Female		24.0	PT	Percent		22.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2008	F	Female		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2009	F	Female		31.0	PT	Percent		28.000000000000004		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2010	F	Female		36.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2011	F	Female		39.0	PT	Percent		35.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2012	F	Female		43.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2013	F	Female		47.0	PT	Percent		43.0		52.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2014	F	Female		52.0	PT	Percent		47.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2015	F	Female		56.00000000000001	PT	Percent		51.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2016	F	Female		61.0	PT	Percent		55.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2017	F	Female		66.0	PT	Percent		59.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2018	F	Female		72.0	PT	Percent		64.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2019	F	Female		76.0	PT	Percent		67.0		83.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2020	F	Female		79.0	PT	Percent		71.0		88.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2006	F	Female		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2007	F	Female		1.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2008	F	Female		9.0	PT	Percent		6.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2009	F	Female		9.0	PT	Percent		7.000000000000001		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2010	F	Female		13.0	PT	Percent		10.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2011	F	Female		12.0	PT	Percent		9.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2012	F	Female		13.0	PT	Percent		10.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2013	F	Female		28.000000000000004	PT	Percent		22.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2014	F	Female		29.0	PT	Percent		23.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2015	F	Female		27.0	PT	Percent		22.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2016	F	Female		35.0	PT	Percent		28.000000000000004		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2017	F	Female		31.0	PT	Percent		25.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2018	F	Female		35.0	PT	Percent		28.000000000000004		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2019	F	Female		40.0	PT	Percent		33.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2020	F	Female		47.0	PT	Percent		36.0		65.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2003	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2004	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2005	F	Female		5.0	PT	Percent		5.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2006	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2007	F	Female		7.000000000000001	PT	Percent		7.000000000000001		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2008	F	Female		10.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2009	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2010	F	Female		23.0	PT	Percent		21.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2011	F	Female		27.0	PT	Percent		26.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2012	F	Female		34.0	PT	Percent		32.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2013	F	Female		38.0	PT	Percent		36.0		40.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2014	F	Female		41.0	PT	Percent		39.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2015	F	Female		46.0	PT	Percent		44.0		49.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2016	F	Female		56.00000000000001	PT	Percent		53.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2017	F	Female		67.0	PT	Percent		64.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2018	F	Female		68.0	PT	Percent		65.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2019	F	Female		79.0	PT	Percent		75.0		84.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2020	F	Female		83.0	PT	Percent		79.0		89.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2001	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2002	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2003	F	Female		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2004	F	Female		12.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2005	F	Female		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2006	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2007	F	Female		22.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2008	F	Female		25.0	PT	Percent		23.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2009	F	Female		32.0	PT	Percent		29.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2010	F	Female		40.0	PT	Percent		37.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2011	F	Female		43.0	PT	Percent		40.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2012	F	Female		49.0	PT	Percent		45.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2013	F	Female		52.0	PT	Percent		48.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2014	F	Female		57.99999999999999	PT	Percent		52.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2015	F	Female		61.0	PT	Percent		55.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2016	F	Female		61.0	PT	Percent		56.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2017	F	Female		56.99999999999999	PT	Percent		52.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2018	F	Female		65.0	PT	Percent		57.99999999999999		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2019	F	Female		72.0	PT	Percent		64.0		80.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2020	F	Female		67.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2001	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2002	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2003	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2004	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2005	F	Female		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2006	F	Female		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2007	F	Female		9.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2008	F	Female		10.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2009	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2010	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2011	F	Female		15.0	PT	Percent		14.000000000000002		16.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2012	F	Female		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2013	F	Female		20.0	PT	Percent		19.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2014	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2015	F	Female		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2016	F	Female		27.0	PT	Percent		24.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2017	F	Female		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2018	F	Female		30.0	PT	Percent		27.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2019	F	Female		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2020	F	Female		34.0	PT	Percent		30.0		39.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2002	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2003	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2004	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2005	F	Female		9.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2006	F	Female		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2007	F	Female		10.0	PT	Percent		10.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2008	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2009	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2010	F	Female		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2011	F	Female		22.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2012	F	Female		34.0	PT	Percent		32.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2013	F	Female		48.0	PT	Percent		45.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2014	F	Female		57.99999999999999	PT	Percent		54.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2015	F	Female		62.0	PT	Percent		57.99999999999999		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2016	F	Female		69.0	PT	Percent		65.0		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2017	F	Female		78.0	PT	Percent		73.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2018	F	Female		78.0	PT	Percent		73.0		86.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2019	F	Female		93.0	PT	Percent		86.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2020	F	Female		96.0	PT	Percent		89.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2004	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2006	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2007	F	Female		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2008	F	Female		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2009	F	Female		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2010	F	Female		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2011	F	Female		12.0	PT	Percent		10.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2012	F	Female		18.0	PT	Percent		15.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2013	F	Female		25.0	PT	Percent		20.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2014	F	Female		29.0	PT	Percent		24.0		36.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2015	F	Female		28.000000000000004	PT	Percent		23.0		34.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2016	F	Female		39.0	PT	Percent		32.0		48.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2017	F	Female		44.0	PT	Percent		36.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2018	F	Female		50.0	PT	Percent		41.0		63.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2019	F	Female		55.00000000000001	PT	Percent		45.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2020	F	Female		56.99999999999999	PT	Percent		46.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2001	F	Female		67.0	PT	Percent		22.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2002	F	Female	>	98.0	PT	Percent		36.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2003	F	Female	>	98.0	PT	Percent		60.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2004	F	Female	>	98.0	PT	Percent		83.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2005	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2006	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2007	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2008	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2009	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2010	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2011	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2012	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2013	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2014	F	Female	>	98.0	PT	Percent	>	98.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2015	F	Female	>	98.0	PT	Percent		91.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2016	F	Female		61.0	PT	Percent		46.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2017	F	Female		77.0	PT	Percent		60.0		93.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2018	F	Female		88.0	PT	Percent		68.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2019	F	Female		63.0	PT	Percent		51.0		73.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2020	F	Female	>	98.0	PT	Percent		83.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2005	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2006	F	Female		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2007	F	Female		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2008	F	Female		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2009	F	Female		15.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2010	F	Female		21.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2011	F	Female		22.0	PT	Percent		21.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2012	F	Female		35.0	PT	Percent		33.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2013	F	Female		41.0	PT	Percent		39.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2014	F	Female		51.0	PT	Percent		49.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2015	F	Female		56.00000000000001	PT	Percent		53.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2016	F	Female		62.0	PT	Percent		57.99999999999999		68.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2017	F	Female		68.0	PT	Percent		64.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2018	F	Female		75.0	PT	Percent		71.0		82.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2019	F	Female		82.0	PT	Percent		78.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2020	F	Female		90.0	PT	Percent		85.0		99.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1996	F	Female		7.000000000000001	PT	Percent		3.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1997	F	Female		8.0	PT	Percent		3.0		11.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1998	F	Female		9.0	PT	Percent		4.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1999	F	Female		11.0	PT	Percent		5.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2000	F	Female		15.0	PT	Percent		8.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2001	F	Female		17.0	PT	Percent		10.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2002	F	Female		19.0	PT	Percent		11.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2003	F	Female		20.0	PT	Percent		13.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2004	F	Female		21.0	PT	Percent		15.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2005	F	Female		22.0	PT	Percent		17.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2006	F	Female		25.0	PT	Percent		20.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2007	F	Female		25.0	PT	Percent		20.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2008	F	Female		25.0	PT	Percent		21.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2009	F	Female		25.0	PT	Percent		21.0		30.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2010	F	Female		31.0	PT	Percent		26.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2011	F	Female		31.0	PT	Percent		27.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2012	F	Female		31.0	PT	Percent		26.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2013	F	Female		44.0	PT	Percent		37.0		53.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2014	F	Female		45.0	PT	Percent		39.0		54.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2015	F	Female		52.0	PT	Percent		44.0		62.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2016	F	Female		50.0	PT	Percent		43.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2017	F	Female		55.00000000000001	PT	Percent		48.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2018	F	Female		64.0	PT	Percent		55.00000000000001		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2019	F	Female		71.0	PT	Percent		61.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2020	F	Female		74.0	PT	Percent		63.0		92.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2006	F	Female		7.000000000000001	PT	Percent		5.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2007	F	Female		11.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2008	F	Female		15.0	PT	Percent		12.0		18.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2009	F	Female		18.0	PT	Percent		15.0		22.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2010	F	Female		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2011	F	Female		24.0	PT	Percent		21.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2012	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2013	F	Female		19.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2014	F	Female		27.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2015	F	Female		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2016	F	Female		41.0	PT	Percent		36.0		46.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2017	F	Female		50.0	PT	Percent		45.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2018	F	Female		60.0	PT	Percent		54.0		70.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2019	F	Female		64.0	PT	Percent		57.99999999999999		76.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2020	F	Female		70.0	PT	Percent		63.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2000	F	Female		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2001	F	Female		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2002	F	Female		5.0	PT	Percent		5.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2003	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2004	F	Female		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2005	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2006	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2007	F	Female		16.0	PT	Percent		15.0		17.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2008	F	Female		19.0	PT	Percent		18.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2009	F	Female		22.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2010	F	Female		25.0	PT	Percent		23.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2011	F	Female		25.0	PT	Percent		24.0		27.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2012	F	Female		26.0	PT	Percent		25.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2013	F	Female		26.0	PT	Percent		24.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2014	F	Female		27.0	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2015	F	Female		36.0	PT	Percent		33.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2016	F	Female		33.0	PT	Percent		30.0		35.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2017	F	Female		26.0	PT	Percent		23.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2018	F	Female		21.0	PT	Percent		19.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2019	F	Female		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2020	F	Female		34.0	PT	Percent		31.0		38.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2005	F	Female		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2006	F	Female		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2007	F	Female		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2008	F	Female		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2009	F	Female		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2010	F	Female		23.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2011	F	Female		29.0	PT	Percent		26.0		32.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2012	F	Female		37.0	PT	Percent		33.0		41.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2013	F	Female		40.0	PT	Percent		36.0		44.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2014	F	Female		43.0	PT	Percent		38.0		47.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2015	F	Female		51.0	PT	Percent		46.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2016	F	Female		56.00000000000001	PT	Percent		51.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2017	F	Female		61.0	PT	Percent		55.00000000000001		66.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2018	F	Female		65.0	PT	Percent		59.0		71.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2019	F	Female		69.0	PT	Percent		62.0		75.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2020	F	Female		72.0	PT	Percent		65.0		79.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2004	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2005	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2006	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2007	F	Female		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2008	F	Female		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2009	F	Female		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2010	F	Female		10.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2011	F	Female		11.0	PT	Percent		11.0		12.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2012	F	Female		12.0	PT	Percent		12.0		13.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2013	F	Female		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2014	F	Female		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2015	F	Female		19.0	PT	Percent		18.0		20.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2016	F	Female		22.0	PT	Percent		21.0		23.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2017	F	Female		24.0	PT	Percent		22.0		25.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2018	F	Female		25.0	PT	Percent		24.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2019	F	Female		27.0	PT	Percent		26.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2020	F	Female		28.000000000000004	PT	Percent		26.0		29.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2003	F	Female		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2004	F	Female		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2005	F	Female		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2006	F	Female		9.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2007	F	Female		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2008	F	Female		24.0	PT	Percent		23.0		26.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2009	F	Female		29.0	PT	Percent		27.0		31.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2010	F	Female		34.0	PT	Percent		33.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2011	F	Female		40.0	PT	Percent		38.0		43.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2012	F	Female		41.0	PT	Percent		40.0		45.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2013	F	Female		47.0	PT	Percent		45.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2014	F	Female		55.00000000000001	PT	Percent		53.0		60.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2015	F	Female		62.0	PT	Percent		59.0		67.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2016	F	Female		63.0	PT	Percent		60.0		69.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2017	F	Female		67.0	PT	Percent		63.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2018	F	Female		74.0	PT	Percent		70.0		81.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2019	F	Female		79.0	PT	Percent		74.0		87.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2020	F	Female		84.0	PT	Percent		78.0		93.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1990	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1991	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1992	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1993	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1994	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1995	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1996	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1997	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1998	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1999	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2000	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2001	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2002	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2003	F	Female	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2004	F	Female		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2005	F	Female		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2006	F	Female		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2007	F	Female		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2008	F	Female		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2009	F	Female		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2010	F	Female		34.0	PT	Percent		31.0		37.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2011	F	Female		46.0	PT	Percent		42.0		51.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2012	F	Female		52.0	PT	Percent		48.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2013	F	Female		56.00000000000001	PT	Percent		51.0		61.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2014	F	Female		66.0	PT	Percent		60.0		72.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2015	F	Female		71.0	PT	Percent		65.0		78.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2016	F	Female		78.0	PT	Percent		71.0		85.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2017	F	Female		87.0	PT	Percent		79.0		95.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2018	F	Female		83.0	PT	Percent		76.0		91.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2019	F	Female		94.0	PT	Percent		86.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2020	F	Female		96.0	PT	Percent		87.0		100.0	E	Estimated	G	Global	2021	6700				SEX	F	Female	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2007	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2008	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2009	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2010	M	Male		1.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2011	M	Male		2.0	PT	Percent		1.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2012	M	Male		3.0	PT	Percent		2.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2013	M	Male		4.0	PT	Percent		2.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2014	M	Male		4.0	PT	Percent		2.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2015	M	Male		5.0	PT	Percent		2.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2016	M	Male		5.0	PT	Percent		2.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2017	M	Male		9.0	PT	Percent		4.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2018	M	Male		9.0	PT	Percent		4.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2019	M	Male		9.0	PT	Percent		4.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	4	Afghanistan	AFG	66.02688198	33.83160199	Central and Southern Asia	2020	M	Male		9.0	PT	Percent		4.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2004	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2005	M	Male		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2006	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2007	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2008	M	Male		14.000000000000002	PT	Percent		12.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2009	M	Male		17.0	PT	Percent		14.000000000000002		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2010	M	Male		18.0	PT	Percent		15.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2011	M	Male		23.0	PT	Percent		19.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2012	M	Male		27.0	PT	Percent		22.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2013	M	Male		33.0	PT	Percent		26.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2014	M	Male		34.0	PT	Percent		27.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2015	M	Male		37.0	PT	Percent		30.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2016	M	Male		41.0	PT	Percent		33.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2017	M	Male		44.0	PT	Percent		36.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2018	M	Male		41.0	PT	Percent		33.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2019	M	Male		42.0	PT	Percent		33.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	8	Albania	ALB	20.06660928	41.13897007	Europe and Northern America	2020	M	Male		45.0	PT	Percent		36.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1998	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	1999	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2000	M	Male		11.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2001	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2002	M	Male		14.000000000000002	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2003	M	Male		16.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2004	M	Male		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2005	M	Male		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2006	M	Male		32.0	PT	Percent		29.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2007	M	Male		29.0	PT	Percent		26.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2008	M	Male		29.0	PT	Percent		26.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2009	M	Male		28.000000000000004	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2010	M	Male		34.0	PT	Percent		30.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2011	M	Male		36.0	PT	Percent		32.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2012	M	Male		42.0	PT	Percent		37.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2013	M	Male		47.0	PT	Percent		42.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2014	M	Male		53.0	PT	Percent		47.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2015	M	Male		62.0	PT	Percent		55.00000000000001		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2016	M	Male		69.0	PT	Percent		61.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2017	M	Male		72.0	PT	Percent		65.0		81.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2018	M	Male		76.0	PT	Percent		68.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2019	M	Male		80.0	PT	Percent		71.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	12	Algeria	DZA	2.678164227	28.15940032	Northern Africa and Western Asia	2020	M	Male		80.0	PT	Percent		72.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2006	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2007	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2008	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2009	M	Male		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2010	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2011	M	Male		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2012	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2013	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2014	M	Male		17.0	PT	Percent		14.000000000000002		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2015	M	Male		20.0	PT	Percent		16.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2016	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2017	M	Male		25.0	PT	Percent		21.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2018	M	Male		27.0	PT	Percent		23.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2019	M	Male		24.0	PT	Percent		20.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	24	Angola	AGO	17.57817062	-12.33724746	Sub-Saharan Africa	2020	M	Male		27.0	PT	Percent		23.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1998	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	1999	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2000	M	Male		19.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2001	M	Male		22.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2002	M	Male		25.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2003	M	Male		28.000000000000004	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2004	M	Male		30.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2005	M	Male		30.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2006	M	Male		32.0	PT	Percent		28.000000000000004		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2007	M	Male		35.0	PT	Percent		31.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2008	M	Male		38.0	PT	Percent		33.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2009	M	Male		40.0	PT	Percent		36.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2010	M	Male		43.0	PT	Percent		38.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2011	M	Male		46.0	PT	Percent		41.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2012	M	Male		48.0	PT	Percent		43.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2013	M	Male		50.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2014	M	Male		52.0	PT	Percent		46.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2015	M	Male		54.0	PT	Percent		48.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2016	M	Male		56.00000000000001	PT	Percent		50.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2017	M	Male		57.99999999999999	PT	Percent		52.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2018	M	Male		60.0	PT	Percent		53.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2019	M	Male		62.0	PT	Percent		55.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	32	Argentina	ARG	-65.14563274	-35.19446255	Latin America and the Caribbean	2020	M	Male		62.0	PT	Percent		55.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2006	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2007	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2008	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2009	M	Male		5.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2010	M	Male		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2011	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2012	M	Male		11.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2013	M	Male		15.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2014	M	Male		19.0	PT	Percent		17.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2015	M	Male		23.0	PT	Percent		21.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2016	M	Male		28.000000000000004	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2017	M	Male		35.0	PT	Percent		32.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2018	M	Male		42.0	PT	Percent		38.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2019	M	Male		48.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	51	Armenia	ARM	44.93839317	40.29499741	Northern Africa and Western Asia	2020	M	Male		48.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1996	M	Male		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1997	M	Male		21.0	PT	Percent		17.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1998	M	Male		30.0	PT	Percent		24.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	1999	M	Male		39.0	PT	Percent		31.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2000	M	Male		43.0	PT	Percent		34.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2001	M	Male		45.0	PT	Percent		36.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2002	M	Male		43.0	PT	Percent		35.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2003	M	Male		44.0	PT	Percent		35.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2004	M	Male		45.0	PT	Percent		37.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2005	M	Male		49.0	PT	Percent		40.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2006	M	Male		52.0	PT	Percent		43.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2007	M	Male		53.0	PT	Percent		43.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2008	M	Male		52.0	PT	Percent		42.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2009	M	Male		53.0	PT	Percent		44.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2010	M	Male		57.99999999999999	PT	Percent		48.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2011	M	Male		61.0	PT	Percent		50.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2012	M	Male		64.0	PT	Percent		52.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2013	M	Male		73.0	PT	Percent		60.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2014	M	Male		75.0	PT	Percent		62.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2015	M	Male		77.0	PT	Percent		63.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2016	M	Male		79.0	PT	Percent		64.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2017	M	Male		81.0	PT	Percent		65.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2018	M	Male		82.0	PT	Percent		66.0		94.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2019	M	Male		83.0	PT	Percent		67.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	36	Australia	AUS	134.3499412	-25.57717202	Australia and New Zealand	2020	M	Male		86.0	PT	Percent		69.0		99.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2007	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2008	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2009	M	Male		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2010	M	Male		8.0	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2011	M	Male		14.000000000000002	PT	Percent		10.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2012	M	Male		18.0	PT	Percent		14.000000000000002		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2013	M	Male		24.0	PT	Percent		18.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2014	M	Male		22.0	PT	Percent		17.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2015	M	Male		28.000000000000004	PT	Percent		22.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2016	M	Male		33.0	PT	Percent		26.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2017	M	Male		42.0	PT	Percent		32.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2018	M	Male		48.0	PT	Percent		38.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2019	M	Male		55.00000000000001	PT	Percent		43.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	31	Azerbaijan	AZE	50.01064725	40.39229544	Northern Africa and Western Asia	2020	M	Male		60.0	PT	Percent		47.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2003	M	Male		17.0	PT	Percent		13.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2004	M	Male		21.0	PT	Percent		16.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2005	M	Male		25.0	PT	Percent		20.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2006	M	Male		28.000000000000004	PT	Percent		23.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2007	M	Male		32.0	PT	Percent		27.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2008	M	Male		29.0	PT	Percent		24.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2009	M	Male		41.0	PT	Percent		35.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2010	M	Male		27.0	PT	Percent		23.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2011	M	Male		27.0	PT	Percent		23.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2012	M	Male		33.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2013	M	Male		39.0	PT	Percent		34.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2014	M	Male		49.0	PT	Percent		42.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2015	M	Male		47.0	PT	Percent		40.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2016	M	Male		49.0	PT	Percent		42.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2017	M	Male		63.0	PT	Percent		55.00000000000001		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2018	M	Male		69.0	PT	Percent		60.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2019	M	Male		66.0	PT	Percent		57.99999999999999		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	44	Bahamas	BHS	-78.05111663	24.69546597	Latin America and the Caribbean	2020	M	Male		61.0	PT	Percent		53.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2005	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2006	M	Male		8.0	PT	Percent		6.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2007	M	Male		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2008	M	Male		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2009	M	Male		13.0	PT	Percent		11.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2010	M	Male		15.0	PT	Percent		12.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2011	M	Male		16.0	PT	Percent		12.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2012	M	Male		19.0	PT	Percent		15.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2013	M	Male		23.0	PT	Percent		18.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2014	M	Male		22.0	PT	Percent		17.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2015	M	Male		24.0	PT	Percent		19.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2016	M	Male		25.0	PT	Percent		20.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2017	M	Male		35.0	PT	Percent		28.000000000000004		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2018	M	Male		48.0	PT	Percent		39.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2019	M	Male		54.0	PT	Percent		43.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	112	Belarus	BLR	28.04940161	53.54193075	Europe and Northern America	2020	M	Male		59.0	PT	Percent		47.0		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2002	M	Male		2.0	PT	Percent		1.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2003	M	Male		7.000000000000001	PT	Percent		4.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2004	M	Male		7.000000000000001	PT	Percent		4.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2005	M	Male		12.0	PT	Percent		7.000000000000001		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2006	M	Male		15.0	PT	Percent		9.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2007	M	Male		14.000000000000002	PT	Percent		9.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2008	M	Male		17.0	PT	Percent		11.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2009	M	Male		22.0	PT	Percent		14.000000000000002		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2010	M	Male		24.0	PT	Percent		16.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2011	M	Male		26.0	PT	Percent		17.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2012	M	Male		26.0	PT	Percent		17.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2013	M	Male		29.0	PT	Percent		19.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2014	M	Male		29.0	PT	Percent		19.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2015	M	Male		31.0	PT	Percent		20.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2016	M	Male		34.0	PT	Percent		23.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2017	M	Male		34.0	PT	Percent		23.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2018	M	Male		36.0	PT	Percent		24.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2019	M	Male		40.0	PT	Percent		26.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	84	Belize	BLZ	-88.70199554	17.19965901	Latin America and the Caribbean	2020	M	Male		37.0	PT	Percent		25.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2007	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2008	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2009	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2010	M	Male		25.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2011	M	Male		32.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2012	M	Male		34.0	PT	Percent		30.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2013	M	Male		30.0	PT	Percent		26.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2014	M	Male		34.0	PT	Percent		30.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2015	M	Male		40.0	PT	Percent		35.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2016	M	Male		45.0	PT	Percent		40.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2017	M	Male		45.0	PT	Percent		40.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2018	M	Male		43.0	PT	Percent		38.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2019	M	Male		56.99999999999999	PT	Percent		50.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	204	Benin	BEN	2.339933594	9.65401646	Sub-Saharan Africa	2020	M	Male		57.99999999999999	PT	Percent		52.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2006	M	Male		1.0	PT	Percent	<	1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2007	M	Male		2.0	PT	Percent	<	1.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2008	M	Male		2.0	PT	Percent		1.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2009	M	Male		3.0	PT	Percent		1.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2010	M	Male		4.0	PT	Percent		1.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2011	M	Male		4.0	PT	Percent		1.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2012	M	Male		6.0	PT	Percent		2.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2013	M	Male		8.0	PT	Percent		3.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2014	M	Male		10.0	PT	Percent		3.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2015	M	Male		15.0	PT	Percent		5.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2016	M	Male		17.0	PT	Percent		6.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2017	M	Male		22.0	PT	Percent		7.000000000000001		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2018	M	Male		27.0	PT	Percent		9.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2019	M	Male		31.0	PT	Percent		11.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	64	Bhutan	BTN	90.45098484	27.39598568	Central and Southern Asia	2020	M	Male		33.0	PT	Percent		12.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2002	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2003	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2004	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2005	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2006	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2007	M	Male		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2008	M	Male		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2009	M	Male		13.0	PT	Percent		11.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2010	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2011	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2012	M	Male		22.0	PT	Percent		19.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2013	M	Male		27.0	PT	Percent		23.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2014	M	Male		33.0	PT	Percent		28.000000000000004		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2015	M	Male		44.0	PT	Percent		36.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2016	M	Male		51.0	PT	Percent		42.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2017	M	Male		56.99999999999999	PT	Percent		48.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2018	M	Male		76.0	PT	Percent		63.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2019	M	Male		85.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	68	Bolivia (Plurinational State of)	BOL	-64.66224284	-16.71273412	Latin America and the Caribbean	2020	M	Male		87.0	PT	Percent		72.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2001	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2002	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2003	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2004	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2005	M	Male		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2006	M	Male		26.0	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2007	M	Male		31.0	PT	Percent		29.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2008	M	Male		38.0	PT	Percent		35.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2009	M	Male		39.0	PT	Percent		37.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2010	M	Male		44.0	PT	Percent		41.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2011	M	Male		49.0	PT	Percent		46.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2012	M	Male		52.0	PT	Percent		48.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2013	M	Male		57.99999999999999	PT	Percent		54.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2014	M	Male		57.99999999999999	PT	Percent		54.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2015	M	Male		62.0	PT	Percent		57.99999999999999		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2016	M	Male		65.0	PT	Percent		61.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2017	M	Male		68.0	PT	Percent		64.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2018	M	Male		71.0	PT	Percent		67.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2019	M	Male		74.0	PT	Percent		69.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	72	Botswana	BWA	23.81380223	-22.18810073	Sub-Saharan Africa	2020	M	Male		77.0	PT	Percent		72.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2004	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2005	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2006	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2007	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2008	M	Male		22.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2009	M	Male		27.0	PT	Percent		23.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2010	M	Male		32.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2011	M	Male		27.0	PT	Percent		23.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2012	M	Male		29.0	PT	Percent		25.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2013	M	Male		31.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2014	M	Male		34.0	PT	Percent		29.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2015	M	Male		40.0	PT	Percent		34.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2016	M	Male		43.0	PT	Percent		37.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2017	M	Male		48.0	PT	Percent		40.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2018	M	Male		46.0	PT	Percent		39.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2019	M	Male		54.0	PT	Percent		46.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	854	Burkina Faso	BFA	-1.742843829	12.27491081	Sub-Saharan Africa	2020	M	Male		62.0	PT	Percent		53.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2001	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2002	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2004	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2005	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2006	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2007	M	Male		12.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2008	M	Male		15.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2009	M	Male		19.0	PT	Percent		17.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2010	M	Male		25.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2011	M	Male		30.0	PT	Percent		27.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2012	M	Male		28.000000000000004	PT	Percent		25.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2013	M	Male		32.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2014	M	Male		36.0	PT	Percent		33.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2015	M	Male		43.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2016	M	Male		53.0	PT	Percent		48.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2017	M	Male		62.0	PT	Percent		56.00000000000001		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2018	M	Male		71.0	PT	Percent		64.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2019	M	Male		79.0	PT	Percent		71.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	108	Burundi	BDI	29.89080992	-3.366387428	Sub-Saharan Africa	2020	M	Male		82.0	PT	Percent		73.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2003	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2004	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2005	M	Male		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2006	M	Male		22.0	PT	Percent		20.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2007	M	Male		29.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2008	M	Male		36.0	PT	Percent		32.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2009	M	Male		43.0	PT	Percent		38.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2010	M	Male		49.0	PT	Percent		43.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2011	M	Male		53.0	PT	Percent		47.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2012	M	Male		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2013	M	Male		59.0	PT	Percent		53.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2014	M	Male		62.0	PT	Percent		56.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2015	M	Male		65.0	PT	Percent		57.99999999999999		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2016	M	Male		69.0	PT	Percent		62.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2017	M	Male		72.0	PT	Percent		65.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2018	M	Male		78.0	PT	Percent		70.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2019	M	Male		83.0	PT	Percent		74.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	116	Cambodia	KHM	104.922836	12.71163737	Eastern and South-Eastern Asia	2020	M	Male		86.0	PT	Percent		78.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2004	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2005	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2006	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2007	M	Male		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2008	M	Male		16.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2009	M	Male		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2010	M	Male		22.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2011	M	Male		26.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2012	M	Male		22.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2013	M	Male		23.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2014	M	Male		25.0	PT	Percent		23.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2015	M	Male		29.0	PT	Percent		27.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2016	M	Male		36.0	PT	Percent		33.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2017	M	Male		45.0	PT	Percent		41.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2018	M	Male		51.0	PT	Percent		47.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2019	M	Male		57.99999999999999	PT	Percent		54.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	120	Cameroon	CMR	12.7419827	5.692387031	Sub-Saharan Africa	2020	M	Male		70.0	PT	Percent		65.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2005	M	Male		7.000000000000001	PT	Percent		6.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2006	M	Male		12.0	PT	Percent		9.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2007	M	Male		17.0	PT	Percent		14.000000000000002		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2008	M	Male		21.0	PT	Percent		17.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2009	M	Male		22.0	PT	Percent		18.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2010	M	Male		29.0	PT	Percent		24.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2011	M	Male		29.0	PT	Percent		25.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2012	M	Male		35.0	PT	Percent		30.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2013	M	Male		41.0	PT	Percent		35.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2014	M	Male		51.0	PT	Percent		44.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2015	M	Male		55.00000000000001	PT	Percent		48.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2016	M	Male		64.0	PT	Percent		55.00000000000001		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2017	M	Male		65.0	PT	Percent		56.00000000000001		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2018	M	Male		80.0	PT	Percent		68.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2019	M	Male		83.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	132	Cabo Verde	CPV	-23.63544151	15.07791834	Sub-Saharan Africa	2020	M	Male		87.0	PT	Percent		73.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2006	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2007	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2008	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2009	M	Male		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2010	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2011	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2012	M	Male		16.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2013	M	Male		18.0	PT	Percent		15.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2014	M	Male		25.0	PT	Percent		21.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2015	M	Male		30.0	PT	Percent		25.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2016	M	Male		24.0	PT	Percent		20.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2017	M	Male		30.0	PT	Percent		25.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2018	M	Male		34.0	PT	Percent		28.000000000000004		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2019	M	Male		40.0	PT	Percent		33.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	140	Central African Republic	CAF	20.93559492	7.003720791	Sub-Saharan Africa	2020	M	Male		47.0	PT	Percent		38.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2006	M	Male		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2007	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2008	M	Male		22.0	PT	Percent		18.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2009	M	Male		27.0	PT	Percent		22.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2010	M	Male		32.0	PT	Percent		26.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2011	M	Male		32.0	PT	Percent		26.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2012	M	Male		35.0	PT	Percent		28.000000000000004		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2013	M	Male		36.0	PT	Percent		29.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2014	M	Male		43.0	PT	Percent		36.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2015	M	Male		53.0	PT	Percent		44.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2016	M	Male		33.0	PT	Percent		27.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2017	M	Male		40.0	PT	Percent		33.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2018	M	Male		49.0	PT	Percent		40.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2019	M	Male		56.99999999999999	PT	Percent		47.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	148	Chad	TCD	18.66618401	15.36279341	Sub-Saharan Africa	2020	M	Male		65.0	PT	Percent		53.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2001	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2002	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2003	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2004	M	Male		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2005	M	Male		7.000000000000001	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2006	M	Male		12.0	PT	Percent		10.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2007	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2008	M	Male		10.0	PT	Percent		8.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2009	M	Male		12.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2010	M	Male		17.0	PT	Percent		13.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2011	M	Male		23.0	PT	Percent		18.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2012	M	Male		26.0	PT	Percent		20.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2013	M	Male		30.0	PT	Percent		24.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2014	M	Male		35.0	PT	Percent		27.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2015	M	Male		40.0	PT	Percent		32.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2016	M	Male		44.0	PT	Percent		35.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2017	M	Male		44.0	PT	Percent		35.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2018	M	Male		45.0	PT	Percent		36.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2019	M	Male		46.0	PT	Percent		37.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	170	Colombia	COL	-73.07446751	3.888209046	Latin America and the Caribbean	2020	M	Male		59.0	PT	Percent		47.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2007	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2008	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2009	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2010	M	Male		14.000000000000002	PT	Percent		7.000000000000001		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2011	M	Male		15.0	PT	Percent		7.000000000000001		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2012	M	Male		19.0	PT	Percent		9.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2013	M	Male		22.0	PT	Percent		11.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2014	M	Male		24.0	PT	Percent		12.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2015	M	Male		37.0	PT	Percent		18.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2016	M	Male		28.000000000000004	PT	Percent		14.000000000000002		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2017	M	Male		35.0	PT	Percent		18.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2018	M	Male		45.0	PT	Percent		23.0		94.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2019	M	Male		55.00000000000001	PT	Percent		29.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	174	Comoros	COM	43.34234565	-11.66121732	Sub-Saharan Africa	2020	M	Male		60.0	PT	Percent		30.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2005	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2006	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2007	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2008	M	Male		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2009	M	Male		21.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2010	M	Male		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2011	M	Male		18.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2012	M	Male		20.0	PT	Percent		16.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2013	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2014	M	Male		21.0	PT	Percent		17.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2015	M	Male		27.0	PT	Percent		21.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2016	M	Male		28.000000000000004	PT	Percent		21.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2017	M	Male		29.0	PT	Percent		22.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2018	M	Male		32.0	PT	Percent		24.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2019	M	Male		23.0	PT	Percent		17.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	178	Congo	COG	15.22052612	-0.840544119	Sub-Saharan Africa	2020	M	Male		24.0	PT	Percent		17.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2000	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2001	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2002	M	Male		21.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2003	M	Male		24.0	PT	Percent		21.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2004	M	Male		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2005	M	Male		30.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2006	M	Male		33.0	PT	Percent		29.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2007	M	Male		35.0	PT	Percent		31.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2008	M	Male		38.0	PT	Percent		34.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2009	M	Male		40.0	PT	Percent		36.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2010	M	Male		67.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2011	M	Male		69.0	PT	Percent		62.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2012	M	Male		70.0	PT	Percent		62.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2013	M	Male		70.0	PT	Percent		62.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2014	M	Male		72.0	PT	Percent		64.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2015	M	Male		79.0	PT	Percent		70.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2016	M	Male		80.0	PT	Percent		70.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2017	M	Male		83.0	PT	Percent		72.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2018	M	Male		89.0	PT	Percent		77.0		99.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2019	M	Male		94.0	PT	Percent		81.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	188	Costa Rica	CRI	-84.19712782	9.970998683	Latin America and the Caribbean	2020	M	Male		66.0	PT	Percent		56.00000000000001		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2006	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2007	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2008	M	Male		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2009	M	Male		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2010	M	Male		13.0	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2011	M	Male		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2012	M	Male		19.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2013	M	Male		22.0	PT	Percent		20.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2014	M	Male		25.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2015	M	Male		29.0	PT	Percent		25.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2016	M	Male		34.0	PT	Percent		30.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2017	M	Male		41.0	PT	Percent		36.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2018	M	Male		49.0	PT	Percent		44.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2019	M	Male		57.99999999999999	PT	Percent		52.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	384	Côte d'Ivoire	CIV	-5.552690016	7.62211586	Sub-Saharan Africa	2020	M	Male		61.0	PT	Percent		55.00000000000001		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1996	M	Male		8.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1997	M	Male		15.0	PT	Percent		12.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1998	M	Male		20.0	PT	Percent		15.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	1999	M	Male		23.0	PT	Percent		18.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2000	M	Male		25.0	PT	Percent		20.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2001	M	Male		27.0	PT	Percent		22.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2002	M	Male		29.0	PT	Percent		23.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2003	M	Male		30.0	PT	Percent		24.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2004	M	Male		31.0	PT	Percent		25.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2005	M	Male		31.0	PT	Percent		25.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2006	M	Male		33.0	PT	Percent		26.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2007	M	Male		35.0	PT	Percent		29.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2008	M	Male		39.0	PT	Percent		32.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2009	M	Male		39.0	PT	Percent		32.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2010	M	Male		43.0	PT	Percent		35.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2011	M	Male		46.0	PT	Percent		37.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2012	M	Male		50.0	PT	Percent		41.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2013	M	Male		52.0	PT	Percent		42.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2014	M	Male		56.00000000000001	PT	Percent		45.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2015	M	Male		62.0	PT	Percent		50.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2016	M	Male		67.0	PT	Percent		54.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2017	M	Male		70.0	PT	Percent		56.00000000000001		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2018	M	Male		72.0	PT	Percent		57.99999999999999		87.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2019	M	Male		73.0	PT	Percent		59.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	191	Croatia	HRV	17.95874553	45.45172212	Europe and Northern America	2020	M	Male		75.0	PT	Percent		60.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2000	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2001	M	Male		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2002	M	Male		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2003	M	Male		26.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2004	M	Male		28.000000000000004	PT	Percent		24.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2005	M	Male		30.0	PT	Percent		25.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2006	M	Male		34.0	PT	Percent		29.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2007	M	Male		37.0	PT	Percent		31.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2008	M	Male		41.0	PT	Percent		35.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2009	M	Male		45.0	PT	Percent		38.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2010	M	Male		49.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2011	M	Male		55.00000000000001	PT	Percent		47.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2012	M	Male		59.0	PT	Percent		49.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2013	M	Male		63.0	PT	Percent		53.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2014	M	Male		72.0	PT	Percent		61.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2015	M	Male		81.0	PT	Percent		69.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2016	M	Male		86.0	PT	Percent		72.0		98.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2017	M	Male		92.0	PT	Percent		77.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2018	M	Male	>	98.0	PT	Percent		82.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2019	M	Male	>	98.0	PT	Percent		86.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	192	Cuba	CUB	-79.54460144	22.10030366	Latin America and the Caribbean	2020	M	Male	>	98.0	PT	Percent		82.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2005	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2006	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2007	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2008	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2009	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2010	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2011	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2012	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2013	M	Male		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2014	M	Male		22.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2015	M	Male		27.0	PT	Percent		23.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2016	M	Male		40.0	PT	Percent		34.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2017	M	Male		50.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2018	M	Male		63.0	PT	Percent		54.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2019	M	Male		83.0	PT	Percent		71.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	180	Democratic Republic of the Congo	COD	23.65496507	-2.877154732	Sub-Saharan Africa	2020	M	Male	>	98.0	PT	Percent		85.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1997	M	Male		43.0	PT	Percent		36.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1998	M	Male		45.0	PT	Percent		37.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	1999	M	Male		49.0	PT	Percent		41.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2000	M	Male		49.0	PT	Percent		40.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2001	M	Male		50.0	PT	Percent		41.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2002	M	Male		51.0	PT	Percent		41.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2003	M	Male		52.0	PT	Percent		42.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2004	M	Male		53.0	PT	Percent		43.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2005	M	Male		53.0	PT	Percent		43.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2006	M	Male		55.00000000000001	PT	Percent		44.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2007	M	Male		55.00000000000001	PT	Percent		44.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2008	M	Male		59.0	PT	Percent		46.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2009	M	Male		62.0	PT	Percent		49.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2010	M	Male		65.0	PT	Percent		52.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2011	M	Male		68.0	PT	Percent		54.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2012	M	Male		71.0	PT	Percent		55.00000000000001		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2013	M	Male		71.0	PT	Percent		55.00000000000001		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2014	M	Male		75.0	PT	Percent		57.99999999999999		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2015	M	Male		77.0	PT	Percent		61.0		94.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2016	M	Male		80.0	PT	Percent		63.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2017	M	Male		83.0	PT	Percent		65.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2018	M	Male		86.0	PT	Percent		67.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2019	M	Male		89.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	208	Denmark	DNK	9.326571283	56.03829721	Europe and Northern America	2020	M	Male		90.0	PT	Percent		71.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2003	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2006	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2007	M	Male		6.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2008	M	Male		7.000000000000001	PT	Percent		5.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2009	M	Male		9.0	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2010	M	Male		10.0	PT	Percent		7.000000000000001		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2011	M	Male		11.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2012	M	Male		15.0	PT	Percent		11.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2013	M	Male		17.0	PT	Percent		12.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2014	M	Male		18.0	PT	Percent		13.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2015	M	Male		26.0	PT	Percent		19.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2016	M	Male		31.0	PT	Percent		23.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2017	M	Male		31.0	PT	Percent		23.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2018	M	Male		35.0	PT	Percent		26.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2019	M	Male		32.0	PT	Percent		23.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	262	Djibouti	DJI	42.18274707	11.56004161	Sub-Saharan Africa	2020	M	Male		35.0	PT	Percent		26.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2004	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2005	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2006	M	Male		4.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2007	M	Male		8.0	PT	Percent		6.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2008	M	Male		10.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2009	M	Male		13.0	PT	Percent		10.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2010	M	Male		16.0	PT	Percent		12.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2011	M	Male		19.0	PT	Percent		15.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2012	M	Male		22.0	PT	Percent		17.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2013	M	Male		25.0	PT	Percent		20.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2014	M	Male		29.0	PT	Percent		23.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2015	M	Male		32.0	PT	Percent		26.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2016	M	Male		35.0	PT	Percent		28.000000000000004		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2017	M	Male		38.0	PT	Percent		31.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2018	M	Male		42.0	PT	Percent		34.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2019	M	Male		46.0	PT	Percent		37.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	214	Dominican Republic	DOM	-70.49847576	18.89832088	Latin America and the Caribbean	2020	M	Male		50.0	PT	Percent		41.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1995	M	Male		2.0	PT	Percent		1.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1996	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1997	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1998	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	1999	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2000	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2001	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2002	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2003	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2004	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2005	M	Male		5.0	PT	Percent		3.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2006	M	Male		6.0	PT	Percent		4.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2007	M	Male		9.0	PT	Percent		7.000000000000001		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2008	M	Male		13.0	PT	Percent		9.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2009	M	Male		18.0	PT	Percent		13.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2010	M	Male		23.0	PT	Percent		16.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2011	M	Male		28.000000000000004	PT	Percent		20.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2012	M	Male		27.0	PT	Percent		19.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2013	M	Male		24.0	PT	Percent		17.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2014	M	Male		29.0	PT	Percent		20.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2015	M	Male		36.0	PT	Percent		25.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2016	M	Male		45.0	PT	Percent		31.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2017	M	Male		51.0	PT	Percent		35.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2018	M	Male		57.99999999999999	PT	Percent		40.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2019	M	Male		69.0	PT	Percent		48.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	218	Ecuador	ECU	-78.37005241	-1.447785891	Latin America and the Caribbean	2020	M	Male		73.0	PT	Percent		50.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2006	M	Male		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2007	M	Male		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2008	M	Male		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2009	M	Male		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2010	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2011	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2012	M	Male		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2013	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2014	M	Male		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2015	M	Male		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2016	M	Male		21.0	PT	Percent		19.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2017	M	Male		28.000000000000004	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2018	M	Male		34.0	PT	Percent		30.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2019	M	Male		39.0	PT	Percent		35.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	818	Egypt	EGY	29.77468534	26.57438204	Northern Africa and Western Asia	2020	M	Male		45.0	PT	Percent		40.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2001	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2002	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2003	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2004	M	Male		14.000000000000002	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2005	M	Male		22.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2006	M	Male		30.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2007	M	Male		35.0	PT	Percent		31.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2008	M	Male		40.0	PT	Percent		35.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2009	M	Male		46.0	PT	Percent		41.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2010	M	Male		52.0	PT	Percent		46.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2011	M	Male		51.0	PT	Percent		45.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2012	M	Male		47.0	PT	Percent		41.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2013	M	Male		50.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2014	M	Male		50.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2015	M	Male		52.0	PT	Percent		47.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2016	M	Male		54.0	PT	Percent		49.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2017	M	Male		54.0	PT	Percent		49.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2018	M	Male		55.00000000000001	PT	Percent		49.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2019	M	Male		66.0	PT	Percent		59.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	222	El Salvador	SLV	-88.86862995	13.73603564	Latin America and the Caribbean	2020	M	Male		69.0	PT	Percent		62.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2005	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2006	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2007	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2008	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2009	M	Male		13.0	PT	Percent		10.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2010	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2011	M	Male		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2012	M	Male		12.0	PT	Percent		10.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2013	M	Male		15.0	PT	Percent		12.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2014	M	Male		16.0	PT	Percent		13.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2015	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2016	M	Male		14.000000000000002	PT	Percent		12.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2017	M	Male		19.0	PT	Percent		15.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2018	M	Male		18.0	PT	Percent		14.000000000000002		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2019	M	Male		19.0	PT	Percent		15.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	226	Equatorial Guinea	GNQ	10.46535826	1.565792376	Sub-Saharan Africa	2020	M	Male		21.0	PT	Percent		16.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2005	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2006	M	Male		9.0	PT	Percent		6.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2007	M	Male		14.000000000000002	PT	Percent		11.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2008	M	Male		20.0	PT	Percent		15.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2009	M	Male		27.0	PT	Percent		21.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2010	M	Male		33.0	PT	Percent		26.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2011	M	Male		38.0	PT	Percent		30.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2012	M	Male		47.0	PT	Percent		37.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2013	M	Male		53.0	PT	Percent		42.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2014	M	Male		59.0	PT	Percent		46.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2015	M	Male		65.0	PT	Percent		50.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2016	M	Male		70.0	PT	Percent		54.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2017	M	Male		64.0	PT	Percent		49.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2018	M	Male		64.0	PT	Percent		49.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2019	M	Male		66.0	PT	Percent		51.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	232	Eritrea	ERI	38.11074289	16.12894644	Sub-Saharan Africa	2020	M	Male		73.0	PT	Percent		56.00000000000001		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2000	M	Male		6.0	PT	Percent		3.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2001	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2002	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2003	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2004	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2005	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2006	M	Male		10.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2007	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2008	M	Male		19.0	PT	Percent		15.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2009	M	Male		24.0	PT	Percent		19.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2010	M	Male		31.0	PT	Percent		25.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2011	M	Male		36.0	PT	Percent		30.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2012	M	Male		41.0	PT	Percent		34.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2013	M	Male		43.0	PT	Percent		36.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2014	M	Male		47.0	PT	Percent		39.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2015	M	Male		53.0	PT	Percent		45.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2016	M	Male		57.99999999999999	PT	Percent		49.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2017	M	Male		60.0	PT	Percent		51.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2018	M	Male		62.0	PT	Percent		53.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2019	M	Male		64.0	PT	Percent		55.00000000000001		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	233	Estonia	EST	25.84093481	58.68487172	Europe and Northern America	2020	M	Male		65.0	PT	Percent		56.00000000000001		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2001	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2002	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2003	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2004	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2005	M	Male		7.000000000000001	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2006	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2007	M	Male		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2008	M	Male		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2009	M	Male		24.0	PT	Percent		22.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2010	M	Male		33.0	PT	Percent		31.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2011	M	Male		36.0	PT	Percent		34.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2012	M	Male		41.0	PT	Percent		38.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2013	M	Male		47.0	PT	Percent		43.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2014	M	Male		56.00000000000001	PT	Percent		52.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2015	M	Male		63.0	PT	Percent		57.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2016	M	Male		71.0	PT	Percent		66.0		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2017	M	Male		78.0	PT	Percent		72.0		85.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2018	M	Male		80.0	PT	Percent		73.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2019	M	Male		87.0	PT	Percent		80.0		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	748	Eswatini	SWZ	31.50149288	-26.56471011	Sub-Saharan Africa	2020	M	Male		94.0	PT	Percent		86.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2005	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2006	M	Male		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2007	M	Male		17.0	PT	Percent		14.000000000000002		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2008	M	Male		24.0	PT	Percent		19.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2009	M	Male		31.0	PT	Percent		25.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2010	M	Male		38.0	PT	Percent		31.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2011	M	Male		45.0	PT	Percent		36.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2012	M	Male		51.0	PT	Percent		42.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2013	M	Male		53.0	PT	Percent		43.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2014	M	Male		60.0	PT	Percent		49.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2015	M	Male		61.0	PT	Percent		50.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2016	M	Male		69.0	PT	Percent		56.00000000000001		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2017	M	Male		71.0	PT	Percent		57.99999999999999		87.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2018	M	Male		73.0	PT	Percent		59.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2019	M	Male		78.0	PT	Percent		63.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	231	Ethiopia	ETH	39.63505296	8.631223181	Sub-Saharan Africa	2020	M	Male		81.0	PT	Percent		65.0		99.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2004	M	Male		3.0	PT	Percent		2.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2005	M	Male		8.0	PT	Percent		6.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2006	M	Male		9.0	PT	Percent		6.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2007	M	Male		11.0	PT	Percent		8.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2008	M	Male		13.0	PT	Percent		9.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2009	M	Male		14.000000000000002	PT	Percent		10.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2010	M	Male		14.000000000000002	PT	Percent		10.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2011	M	Male		17.0	PT	Percent		12.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2012	M	Male		24.0	PT	Percent		18.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2013	M	Male		23.0	PT	Percent		17.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2014	M	Male		25.0	PT	Percent		18.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2015	M	Male		24.0	PT	Percent		17.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2016	M	Male		20.0	PT	Percent		14.000000000000002		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2017	M	Male		22.0	PT	Percent		15.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2018	M	Male		26.0	PT	Percent		17.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2019	M	Male		30.0	PT	Percent		19.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	242	Fiji	FJI	177.9660884	-17.83301566	Oceania, exc. Australia and New Zealand	2020	M	Male		35.0	PT	Percent		21.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2002	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2003	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2004	M	Male		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2005	M	Male		19.0	PT	Percent		15.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2006	M	Male		21.0	PT	Percent		17.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2007	M	Male		25.0	PT	Percent		19.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2008	M	Male		28.000000000000004	PT	Percent		22.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2009	M	Male		35.0	PT	Percent		28.000000000000004		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2010	M	Male		37.0	PT	Percent		30.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2011	M	Male		41.0	PT	Percent		34.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2012	M	Male		38.0	PT	Percent		31.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2013	M	Male		49.0	PT	Percent		41.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2014	M	Male		53.0	PT	Percent		45.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2015	M	Male		64.0	PT	Percent		54.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2016	M	Male		66.0	PT	Percent		55.00000000000001		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2017	M	Male		78.0	PT	Percent		65.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2018	M	Male		85.0	PT	Percent		71.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2019	M	Male		61.0	PT	Percent		51.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	266	Gabon	GAB	11.78727747	-0.60687619	Sub-Saharan Africa	2020	M	Male		56.00000000000001	PT	Percent		47.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2006	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2007	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2008	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2009	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2010	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2011	M	Male		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2012	M	Male		13.0	PT	Percent		10.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2013	M	Male		13.0	PT	Percent		10.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2014	M	Male		14.000000000000002	PT	Percent		11.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2015	M	Male		14.000000000000002	PT	Percent		11.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2016	M	Male		16.0	PT	Percent		13.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2017	M	Male		16.0	PT	Percent		12.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2018	M	Male		17.0	PT	Percent		13.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2019	M	Male		18.0	PT	Percent		14.000000000000002		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	270	Gambia	GMB	-15.39944785	13.45295927	Sub-Saharan Africa	2020	M	Male		19.0	PT	Percent		15.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2004	M	Male		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2005	M	Male		14.000000000000002	PT	Percent		11.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2006	M	Male		20.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2007	M	Male		20.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2008	M	Male		24.0	PT	Percent		21.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2009	M	Male		26.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2010	M	Male		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2011	M	Male		32.0	PT	Percent		29.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2012	M	Male		41.0	PT	Percent		37.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2013	M	Male		45.0	PT	Percent		42.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2014	M	Male		48.0	PT	Percent		44.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2015	M	Male		53.0	PT	Percent		49.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2016	M	Male		57.99999999999999	PT	Percent		53.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2017	M	Male		61.0	PT	Percent		56.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2018	M	Male		64.0	PT	Percent		57.99999999999999		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2019	M	Male		66.0	PT	Percent		60.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	268	Georgia	GEO	43.3713615	42.04813028	Northern Africa and Western Asia	2020	M	Male		67.0	PT	Percent		57.99999999999999		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1995	M	Male		25.0	PT	Percent		20.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1996	M	Male		28.000000000000004	PT	Percent		22.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1997	M	Male		33.0	PT	Percent		26.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1998	M	Male		37.0	PT	Percent		29.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	1999	M	Male		41.0	PT	Percent		32.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2000	M	Male		45.0	PT	Percent		35.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2001	M	Male		48.0	PT	Percent		38.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2002	M	Male		51.0	PT	Percent		40.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2003	M	Male		53.0	PT	Percent		41.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2004	M	Male		55.00000000000001	PT	Percent		43.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2005	M	Male		56.99999999999999	PT	Percent		44.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2006	M	Male		55.00000000000001	PT	Percent		43.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2007	M	Male		56.99999999999999	PT	Percent		44.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2008	M	Male		59.0	PT	Percent		46.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2009	M	Male		61.0	PT	Percent		47.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2010	M	Male		64.0	PT	Percent		49.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2011	M	Male		67.0	PT	Percent		51.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2012	M	Male		69.0	PT	Percent		53.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2013	M	Male		71.0	PT	Percent		54.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2014	M	Male		72.0	PT	Percent		56.00000000000001		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2015	M	Male		75.0	PT	Percent		56.99999999999999		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2016	M	Male		77.0	PT	Percent		59.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2017	M	Male		79.0	PT	Percent		60.0		94.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2018	M	Male		81.0	PT	Percent		62.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2019	M	Male		85.0	PT	Percent		65.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	276	Germany	DEU	10.3806066	51.08862743	Europe and Northern America	2020	M	Male		86.0	PT	Percent		66.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2006	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2007	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2008	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2009	M	Male		13.0	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2010	M	Male		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2011	M	Male		22.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2012	M	Male		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2013	M	Male		25.0	PT	Percent		22.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2014	M	Male		26.0	PT	Percent		23.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2015	M	Male		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2016	M	Male		20.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2017	M	Male		22.0	PT	Percent		20.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2018	M	Male		25.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2019	M	Male		35.0	PT	Percent		31.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	288	Ghana	GHA	-1.205623522	7.964825185	Sub-Saharan Africa	2020	M	Male		49.0	PT	Percent		43.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1995	M	Male		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1996	M	Male		25.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1997	M	Male		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1998	M	Male		38.0	PT	Percent		34.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	1999	M	Male		42.0	PT	Percent		37.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2000	M	Male		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2001	M	Male		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2002	M	Male		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2003	M	Male		44.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2004	M	Male		43.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2005	M	Male		43.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2006	M	Male		43.0	PT	Percent		39.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2007	M	Male		43.0	PT	Percent		39.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2008	M	Male		42.0	PT	Percent		39.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2009	M	Male		42.0	PT	Percent		38.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2010	M	Male		41.0	PT	Percent		38.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2011	M	Male		42.0	PT	Percent		39.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2012	M	Male		44.0	PT	Percent		41.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2013	M	Male		47.0	PT	Percent		44.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2014	M	Male		51.0	PT	Percent		47.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2015	M	Male		56.00000000000001	PT	Percent		52.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2016	M	Male		61.0	PT	Percent		56.00000000000001		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2017	M	Male		63.0	PT	Percent		57.99999999999999		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2018	M	Male		66.0	PT	Percent		61.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2019	M	Male		68.0	PT	Percent		62.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	300	Greece	GRC	22.58307827	39.47301873	Europe and Northern America	2020	M	Male		67.0	PT	Percent		61.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2003	M	Male		15.0	PT	Percent		12.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2004	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2005	M	Male		14.000000000000002	PT	Percent		11.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2006	M	Male		21.0	PT	Percent		17.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2007	M	Male		30.0	PT	Percent		25.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2008	M	Male		38.0	PT	Percent		31.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2009	M	Male		37.0	PT	Percent		30.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2010	M	Male		41.0	PT	Percent		34.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2011	M	Male		41.0	PT	Percent		33.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2012	M	Male		47.0	PT	Percent		38.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2013	M	Male		49.0	PT	Percent		40.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2014	M	Male		49.0	PT	Percent		40.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2015	M	Male		49.0	PT	Percent		40.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2016	M	Male		52.0	PT	Percent		42.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2017	M	Male		56.99999999999999	PT	Percent		48.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2018	M	Male		66.0	PT	Percent		55.00000000000001		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2019	M	Male		71.0	PT	Percent		59.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	320	Guatemala	GTM	-91.2312746	15.00273719	Latin America and the Caribbean	2020	M	Male		73.0	PT	Percent		61.0		94.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2005	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2006	M	Male		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2007	M	Male		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2008	M	Male		14.000000000000002	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2009	M	Male		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2010	M	Male		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2011	M	Male		32.0	PT	Percent		30.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2012	M	Male		29.0	PT	Percent		27.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2013	M	Male		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2014	M	Male		30.0	PT	Percent		28.000000000000004		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2015	M	Male		30.0	PT	Percent		28.000000000000004		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2016	M	Male		31.0	PT	Percent		29.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2017	M	Male		43.0	PT	Percent		40.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2018	M	Male		36.0	PT	Percent		34.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2019	M	Male		43.0	PT	Percent		41.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	324	Guinea	GIN	-11.28173419	11.00210343	Sub-Saharan Africa	2020	M	Male		46.0	PT	Percent		43.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2006	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2007	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2008	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2009	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2010	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2011	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2012	M	Male		13.0	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2013	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2014	M	Male		16.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2015	M	Male		19.0	PT	Percent		17.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2016	M	Male		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2017	M	Male		22.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2018	M	Male		20.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2019	M	Male		31.0	PT	Percent		28.000000000000004		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	624	Guinea-Bissau	GNB	-14.40182514	12.11760394	Sub-Saharan Africa	2020	M	Male		40.0	PT	Percent		35.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2003	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2004	M	Male		11.0	PT	Percent		9.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2005	M	Male		25.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2006	M	Male		30.0	PT	Percent		25.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2007	M	Male		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2008	M	Male		36.0	PT	Percent		31.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2009	M	Male		39.0	PT	Percent		34.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2010	M	Male		40.0	PT	Percent		35.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2011	M	Male		42.0	PT	Percent		37.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2012	M	Male		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2013	M	Male		46.0	PT	Percent		41.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2014	M	Male		48.0	PT	Percent		43.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2015	M	Male		49.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2016	M	Male		52.0	PT	Percent		46.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2017	M	Male		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2018	M	Male		59.0	PT	Percent		52.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2019	M	Male		62.0	PT	Percent		54.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	328	Guyana	GUY	-58.97322037	4.788012784	Latin America and the Caribbean	2020	M	Male		60.0	PT	Percent		53.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2005	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2006	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2007	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2008	M	Male		15.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2009	M	Male		19.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2010	M	Male		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2011	M	Male		24.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2012	M	Male		27.0	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2013	M	Male		33.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2014	M	Male		38.0	PT	Percent		34.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2015	M	Male		41.0	PT	Percent		37.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2016	M	Male		49.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2017	M	Male		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2018	M	Male		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2019	M	Male		67.0	PT	Percent		60.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	332	Haiti	HTI	-72.33640958	18.40426539	Latin America and the Caribbean	2020	M	Male		75.0	PT	Percent		66.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2002	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2003	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2004	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2005	M	Male		11.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2006	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2007	M	Male		17.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2008	M	Male		19.0	PT	Percent		17.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2009	M	Male		22.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2010	M	Male		26.0	PT	Percent		22.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2011	M	Male		29.0	PT	Percent		25.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2012	M	Male		31.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2013	M	Male		34.0	PT	Percent		30.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2014	M	Male		36.0	PT	Percent		32.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2015	M	Male		39.0	PT	Percent		34.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2016	M	Male		41.0	PT	Percent		36.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2017	M	Male		45.0	PT	Percent		39.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2018	M	Male		47.0	PT	Percent		41.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2019	M	Male		49.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	340	Honduras	HND	-86.59974381	14.82243161	Latin America and the Caribbean	2020	M	Male		50.0	PT	Percent		44.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1998	M	Male		11.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	1999	M	Male		20.0	PT	Percent		14.000000000000002		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2000	M	Male		27.0	PT	Percent		20.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2001	M	Male		33.0	PT	Percent		25.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2002	M	Male		36.0	PT	Percent		27.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2003	M	Male		40.0	PT	Percent		31.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2004	M	Male		43.0	PT	Percent		34.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2005	M	Male		47.0	PT	Percent		37.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2006	M	Male		48.0	PT	Percent		38.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2007	M	Male		50.0	PT	Percent		39.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2008	M	Male		52.0	PT	Percent		41.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2009	M	Male		53.0	PT	Percent		42.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2010	M	Male		55.00000000000001	PT	Percent		44.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2011	M	Male		56.00000000000001	PT	Percent		46.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2012	M	Male		56.99999999999999	PT	Percent		47.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2013	M	Male		59.0	PT	Percent		49.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2014	M	Male		61.0	PT	Percent		50.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2015	M	Male		62.0	PT	Percent		50.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2016	M	Male		64.0	PT	Percent		52.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2017	M	Male		75.0	PT	Percent		61.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2018	M	Male		78.0	PT	Percent		64.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2019	M	Male		82.0	PT	Percent		68.0		98.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	352	Iceland	ISL	-19.02116966	64.79134763	Europe and Northern America	2020	M	Male		86.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2006	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2007	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2008	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2009	M	Male		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2010	M	Male		5.0	PT	Percent		5.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2011	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2012	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2013	M	Male		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2014	M	Male		9.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2015	M	Male		11.0	PT	Percent		11.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2016	M	Male		14.000000000000002	PT	Percent		14.000000000000002		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2017	M	Male		17.0	PT	Percent		16.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2018	M	Male		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2019	M	Male		24.0	PT	Percent		23.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	360	Indonesia	IDN	113.9174	-0.994582204	Eastern and South-Eastern Asia	2020	M	Male		28.000000000000004	PT	Percent		26.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2006	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2007	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2008	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2009	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2010	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2011	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2012	M	Male		4.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2013	M	Male		6.0	PT	Percent		4.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2014	M	Male		7.000000000000001	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2015	M	Male		10.0	PT	Percent		7.000000000000001		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2016	M	Male		13.0	PT	Percent		10.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2017	M	Male		17.0	PT	Percent		13.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2018	M	Male		21.0	PT	Percent		16.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2019	M	Male		25.0	PT	Percent		18.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	364	Iran (Islamic Republic of)	IRN	54.19766348	32.74370885	Central and Southern Asia	2020	M	Male		26.0	PT	Percent		19.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1996	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1997	M	Male		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1998	M	Male		30.0	PT	Percent		26.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	1999	M	Male		40.0	PT	Percent		34.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2000	M	Male		48.0	PT	Percent		41.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2001	M	Male		53.0	PT	Percent		45.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2002	M	Male		56.00000000000001	PT	Percent		48.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2003	M	Male		59.0	PT	Percent		50.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2004	M	Male		60.0	PT	Percent		51.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2005	M	Male		61.0	PT	Percent		52.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2006	M	Male		61.0	PT	Percent		52.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2007	M	Male		60.0	PT	Percent		51.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2008	M	Male		60.0	PT	Percent		51.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2009	M	Male		59.0	PT	Percent		50.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2010	M	Male		57.99999999999999	PT	Percent		49.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2011	M	Male		61.0	PT	Percent		52.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2012	M	Male		64.0	PT	Percent		54.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2013	M	Male		67.0	PT	Percent		56.00000000000001		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2014	M	Male		70.0	PT	Percent		57.99999999999999		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2015	M	Male		71.0	PT	Percent		59.0		87.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2016	M	Male		76.0	PT	Percent		62.0		94.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2017	M	Male		77.0	PT	Percent		61.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2018	M	Male		80.0	PT	Percent		62.0		99.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2019	M	Male		84.0	PT	Percent		66.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	372	Ireland	IRL	-7.121425272	53.25274054	Europe and Northern America	2020	M	Male		85.0	PT	Percent		65.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1996	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1997	M	Male		9.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1998	M	Male		17.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	1999	M	Male		23.0	PT	Percent		20.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2000	M	Male		30.0	PT	Percent		25.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2001	M	Male		35.0	PT	Percent		29.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2002	M	Male		39.0	PT	Percent		33.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2003	M	Male		43.0	PT	Percent		36.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2004	M	Male		47.0	PT	Percent		39.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2005	M	Male		50.0	PT	Percent		41.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2006	M	Male		53.0	PT	Percent		44.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2007	M	Male		56.00000000000001	PT	Percent		46.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2008	M	Male		59.0	PT	Percent		49.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2009	M	Male		61.0	PT	Percent		51.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2010	M	Male		64.0	PT	Percent		53.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2011	M	Male		66.0	PT	Percent		55.00000000000001		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2012	M	Male		67.0	PT	Percent		55.00000000000001		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2013	M	Male		70.0	PT	Percent		57.99999999999999		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2014	M	Male		73.0	PT	Percent		60.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2015	M	Male		75.0	PT	Percent		61.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2016	M	Male		76.0	PT	Percent		62.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2017	M	Male		81.0	PT	Percent		66.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2018	M	Male		85.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2019	M	Male		86.0	PT	Percent		69.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	380	Italy	ITA	12.57022427	42.79917282	Europe and Northern America	2020	M	Male		89.0	PT	Percent		72.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2004	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2005	M	Male		6.0	PT	Percent		5.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2006	M	Male		7.000000000000001	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2007	M	Male		11.0	PT	Percent		8.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2008	M	Male		13.0	PT	Percent		10.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2009	M	Male		18.0	PT	Percent		15.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2010	M	Male		22.0	PT	Percent		17.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2011	M	Male		24.0	PT	Percent		19.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2012	M	Male		27.0	PT	Percent		22.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2013	M	Male		28.000000000000004	PT	Percent		22.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2014	M	Male		30.0	PT	Percent		24.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2015	M	Male		32.0	PT	Percent		25.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2016	M	Male		34.0	PT	Percent		27.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2017	M	Male		35.0	PT	Percent		28.000000000000004		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2018	M	Male		37.0	PT	Percent		30.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2019	M	Male		41.0	PT	Percent		32.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	388	Jamaica	JAM	-77.31068409	18.15616857	Latin America and the Caribbean	2020	M	Male		37.0	PT	Percent		30.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2000	M	Male		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2001	M	Male		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2002	M	Male		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2003	M	Male		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2004	M	Male		14.000000000000002	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2005	M	Male		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2006	M	Male		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2007	M	Male		23.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2008	M	Male		24.0	PT	Percent		22.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2009	M	Male		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2010	M	Male		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2011	M	Male		27.0	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2012	M	Male		28.000000000000004	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2013	M	Male		30.0	PT	Percent		27.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2014	M	Male		30.0	PT	Percent		27.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2015	M	Male		32.0	PT	Percent		29.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2016	M	Male		36.0	PT	Percent		33.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2017	M	Male		38.0	PT	Percent		34.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2018	M	Male		41.0	PT	Percent		37.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2019	M	Male		44.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	400	Jordan	JOR	37.13024774	30.65365973	Northern Africa and Western Asia	2020	M	Male		44.0	PT	Percent		40.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2005	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2006	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2007	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2008	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2009	M	Male		5.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2010	M	Male		6.0	PT	Percent		4.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2011	M	Male		9.0	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2012	M	Male		13.0	PT	Percent		8.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2013	M	Male		16.0	PT	Percent		10.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2014	M	Male		19.0	PT	Percent		12.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2015	M	Male		23.0	PT	Percent		15.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2016	M	Male		27.0	PT	Percent		18.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2017	M	Male		34.0	PT	Percent		22.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2018	M	Male		42.0	PT	Percent		27.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2019	M	Male		46.0	PT	Percent		30.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	398	Kazakhstan	KAZ	66.65359159	48.01963494	Central and Southern Asia	2020	M	Male		49.0	PT	Percent		31.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2004	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2005	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2006	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2007	M	Male		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2008	M	Male		23.0	PT	Percent		20.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2009	M	Male		31.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2010	M	Male		37.0	PT	Percent		33.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2011	M	Male		36.0	PT	Percent		31.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2012	M	Male		39.0	PT	Percent		35.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2013	M	Male		41.0	PT	Percent		36.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2014	M	Male		46.0	PT	Percent		40.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2015	M	Male		55.00000000000001	PT	Percent		48.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2016	M	Male		61.0	PT	Percent		53.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2017	M	Male		67.0	PT	Percent		59.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2018	M	Male		67.0	PT	Percent		59.0		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2019	M	Male		72.0	PT	Percent		63.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	404	Kenya	KEN	37.86096816	0.534797278	Sub-Saharan Africa	2020	M	Male		77.0	PT	Percent		68.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2005	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2006	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2007	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2008	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2009	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2010	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2011	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2012	M	Male		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2013	M	Male		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2014	M	Male		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2015	M	Male		21.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2016	M	Male		26.0	PT	Percent		24.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2017	M	Male		29.0	PT	Percent		27.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2018	M	Male		33.0	PT	Percent		30.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2019	M	Male		34.0	PT	Percent		31.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	417	Kyrgyzstan	KGZ	74.52324839	41.46204516	Central and Southern Asia	2020	M	Male		36.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2002	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2004	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2005	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2006	M	Male		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2007	M	Male		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2008	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2009	M	Male		16.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2010	M	Male		16.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2011	M	Male		17.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2012	M	Male		19.0	PT	Percent		18.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2013	M	Male		21.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2014	M	Male		24.0	PT	Percent		22.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2015	M	Male		27.0	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2016	M	Male		31.0	PT	Percent		28.000000000000004		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2017	M	Male		37.0	PT	Percent		34.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2018	M	Male		43.0	PT	Percent		39.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2019	M	Male		48.0	PT	Percent		43.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	418	Lao People's Democratic Republic	LAO	101.9901968	20.27482773	Eastern and South-Eastern Asia	2020	M	Male		53.0	PT	Percent		49.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2000	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2001	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2002	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2003	M	Male		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2004	M	Male		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2005	M	Male		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2006	M	Male		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2007	M	Male		24.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2008	M	Male		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2009	M	Male		30.0	PT	Percent		27.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2010	M	Male		33.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2011	M	Male		36.0	PT	Percent		32.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2012	M	Male		38.0	PT	Percent		34.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2013	M	Male		40.0	PT	Percent		37.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2014	M	Male		43.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2015	M	Male		46.0	PT	Percent		41.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2016	M	Male		50.0	PT	Percent		45.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2017	M	Male		56.99999999999999	PT	Percent		50.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2018	M	Male		62.0	PT	Percent		55.00000000000001		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2019	M	Male		69.0	PT	Percent		61.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	422	Lebanon	LBN	35.89391711	33.92152458	Northern Africa and Western Asia	2020	M	Male		72.0	PT	Percent		63.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2005	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2006	M	Male		7.000000000000001	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2007	M	Male		16.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2008	M	Male		21.0	PT	Percent		20.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2009	M	Male		26.0	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2010	M	Male		31.0	PT	Percent		29.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2011	M	Male		33.0	PT	Percent		31.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2012	M	Male		34.0	PT	Percent		31.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2013	M	Male		37.0	PT	Percent		34.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2014	M	Male		40.0	PT	Percent		37.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2015	M	Male		47.0	PT	Percent		44.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2016	M	Male		56.99999999999999	PT	Percent		53.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2017	M	Male		62.0	PT	Percent		56.99999999999999		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2018	M	Male		67.0	PT	Percent		61.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2019	M	Male		72.0	PT	Percent		66.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	426	Lesotho	LSO	28.25362195	-29.58041814	Sub-Saharan Africa	2020	M	Male		74.0	PT	Percent		69.0		85.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2006	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2007	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2008	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2009	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2010	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2011	M	Male		15.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2012	M	Male		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2013	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2014	M	Male		13.0	PT	Percent		11.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2015	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2016	M	Male		15.0	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2017	M	Male		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2018	M	Male		27.0	PT	Percent		23.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2019	M	Male		30.0	PT	Percent		25.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	430	Liberia	LBR	-9.311879038	6.448381009	Sub-Saharan Africa	2020	M	Male		37.0	PT	Percent		30.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2000	M	Male		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2001	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2002	M	Male		17.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2003	M	Male		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2004	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2005	M	Male		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2006	M	Male		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2007	M	Male		21.0	PT	Percent		19.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2008	M	Male		25.0	PT	Percent		22.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2009	M	Male		30.0	PT	Percent		27.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2010	M	Male		34.0	PT	Percent		31.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2011	M	Male		36.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2012	M	Male		40.0	PT	Percent		37.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2013	M	Male		43.0	PT	Percent		39.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2014	M	Male		48.0	PT	Percent		44.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2015	M	Male		54.0	PT	Percent		49.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2016	M	Male		56.99999999999999	PT	Percent		52.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2017	M	Male		57.99999999999999	PT	Percent		53.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2018	M	Male		65.0	PT	Percent		59.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2019	M	Male		46.0	PT	Percent		42.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	434	Libya	LBY	18.0295985	27.04042819	Northern Africa and Western Asia	2020	M	Male		42.0	PT	Percent		38.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2005	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2006	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2007	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2008	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2009	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2010	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2011	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2012	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2013	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2014	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2015	M	Male		4.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2016	M	Male		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2017	M	Male		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2018	M	Male		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2019	M	Male		12.0	PT	Percent		10.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	450	Madagascar	MDG	46.6982339	-19.38514785	Sub-Saharan Africa	2020	M	Male		12.0	PT	Percent		9.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2005	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2006	M	Male		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2007	M	Male		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2008	M	Male		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2009	M	Male		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2010	M	Male		28.000000000000004	PT	Percent		26.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2011	M	Male		35.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2012	M	Male		41.0	PT	Percent		38.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2013	M	Male		47.0	PT	Percent		44.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2014	M	Male		53.0	PT	Percent		49.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2015	M	Male		56.99999999999999	PT	Percent		54.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2016	M	Male		65.0	PT	Percent		61.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2017	M	Male		73.0	PT	Percent		68.0		81.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2018	M	Male		79.0	PT	Percent		74.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2019	M	Male		81.0	PT	Percent		75.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	454	Malawi	MWI	33.4884625	-13.40819859	Sub-Saharan Africa	2020	M	Male		83.0	PT	Percent		77.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2001	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2002	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2003	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2004	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2005	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2006	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2007	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2008	M	Male		12.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2009	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2010	M	Male		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2011	M	Male		16.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2012	M	Male		16.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2013	M	Male		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2014	M	Male		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2015	M	Male		29.0	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2016	M	Male		41.0	PT	Percent		37.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2017	M	Male		43.0	PT	Percent		39.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2018	M	Male		45.0	PT	Percent		41.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2019	M	Male		47.0	PT	Percent		43.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	458	Malaysia	MYS	116.8346314	5.452415309	Eastern and South-Eastern Asia	2020	M	Male		48.0	PT	Percent		44.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2004	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2005	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2006	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2007	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2008	M	Male		17.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2009	M	Male		20.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2010	M	Male		24.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2011	M	Male		22.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2012	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2013	M	Male		20.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2014	M	Male		22.0	PT	Percent		19.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2015	M	Male		25.0	PT	Percent		21.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2016	M	Male		29.0	PT	Percent		24.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2017	M	Male		32.0	PT	Percent		27.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2018	M	Male		36.0	PT	Percent		30.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2019	M	Male		40.0	PT	Percent		33.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	466	Mali	MLI	-3.522016039	17.35311254	Sub-Saharan Africa	2020	M	Male		44.0	PT	Percent		35.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2006	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2007	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2008	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2009	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2010	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2011	M	Male		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2012	M	Male		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2013	M	Male		19.0	PT	Percent		16.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2014	M	Male		20.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2015	M	Male		23.0	PT	Percent		19.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2016	M	Male		26.0	PT	Percent		22.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2017	M	Male		30.0	PT	Percent		25.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2018	M	Male		31.0	PT	Percent		25.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2019	M	Male		35.0	PT	Percent		28.000000000000004		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	478	Mauritania	MRT	-10.33187259	20.26089546	Sub-Saharan Africa	2020	M	Male		37.0	PT	Percent		30.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2006	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2007	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2008	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2009	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2010	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2011	M	Male		14.000000000000002	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2012	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2013	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2014	M	Male		20.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2015	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2016	M	Male		20.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2017	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2018	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2019	M	Male		20.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	480	Mauritius	MUS	57.568022	-20.28581998	Sub-Saharan Africa	2020	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1995	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1996	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1997	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1998	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	1999	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2000	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2001	M	Male		9.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2002	M	Male		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2003	M	Male		14.000000000000002	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2004	M	Male		16.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2005	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2006	M	Male		20.0	PT	Percent		17.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2007	M	Male		23.0	PT	Percent		19.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2008	M	Male		25.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2009	M	Male		27.0	PT	Percent		23.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2010	M	Male		28.000000000000004	PT	Percent		24.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2011	M	Male		30.0	PT	Percent		26.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2012	M	Male		32.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2013	M	Male		33.0	PT	Percent		28.000000000000004		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2014	M	Male		34.0	PT	Percent		30.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2015	M	Male		40.0	PT	Percent		35.0		45.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2016	M	Male		44.0	PT	Percent		38.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2017	M	Male		46.0	PT	Percent		40.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2018	M	Male		51.0	PT	Percent		45.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2019	M	Male		52.0	PT	Percent		45.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	484	Mexico	MEX	-102.5148166	23.93378032	Latin America and the Caribbean	2020	M	Male		55.00000000000001	PT	Percent		47.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2005	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2006	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2007	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2008	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2009	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2010	M	Male		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2011	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2012	M	Male		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2013	M	Male		21.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2014	M	Male		26.0	PT	Percent		22.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2015	M	Male		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2016	M	Male		29.0	PT	Percent		25.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2017	M	Male		32.0	PT	Percent		29.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2018	M	Male		34.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2019	M	Male		34.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	496	Mongolia	MNG	103.0728057	46.83892054	Eastern and South-Eastern Asia	2020	M	Male		36.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	1999	M	Male		6.0	PT	Percent		2.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2000	M	Male		5.0	PT	Percent		2.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2001	M	Male		8.0	PT	Percent		3.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2002	M	Male		9.0	PT	Percent		3.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2003	M	Male		9.0	PT	Percent		3.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2004	M	Male		9.0	PT	Percent		3.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2005	M	Male		15.0	PT	Percent		6.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2006	M	Male		16.0	PT	Percent		6.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2007	M	Male		17.0	PT	Percent		6.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2008	M	Male		18.0	PT	Percent		5.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2009	M	Male		20.0	PT	Percent		6.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2010	M	Male		23.0	PT	Percent		8.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2011	M	Male		23.0	PT	Percent		8.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2012	M	Male		24.0	PT	Percent		8.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2013	M	Male		27.0	PT	Percent		9.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2014	M	Male		29.0	PT	Percent		9.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2015	M	Male		31.0	PT	Percent		10.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2016	M	Male		37.0	PT	Percent		12.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2017	M	Male		42.0	PT	Percent		14.000000000000002		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2018	M	Male		46.0	PT	Percent		14.000000000000002		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2019	M	Male		49.0	PT	Percent		15.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	499	Montenegro	MNE	19.25214024	42.78717043	Europe and Northern America	2020	M	Male		51.0	PT	Percent		14.000000000000002		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2003	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2004	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2005	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2006	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2007	M	Male		11.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2008	M	Male		14.000000000000002	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2009	M	Male		15.0	PT	Percent		14.000000000000002		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2010	M	Male		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2011	M	Male		21.0	PT	Percent		19.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2012	M	Male		26.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2013	M	Male		31.0	PT	Percent		27.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2014	M	Male		34.0	PT	Percent		30.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2015	M	Male		36.0	PT	Percent		32.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2016	M	Male		43.0	PT	Percent		37.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2017	M	Male		49.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2018	M	Male		57.99999999999999	PT	Percent		50.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2019	M	Male		63.0	PT	Percent		55.00000000000001		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	504	Morocco	MAR	-6.281942841	31.8440131	Northern Africa and Western Asia	2020	M	Male		68.0	PT	Percent		59.0		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2006	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2007	M	Male		8.0	PT	Percent		6.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2008	M	Male		10.0	PT	Percent		8.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2009	M	Male		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2010	M	Male		14.000000000000002	PT	Percent		11.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2011	M	Male		16.0	PT	Percent		13.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2012	M	Male		17.0	PT	Percent		13.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2013	M	Male		24.0	PT	Percent		19.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2014	M	Male		27.0	PT	Percent		22.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2015	M	Male		32.0	PT	Percent		26.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2016	M	Male		38.0	PT	Percent		31.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2017	M	Male		45.0	PT	Percent		36.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2018	M	Male		49.0	PT	Percent		40.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2019	M	Male		53.0	PT	Percent		43.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	508	Mozambique	MOZ	38.18479941	-14.27963886	Sub-Saharan Africa	2020	M	Male		62.0	PT	Percent		50.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2004	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2005	M	Male		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2006	M	Male		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2007	M	Male		24.0	PT	Percent		22.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2008	M	Male		30.0	PT	Percent		28.000000000000004		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2009	M	Male		33.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2010	M	Male		38.0	PT	Percent		35.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2011	M	Male		45.0	PT	Percent		42.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2012	M	Male		49.0	PT	Percent		45.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2013	M	Male		55.00000000000001	PT	Percent		51.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2014	M	Male		54.0	PT	Percent		50.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2015	M	Male		64.0	PT	Percent		59.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2016	M	Male		56.99999999999999	PT	Percent		52.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2017	M	Male		67.0	PT	Percent		62.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2018	M	Male		72.0	PT	Percent		67.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2019	M	Male		79.0	PT	Percent		73.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	516	Namibia	NAM	17.21907885	-22.13817068	Sub-Saharan Africa	2020	M	Male		82.0	PT	Percent		76.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2006	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2007	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2008	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2009	M	Male		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2010	M	Male		14.000000000000002	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2011	M	Male		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2012	M	Male		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2013	M	Male		27.0	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2014	M	Male		33.0	PT	Percent		31.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2015	M	Male		39.0	PT	Percent		36.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2016	M	Male		43.0	PT	Percent		39.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2017	M	Male		49.0	PT	Percent		44.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2018	M	Male		54.0	PT	Percent		49.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2019	M	Male		60.0	PT	Percent		54.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	524	Nepal	NPL	83.94678863	28.25866332	Central and Southern Asia	2020	M	Male		62.0	PT	Percent		56.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1996	M	Male		33.0	PT	Percent		27.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1997	M	Male		41.0	PT	Percent		35.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1998	M	Male		43.0	PT	Percent		37.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	1999	M	Male		45.0	PT	Percent		39.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2000	M	Male		46.0	PT	Percent		39.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2001	M	Male		48.0	PT	Percent		41.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2002	M	Male		49.0	PT	Percent		42.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2003	M	Male		49.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2004	M	Male		49.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2005	M	Male		49.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2006	M	Male		50.0	PT	Percent		44.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2007	M	Male		52.0	PT	Percent		46.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2008	M	Male		55.00000000000001	PT	Percent		49.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2009	M	Male		59.0	PT	Percent		52.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2010	M	Male		62.0	PT	Percent		55.00000000000001		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2011	M	Male		65.0	PT	Percent		57.99999999999999		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2012	M	Male		68.0	PT	Percent		61.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2013	M	Male		72.0	PT	Percent		64.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2014	M	Male		76.0	PT	Percent		68.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2015	M	Male		79.0	PT	Percent		70.0		87.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2016	M	Male		81.0	PT	Percent		72.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2017	M	Male		83.0	PT	Percent		74.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2018	M	Male		85.0	PT	Percent		75.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2019	M	Male		86.0	PT	Percent		76.0		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	528	Netherlands	NLD	5.331480568	51.86728884	Europe and Northern America	2020	M	Male		88.0	PT	Percent		77.0		99.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1995	M	Male		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1996	M	Male		29.0	PT	Percent		24.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1997	M	Male		33.0	PT	Percent		28.000000000000004		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1998	M	Male		37.0	PT	Percent		32.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	1999	M	Male		37.0	PT	Percent		32.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2000	M	Male		37.0	PT	Percent		32.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2001	M	Male		41.0	PT	Percent		35.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2002	M	Male		44.0	PT	Percent		38.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2003	M	Male		47.0	PT	Percent		40.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2004	M	Male		49.0	PT	Percent		43.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2005	M	Male		48.0	PT	Percent		42.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2006	M	Male		48.0	PT	Percent		41.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2007	M	Male		49.0	PT	Percent		42.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2008	M	Male		50.0	PT	Percent		42.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2009	M	Male		52.0	PT	Percent		44.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2010	M	Male		55.00000000000001	PT	Percent		47.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2011	M	Male		57.99999999999999	PT	Percent		49.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2012	M	Male		60.0	PT	Percent		50.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2013	M	Male		61.0	PT	Percent		51.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2014	M	Male		64.0	PT	Percent		54.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2015	M	Male		68.0	PT	Percent		56.99999999999999		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2016	M	Male		73.0	PT	Percent		61.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2017	M	Male		77.0	PT	Percent		64.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2018	M	Male		79.0	PT	Percent		66.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2019	M	Male		84.0	PT	Percent		70.0		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	554	New Zealand	NZL	170.4755673	-43.98721568	Australia and New Zealand	2020	M	Male		80.0	PT	Percent		67.0		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2003	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2005	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2006	M	Male		6.0	PT	Percent		4.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2007	M	Male		11.0	PT	Percent		7.000000000000001		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2008	M	Male		12.0	PT	Percent		8.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2009	M	Male		16.0	PT	Percent		11.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2010	M	Male		16.0	PT	Percent		12.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2011	M	Male		21.0	PT	Percent		16.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2012	M	Male		25.0	PT	Percent		19.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2013	M	Male		27.0	PT	Percent		20.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2014	M	Male		29.0	PT	Percent		22.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2015	M	Male		33.0	PT	Percent		25.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2016	M	Male		37.0	PT	Percent		29.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2017	M	Male		41.0	PT	Percent		31.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2018	M	Male		46.0	PT	Percent		35.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2019	M	Male		51.0	PT	Percent		38.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	558	Nicaragua	NIC	-85.03060315	12.84210839	Latin America and the Caribbean	2020	M	Male		51.0	PT	Percent		38.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2006	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2007	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2008	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2009	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2010	M	Male		18.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2011	M	Male		25.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2012	M	Male		30.0	PT	Percent		26.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2013	M	Male		30.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2014	M	Male		29.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2015	M	Male		32.0	PT	Percent		29.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2016	M	Male		39.0	PT	Percent		35.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2017	M	Male		51.0	PT	Percent		46.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2018	M	Male		54.0	PT	Percent		48.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2019	M	Male		55.00000000000001	PT	Percent		50.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	562	Niger	NER	9.400167877	17.42143036	Sub-Saharan Africa	2020	M	Male		59.0	PT	Percent		53.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2004	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2005	M	Male		4.0	PT	Percent		3.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2006	M	Male		8.0	PT	Percent		6.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2007	M	Male		9.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2008	M	Male		15.0	PT	Percent		11.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2009	M	Male		19.0	PT	Percent		14.000000000000002		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2010	M	Male		21.0	PT	Percent		16.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2011	M	Male		23.0	PT	Percent		18.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2012	M	Male		23.0	PT	Percent		17.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2013	M	Male		29.0	PT	Percent		22.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2014	M	Male		33.0	PT	Percent		25.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2015	M	Male		36.0	PT	Percent		27.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2016	M	Male		40.0	PT	Percent		30.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2017	M	Male		43.0	PT	Percent		32.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2018	M	Male		45.0	PT	Percent		34.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2019	M	Male		52.0	PT	Percent		39.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	566	Nigeria	NGA	8.097363256	9.585789025	Sub-Saharan Africa	2020	M	Male		73.0	PT	Percent		55.00000000000001		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1996	M	Male		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1997	M	Male		21.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1998	M	Male		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	1999	M	Male		33.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2000	M	Male		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2001	M	Male		52.0	PT	Percent		47.0		56.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2002	M	Male		59.0	PT	Percent		54.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2003	M	Male		65.0	PT	Percent		59.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2004	M	Male		70.0	PT	Percent		63.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2005	M	Male		73.0	PT	Percent		67.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2006	M	Male		75.0	PT	Percent		69.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2007	M	Male		77.0	PT	Percent		70.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2008	M	Male		76.0	PT	Percent		69.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2009	M	Male		75.0	PT	Percent		68.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2010	M	Male		74.0	PT	Percent		67.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2011	M	Male		73.0	PT	Percent		66.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2012	M	Male		73.0	PT	Percent		66.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2013	M	Male		73.0	PT	Percent		66.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2014	M	Male		73.0	PT	Percent		65.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2015	M	Male		73.0	PT	Percent		66.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2016	M	Male		74.0	PT	Percent		66.0		81.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2017	M	Male		75.0	PT	Percent		66.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2018	M	Male		77.0	PT	Percent		67.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2019	M	Male		78.0	PT	Percent		68.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	578	Norway	NOR	11.47846389	61.34311134	Europe and Northern America	2020	M	Male		80.0	PT	Percent		68.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2002	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2003	M	Male		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2004	M	Male		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2006	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2007	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2008	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2009	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2010	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2011	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2012	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2013	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2014	M	Male		4.0	PT	Percent		4.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2015	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2016	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2017	M	Male		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2018	M	Male		9.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2019	M	Male		11.0	PT	Percent		11.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	586	Pakistan	PAK	68.80479684	29.36491634	Central and Southern Asia	2020	M	Male		11.0	PT	Percent		10.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	1999	M	Male		7.000000000000001	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2000	M	Male		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2001	M	Male		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2002	M	Male		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2003	M	Male		13.0	PT	Percent		12.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2004	M	Male		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2005	M	Male		17.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2006	M	Male		19.0	PT	Percent		17.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2007	M	Male		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2008	M	Male		21.0	PT	Percent		19.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2009	M	Male		27.0	PT	Percent		24.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2010	M	Male		28.000000000000004	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2011	M	Male		29.0	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2012	M	Male		33.0	PT	Percent		30.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2013	M	Male		34.0	PT	Percent		31.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2014	M	Male		37.0	PT	Percent		33.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2015	M	Male		38.0	PT	Percent		34.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2016	M	Male		43.0	PT	Percent		39.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2017	M	Male		47.0	PT	Percent		42.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2018	M	Male		52.0	PT	Percent		47.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2019	M	Male		56.99999999999999	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	591	Panama	PAN	-81.26616623	8.450965746	Latin America and the Caribbean	2020	M	Male		55.00000000000001	PT	Percent		49.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2005	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2006	M	Male		5.0	PT	Percent		3.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2007	M	Male		13.0	PT	Percent		8.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2008	M	Male		17.0	PT	Percent		11.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2009	M	Male		21.0	PT	Percent		14.000000000000002		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2010	M	Male		23.0	PT	Percent		16.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2011	M	Male		26.0	PT	Percent		17.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2012	M	Male		31.0	PT	Percent		21.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2013	M	Male		38.0	PT	Percent		26.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2014	M	Male		44.0	PT	Percent		31.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2015	M	Male		49.0	PT	Percent		34.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2016	M	Male		52.0	PT	Percent		36.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2017	M	Male		54.0	PT	Percent		37.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2018	M	Male		56.99999999999999	PT	Percent		39.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2019	M	Male		59.0	PT	Percent		41.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	598	Papua New Guinea	PNG	145.8587761	-6.756057077	Oceania, exc. Australia and New Zealand	2020	M	Male		63.0	PT	Percent		43.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2005	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2006	M	Male		6.0	PT	Percent		4.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2007	M	Male		8.0	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2008	M	Male		12.0	PT	Percent		9.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2009	M	Male		17.0	PT	Percent		13.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2010	M	Male		22.0	PT	Percent		17.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2011	M	Male		22.0	PT	Percent		17.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2012	M	Male		24.0	PT	Percent		18.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2013	M	Male		28.000000000000004	PT	Percent		21.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2014	M	Male		32.0	PT	Percent		24.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2015	M	Male		36.0	PT	Percent		27.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2016	M	Male		41.0	PT	Percent		32.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2017	M	Male		51.0	PT	Percent		39.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2018	M	Male		55.00000000000001	PT	Percent		41.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2019	M	Male		60.0	PT	Percent		45.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	600	Paraguay	PRY	-60.54854225	-21.70216237	Latin America and the Caribbean	2020	M	Male		61.0	PT	Percent		45.0		85.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2002	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2003	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2004	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2005	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2006	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2007	M	Male		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2008	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2009	M	Male		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2010	M	Male		30.0	PT	Percent		26.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2011	M	Male		31.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2012	M	Male		39.0	PT	Percent		34.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2013	M	Male		39.0	PT	Percent		33.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2014	M	Male		44.0	PT	Percent		37.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2015	M	Male		42.0	PT	Percent		36.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2016	M	Male		52.0	PT	Percent		45.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2017	M	Male		57.99999999999999	PT	Percent		49.0		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2018	M	Male		66.0	PT	Percent		56.00000000000001		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2019	M	Male		74.0	PT	Percent		63.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	604	Peru	PER	-71.82093277	-13.58939705	Latin America and the Caribbean	2020	M	Male		77.0	PT	Percent		65.0		85.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2006	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2007	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2008	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2009	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2010	M	Male		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2011	M	Male		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2012	M	Male		13.0	PT	Percent		12.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2013	M	Male		16.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2014	M	Male		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2015	M	Male		25.0	PT	Percent		23.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2016	M	Male		30.0	PT	Percent		28.000000000000004		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2017	M	Male		35.0	PT	Percent		32.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2018	M	Male		40.0	PT	Percent		37.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2019	M	Male		45.0	PT	Percent		41.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	608	Philippines	PHL	120.8601418	14.16591706	Eastern and South-Eastern Asia	2020	M	Male		43.0	PT	Percent		39.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1997	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1998	M	Male		8.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	1999	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2000	M	Male		17.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2001	M	Male		21.0	PT	Percent		18.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2002	M	Male		25.0	PT	Percent		21.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2003	M	Male		29.0	PT	Percent		24.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2004	M	Male		32.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2005	M	Male		35.0	PT	Percent		30.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2006	M	Male		38.0	PT	Percent		33.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2007	M	Male		41.0	PT	Percent		36.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2008	M	Male		44.0	PT	Percent		38.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2009	M	Male		47.0	PT	Percent		41.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2010	M	Male		52.0	PT	Percent		45.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2011	M	Male		56.00000000000001	PT	Percent		49.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2012	M	Male		61.0	PT	Percent		53.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2013	M	Male		65.0	PT	Percent		56.99999999999999		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2014	M	Male		69.0	PT	Percent		61.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2015	M	Male		73.0	PT	Percent		64.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2016	M	Male		76.0	PT	Percent		67.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2017	M	Male		87.0	PT	Percent		77.0		99.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2018	M	Male		90.0	PT	Percent		78.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2019	M	Male		82.0	PT	Percent		71.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	620	Portugal	PRT	-7.961599811	39.68509315	Europe and Northern America	2020	M	Male		84.0	PT	Percent		73.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2007	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2008	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2009	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2010	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2011	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2012	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2013	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2014	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2015	M	Male		25.0	PT	Percent		12.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2016	M	Male		47.0	PT	Percent		23.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2017	M	Male		64.0	PT	Percent		33.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2018	M	Male		77.0	PT	Percent		44.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2019	M	Male		85.0	PT	Percent		53.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	634	Qatar	QAT	51.19152467	25.28355379	Northern Africa and Western Asia	2020	M	Male		88.0	PT	Percent		59.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2005	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2006	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2007	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2008	M	Male		5.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2009	M	Male		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2010	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2011	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2012	M	Male		11.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2013	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2014	M	Male		16.0	PT	Percent		14.000000000000002		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2015	M	Male		20.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2016	M	Male		23.0	PT	Percent		20.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2017	M	Male		27.0	PT	Percent		24.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2018	M	Male		33.0	PT	Percent		28.000000000000004		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2019	M	Male		38.0	PT	Percent		33.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	498	Republic of Moldova	MDA	28.4650624	47.20236795	Europe and Northern America	2020	M	Male		39.0	PT	Percent		33.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1998	M	Male		33.0	PT	Percent		19.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	1999	M	Male		43.0	PT	Percent		25.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2000	M	Male		51.0	PT	Percent		29.0		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2001	M	Male		56.00000000000001	PT	Percent		32.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2002	M	Male		63.0	PT	Percent		36.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2003	M	Male		61.0	PT	Percent		35.0		87.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2004	M	Male		59.0	PT	Percent		34.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2005	M	Male		56.99999999999999	PT	Percent		33.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2006	M	Male		55.00000000000001	PT	Percent		32.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2007	M	Male		54.0	PT	Percent		31.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2008	M	Male		53.0	PT	Percent		31.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2009	M	Male		52.0	PT	Percent		30.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2010	M	Male		51.0	PT	Percent		30.0		70.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2011	M	Male		51.0	PT	Percent		29.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2012	M	Male		51.0	PT	Percent		29.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2013	M	Male		60.0	PT	Percent		35.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2014	M	Male		62.0	PT	Percent		35.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2015	M	Male		64.0	PT	Percent		37.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2016	M	Male		62.0	PT	Percent		36.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2017	M	Male		64.0	PT	Percent		37.0		85.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2018	M	Male		65.0	PT	Percent		38.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2019	M	Male		68.0	PT	Percent		39.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	642	Romania	ROU	24.98481009	45.83893563	Europe and Northern America	2020	M	Male		67.0	PT	Percent		38.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2004	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2005	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2006	M	Male		16.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2007	M	Male		21.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2008	M	Male		29.0	PT	Percent		27.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2009	M	Male		36.0	PT	Percent		33.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2010	M	Male		41.0	PT	Percent		38.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2011	M	Male		46.0	PT	Percent		43.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2012	M	Male		52.0	PT	Percent		48.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2013	M	Male		56.99999999999999	PT	Percent		53.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2014	M	Male		63.0	PT	Percent		57.99999999999999		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2015	M	Male		70.0	PT	Percent		64.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2016	M	Male		79.0	PT	Percent		73.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2017	M	Male		82.0	PT	Percent		76.0		94.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2018	M	Male		85.0	PT	Percent		79.0		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2019	M	Male		89.0	PT	Percent		82.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	646	Rwanda	RWA	29.92310194	-1.999842114	Sub-Saharan Africa	2020	M	Male		92.0	PT	Percent		84.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1995	M	Male		32.0	PT	Percent		16.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1996	M	Male		50.0	PT	Percent		26.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1997	M	Male		62.0	PT	Percent		35.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1998	M	Male		69.0	PT	Percent		42.0		88.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	1999	M	Male		74.0	PT	Percent		48.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2000	M	Male		76.0	PT	Percent		53.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2001	M	Male		77.0	PT	Percent		56.99999999999999		92.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2002	M	Male		77.0	PT	Percent		60.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2003	M	Male		75.0	PT	Percent		62.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2004	M	Male		73.0	PT	Percent		63.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2005	M	Male		72.0	PT	Percent		65.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2006	M	Male		72.0	PT	Percent		66.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2007	M	Male		72.0	PT	Percent		66.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2008	M	Male		71.0	PT	Percent		65.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2009	M	Male		70.0	PT	Percent		64.0		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2010	M	Male		69.0	PT	Percent		63.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2011	M	Male		67.0	PT	Percent		61.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2012	M	Male		65.0	PT	Percent		59.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2013	M	Male		63.0	PT	Percent		56.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2014	M	Male		60.0	PT	Percent		54.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2015	M	Male		56.99999999999999	PT	Percent		51.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2016	M	Male		59.0	PT	Percent		53.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2017	M	Male		61.0	PT	Percent		54.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2018	M	Male		65.0	PT	Percent		56.99999999999999		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2019	M	Male		74.0	PT	Percent		64.0		86.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	682	Saudi Arabia	SAU	44.54763347	24.12594211	Northern Africa and Western Asia	2020	M	Male		68.0	PT	Percent		59.0		81.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2006	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2007	M	Male		10.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2008	M	Male		12.0	PT	Percent		10.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2009	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2010	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2011	M	Male		19.0	PT	Percent		16.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2012	M	Male		19.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2013	M	Male		24.0	PT	Percent		21.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2014	M	Male		29.0	PT	Percent		25.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2015	M	Male		35.0	PT	Percent		31.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2016	M	Male		37.0	PT	Percent		32.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2017	M	Male		42.0	PT	Percent		38.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2018	M	Male		50.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2019	M	Male		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	686	Senegal	SEN	-14.46636926	14.35920905	Sub-Saharan Africa	2020	M	Male		61.0	PT	Percent		54.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2003	M	Male		41.0	PT	Percent		31.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2004	M	Male		50.0	PT	Percent		39.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2005	M	Male		57.99999999999999	PT	Percent		46.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2006	M	Male		56.00000000000001	PT	Percent		45.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2007	M	Male		55.00000000000001	PT	Percent		44.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2008	M	Male		53.0	PT	Percent		44.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2009	M	Male		52.0	PT	Percent		44.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2010	M	Male		53.0	PT	Percent		45.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2011	M	Male		52.0	PT	Percent		44.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2012	M	Male		52.0	PT	Percent		44.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2013	M	Male		51.0	PT	Percent		44.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2014	M	Male		52.0	PT	Percent		44.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2015	M	Male		53.0	PT	Percent		45.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2016	M	Male		56.00000000000001	PT	Percent		47.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2017	M	Male		59.0	PT	Percent		48.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2018	M	Male		65.0	PT	Percent		52.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2019	M	Male		65.0	PT	Percent		51.0		79.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	688	Serbia	SRB	20.805876	44.03145697	Europe and Northern America	2020	M	Male		65.0	PT	Percent		50.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2006	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2007	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2008	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2009	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2010	M	Male		10.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2011	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2012	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2013	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2014	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2015	M	Male		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2016	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2017	M	Male		22.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2018	M	Male		27.0	PT	Percent		24.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2019	M	Male		32.0	PT	Percent		28.000000000000004		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	694	Sierra Leone	SLE	-11.78306584	8.568604164	Sub-Saharan Africa	2020	M	Male		35.0	PT	Percent		31.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2006	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2007	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2008	M	Male		3.0	PT	Percent		3.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2009	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2010	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2011	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2012	M	Male		9.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2013	M	Male		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2014	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2015	M	Male		19.0	PT	Percent		16.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2016	M	Male		23.0	PT	Percent		20.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2017	M	Male		27.0	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2018	M	Male		31.0	PT	Percent		27.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2019	M	Male		35.0	PT	Percent		30.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	706	Somalia	SOM	46.20367477	4.406485729	Sub-Saharan Africa	2020	M	Male		39.0	PT	Percent		34.0		44.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2006	M	Male		3.0	PT	Percent		2.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2007	M	Male		6.0	PT	Percent		4.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2008	M	Male		10.0	PT	Percent		6.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2009	M	Male		14.000000000000002	PT	Percent		9.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2010	M	Male		19.0	PT	Percent		12.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2011	M	Male		25.0	PT	Percent		16.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2012	M	Male		31.0	PT	Percent		20.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2013	M	Male		36.0	PT	Percent		23.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2014	M	Male		40.0	PT	Percent		26.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2015	M	Male		44.0	PT	Percent		29.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2016	M	Male		48.0	PT	Percent		32.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2017	M	Male		53.0	PT	Percent		34.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2018	M	Male		56.00000000000001	PT	Percent		37.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2019	M	Male		60.0	PT	Percent		40.0		76.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	710	South Africa	ZAF	24.67184355	-29.99957544	Sub-Saharan Africa	2020	M	Male		63.0	PT	Percent		42.0		81.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2007	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2008	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2009	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2010	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2011	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2012	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2013	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2014	M	Male		6.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2015	M	Male		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2016	M	Male		10.0	PT	Percent		7.000000000000001		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2017	M	Male		13.0	PT	Percent		10.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2018	M	Male		16.0	PT	Percent		13.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2019	M	Male		19.0	PT	Percent		15.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	728	South Sudan	SSD	30.32618773	7.290839152	Sub-Saharan Africa	2020	M	Male		23.0	PT	Percent		17.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1996	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1997	M	Male		12.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1998	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	1999	M	Male		23.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2000	M	Male		28.000000000000004	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2001	M	Male		33.0	PT	Percent		28.000000000000004		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2002	M	Male		37.0	PT	Percent		32.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2003	M	Male		41.0	PT	Percent		36.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2004	M	Male		45.0	PT	Percent		40.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2005	M	Male		49.0	PT	Percent		43.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2006	M	Male		52.0	PT	Percent		46.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2007	M	Male		56.00000000000001	PT	Percent		49.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2008	M	Male		59.0	PT	Percent		52.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2009	M	Male		61.0	PT	Percent		54.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2010	M	Male		66.0	PT	Percent		57.99999999999999		73.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2011	M	Male		66.0	PT	Percent		57.99999999999999		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2012	M	Male		69.0	PT	Percent		61.0		78.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2013	M	Male		71.0	PT	Percent		62.0		80.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2014	M	Male		72.0	PT	Percent		63.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2015	M	Male		75.0	PT	Percent		64.0		85.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2016	M	Male		82.0	PT	Percent		71.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2017	M	Male		83.0	PT	Percent		72.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2018	M	Male		84.0	PT	Percent		72.0		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2019	M	Male		85.0	PT	Percent		72.0		97.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	724	Spain	ESP	-3.554078296	40.39211472	Europe and Northern America	2020	M	Male		85.0	PT	Percent		72.0		98.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2006	M	Male		2.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2007	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2008	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2009	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2010	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2011	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2012	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2013	M	Male		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2014	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2015	M	Male		19.0	PT	Percent		17.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2016	M	Male		26.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2017	M	Male		33.0	PT	Percent		29.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2018	M	Male		41.0	PT	Percent		37.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2019	M	Male		50.0	PT	Percent		45.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	144	Sri Lanka	LKA	80.70489654	7.614693343	Central and Southern Asia	2020	M	Male		61.0	PT	Percent		55.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2007	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2008	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2009	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2010	M	Male		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2011	M	Male		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2012	M	Male		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2013	M	Male		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2014	M	Male		9.0	PT	Percent		8.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2015	M	Male		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2016	M	Male		14.000000000000002	PT	Percent		12.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2017	M	Male		18.0	PT	Percent		16.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2018	M	Male		20.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2019	M	Male		24.0	PT	Percent		21.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	729	Sudan	SDN	29.95650159	16.02643066	Northern Africa and Western Asia	2020	M	Male		25.0	PT	Percent		22.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2002	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2003	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2004	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2005	M	Male		8.0	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2006	M	Male		10.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2007	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2008	M	Male		15.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2009	M	Male		18.0	PT	Percent		15.0		21.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2010	M	Male		20.0	PT	Percent		17.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2011	M	Male		22.0	PT	Percent		19.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2012	M	Male		27.0	PT	Percent		22.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2013	M	Male		29.0	PT	Percent		25.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2014	M	Male		33.0	PT	Percent		27.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2015	M	Male		35.0	PT	Percent		29.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2016	M	Male		41.0	PT	Percent		33.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2017	M	Male		44.0	PT	Percent		36.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2018	M	Male		48.0	PT	Percent		39.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2019	M	Male		48.0	PT	Percent		40.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	740	Suriname	SUR	-55.90626394	4.132603197	Latin America and the Caribbean	2020	M	Male		32.0	PT	Percent		25.0		40.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	1999	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2003	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2004	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2005	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2006	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2007	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2008	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2009	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2010	M	Male		9.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2011	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2012	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2013	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2014	M	Male		15.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2015	M	Male		15.0	PT	Percent		13.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2016	M	Male		16.0	PT	Percent		14.000000000000002		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2017	M	Male		21.0	PT	Percent		18.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2018	M	Male		28.000000000000004	PT	Percent		23.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2019	M	Male		34.0	PT	Percent		28.000000000000004		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	760	Syrian Arab Republic	SYR	38.50466565	35.01676176	Northern Africa and Western Asia	2020	M	Male		36.0	PT	Percent		29.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2006	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2007	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2008	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2009	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2010	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2011	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2012	M	Male		9.0	PT	Percent		9.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2013	M	Male		10.0	PT	Percent		10.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2014	M	Male		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2015	M	Male		20.0	PT	Percent		19.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2016	M	Male		26.0	PT	Percent		24.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2017	M	Male		32.0	PT	Percent		30.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2018	M	Male		39.0	PT	Percent		36.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2019	M	Male		43.0	PT	Percent		40.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	762	Tajikistan	TJK	69.294998	38.43069666	Central and Southern Asia	2020	M	Male		49.0	PT	Percent		44.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2002	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2003	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2004	M	Male		7.000000000000001	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2005	M	Male		13.0	PT	Percent		11.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2006	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2007	M	Male		21.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2008	M	Male		24.0	PT	Percent		22.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2009	M	Male		28.000000000000004	PT	Percent		25.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2010	M	Male		32.0	PT	Percent		28.000000000000004		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2011	M	Male		36.0	PT	Percent		32.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2012	M	Male		38.0	PT	Percent		35.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2013	M	Male		42.0	PT	Percent		38.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2014	M	Male		47.0	PT	Percent		42.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2015	M	Male		51.0	PT	Percent		46.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2016	M	Male		56.99999999999999	PT	Percent		51.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2017	M	Male		63.0	PT	Percent		56.99999999999999		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2018	M	Male		69.0	PT	Percent		63.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2019	M	Male		74.0	PT	Percent		67.0		82.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	764	Thailand	THA	101.0202951	15.13089239	Eastern and South-Eastern Asia	2020	M	Male		78.0	PT	Percent		71.0		87.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2005	M	Male		1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2006	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2007	M	Male		2.0	PT	Percent		1.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2008	M	Male		6.0	PT	Percent		4.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2009	M	Male		5.0	PT	Percent		4.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2010	M	Male		8.0	PT	Percent		6.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2011	M	Male		7.000000000000001	PT	Percent		5.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2012	M	Male		13.0	PT	Percent		10.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2013	M	Male		16.0	PT	Percent		12.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2014	M	Male		18.0	PT	Percent		13.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2015	M	Male		21.0	PT	Percent		16.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2016	M	Male		22.0	PT	Percent		17.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2017	M	Male		26.0	PT	Percent		20.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2018	M	Male		35.0	PT	Percent		27.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2019	M	Male		46.0	PT	Percent		35.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	626	Timor-Leste	TLS	125.9451052	-8.797497247	Eastern and South-Eastern Asia	2020	M	Male		52.0	PT	Percent		38.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2003	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2004	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2005	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2006	M	Male		8.0	PT	Percent		7.000000000000001		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2007	M	Male		8.0	PT	Percent		8.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2008	M	Male		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2009	M	Male		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2010	M	Male		27.0	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2011	M	Male		30.0	PT	Percent		29.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2012	M	Male		21.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2013	M	Male		24.0	PT	Percent		22.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2014	M	Male		26.0	PT	Percent		24.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2015	M	Male		31.0	PT	Percent		29.0		34.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2016	M	Male		34.0	PT	Percent		32.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2017	M	Male		36.0	PT	Percent		34.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2018	M	Male		46.0	PT	Percent		43.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2019	M	Male		55.00000000000001	PT	Percent		52.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	768	Togo	TGO	0.97835765	8.532096072	Sub-Saharan Africa	2020	M	Male		59.0	PT	Percent		55.00000000000001		64.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2001	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2002	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2003	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2004	M	Male		11.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2005	M	Male		14.000000000000002	PT	Percent		12.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2006	M	Male		17.0	PT	Percent		15.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2007	M	Male		21.0	PT	Percent		18.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2008	M	Male		23.0	PT	Percent		21.0		26.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2009	M	Male		30.0	PT	Percent		27.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2010	M	Male		38.0	PT	Percent		34.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2011	M	Male		41.0	PT	Percent		37.0		46.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2012	M	Male		47.0	PT	Percent		41.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2013	M	Male		55.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2014	M	Male		55.00000000000001	PT	Percent		49.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2015	M	Male		59.0	PT	Percent		52.0		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2016	M	Male		60.0	PT	Percent		53.0		66.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2017	M	Male		66.0	PT	Percent		59.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2018	M	Male		73.0	PT	Percent		64.0		81.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2019	M	Male		79.0	PT	Percent		70.0		89.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	780	Trinidad and Tobago	TTO	-61.29389504	10.41877263	Latin America and the Caribbean	2020	M	Male		76.0	PT	Percent		66.0		85.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2001	M	Male		2.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2002	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2003	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2004	M	Male		5.0	PT	Percent		4.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2005	M	Male		6.0	PT	Percent		5.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2006	M	Male		7.000000000000001	PT	Percent		6.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2007	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2008	M	Male		11.0	PT	Percent		9.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2009	M	Male		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2010	M	Male		15.0	PT	Percent		13.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2011	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2012	M	Male		14.000000000000002	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2013	M	Male		16.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2014	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2015	M	Male		19.0	PT	Percent		17.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2016	M	Male		22.0	PT	Percent		20.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2017	M	Male		22.0	PT	Percent		19.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2018	M	Male		25.0	PT	Percent		22.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2019	M	Male		28.000000000000004	PT	Percent		24.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	788	Tunisia	TUN	9.572737411	34.11439971	Northern Africa and Western Asia	2020	M	Male		31.0	PT	Percent		26.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2001	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2002	M	Male		1.0	PT	Percent		1.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2003	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2004	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2005	M	Male		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2006	M	Male		10.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2007	M	Male		13.0	PT	Percent		12.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2008	M	Male		17.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2009	M	Male		20.0	PT	Percent		18.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2010	M	Male		24.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2011	M	Male		27.0	PT	Percent		25.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2012	M	Male		30.0	PT	Percent		28.000000000000004		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2013	M	Male		35.0	PT	Percent		33.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2014	M	Male		44.0	PT	Percent		42.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2015	M	Male		48.0	PT	Percent		46.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2016	M	Male		55.00000000000001	PT	Percent		52.0		61.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2017	M	Male		65.0	PT	Percent		61.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2018	M	Male		67.0	PT	Percent		63.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2019	M	Male		82.0	PT	Percent		77.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	800	Uganda	UGA	32.39100438	1.279557331	Sub-Saharan Africa	2020	M	Male		86.0	PT	Percent		81.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2004	M	Male	<	1.0	PT	Percent	<	1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2006	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2007	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2008	M	Male		4.0	PT	Percent		3.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2009	M	Male		6.0	PT	Percent		5.0		8.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2010	M	Male		9.0	PT	Percent		7.000000000000001		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2011	M	Male		11.0	PT	Percent		9.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2012	M	Male		17.0	PT	Percent		14.000000000000002		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2013	M	Male		23.0	PT	Percent		19.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2014	M	Male		28.000000000000004	PT	Percent		23.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2015	M	Male		28.000000000000004	PT	Percent		23.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2016	M	Male		38.0	PT	Percent		31.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2017	M	Male		43.0	PT	Percent		35.0		53.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2018	M	Male		50.0	PT	Percent		40.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2019	M	Male		54.0	PT	Percent		44.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	804	Ukraine	UKR	31.40270802	49.00735945	Europe and Northern America	2020	M	Male		56.00000000000001	PT	Percent		46.0		71.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2001	M	Male		38.0	PT	Percent		13.0		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2002	M	Male		69.0	PT	Percent		24.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2003	M	Male		95.0	PT	Percent		35.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2004	M	Male	>	98.0	PT	Percent		44.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2005	M	Male	>	98.0	PT	Percent		54.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2006	M	Male	>	98.0	PT	Percent		59.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2007	M	Male	>	98.0	PT	Percent		66.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2008	M	Male	>	98.0	PT	Percent		69.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2009	M	Male	>	98.0	PT	Percent		69.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2010	M	Male	>	98.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2011	M	Male	>	98.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2012	M	Male	>	98.0	PT	Percent		83.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2013	M	Male	>	98.0	PT	Percent		78.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2014	M	Male		67.0	PT	Percent		48.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2015	M	Male		60.0	PT	Percent		45.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2016	M	Male		56.99999999999999	PT	Percent		43.0		69.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2017	M	Male		52.0	PT	Percent		40.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2018	M	Male		43.0	PT	Percent		34.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2019	M	Male		44.0	PT	Percent		35.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	784	United Arab Emirates	ARE	53.98279159	23.43322219	Northern Africa and Western Asia	2020	M	Male		81.0	PT	Percent		67.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2005	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2006	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2007	M	Male		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2008	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2009	M	Male		17.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2010	M	Male		15.0	PT	Percent		14.000000000000002		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2011	M	Male		18.0	PT	Percent		17.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2012	M	Male		26.0	PT	Percent		24.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2013	M	Male		29.0	PT	Percent		27.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2014	M	Male		33.0	PT	Percent		31.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2015	M	Male		38.0	PT	Percent		35.0		42.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2016	M	Male		43.0	PT	Percent		40.0		48.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2017	M	Male		48.0	PT	Percent		45.0		54.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2018	M	Male		56.00000000000001	PT	Percent		52.0		62.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2019	M	Male		66.0	PT	Percent		62.0		74.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	834	United Republic of Tanzania	TZA	34.80521182	-6.265332606	Sub-Saharan Africa	2020	M	Male		74.0	PT	Percent		69.0		83.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1996	M	Male		9.0	PT	Percent		3.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1997	M	Male		9.0	PT	Percent		4.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1998	M	Male		11.0	PT	Percent		5.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	1999	M	Male		13.0	PT	Percent		6.0		17.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2000	M	Male		14.000000000000002	PT	Percent		8.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2001	M	Male		16.0	PT	Percent		10.0		22.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2002	M	Male		18.0	PT	Percent		11.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2003	M	Male		19.0	PT	Percent		13.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2004	M	Male		21.0	PT	Percent		15.0		28.000000000000004	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2005	M	Male		24.0	PT	Percent		18.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2006	M	Male		28.000000000000004	PT	Percent		22.0		35.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2007	M	Male		31.0	PT	Percent		24.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2008	M	Male		32.0	PT	Percent		26.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2009	M	Male		33.0	PT	Percent		27.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2010	M	Male		46.0	PT	Percent		37.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2011	M	Male		50.0	PT	Percent		40.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2012	M	Male		46.0	PT	Percent		37.0		56.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2013	M	Male		76.0	PT	Percent		61.0		91.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2014	M	Male		79.0	PT	Percent		64.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2015	M	Male		76.0	PT	Percent		62.0		93.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2016	M	Male		78.0	PT	Percent		63.0		96.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2017	M	Male		80.0	PT	Percent		65.0		99.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2018	M	Male		87.0	PT	Percent		70.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2019	M	Male		83.0	PT	Percent		67.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	858	Uruguay	URY	-56.01387025	-32.8002838	Latin America and the Caribbean	2020	M	Male		87.0	PT	Percent		69.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2006	M	Male		3.0	PT	Percent		2.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2007	M	Male		5.0	PT	Percent		4.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2008	M	Male		7.000000000000001	PT	Percent		6.0		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2009	M	Male		9.0	PT	Percent		7.000000000000001		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2010	M	Male		10.0	PT	Percent		8.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2011	M	Male		11.0	PT	Percent		10.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2012	M	Male		4.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2013	M	Male		9.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2014	M	Male		13.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2015	M	Male		17.0	PT	Percent		15.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2016	M	Male		21.0	PT	Percent		19.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2017	M	Male		27.0	PT	Percent		24.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2018	M	Male		34.0	PT	Percent		30.0		39.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2019	M	Male		34.0	PT	Percent		31.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	860	Uzbekistan	UZB	63.11944558	41.77560518	Central and Southern Asia	2020	M	Male		41.0	PT	Percent		37.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2000	M	Male		3.0	PT	Percent		2.0		3.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2001	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2002	M	Male		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2003	M	Male		12.0	PT	Percent		11.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2004	M	Male		15.0	PT	Percent		13.0		16.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2005	M	Male		17.0	PT	Percent		15.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2006	M	Male		27.0	PT	Percent		24.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2007	M	Male		30.0	PT	Percent		27.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2008	M	Male		35.0	PT	Percent		31.0		38.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2009	M	Male		39.0	PT	Percent		36.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2010	M	Male		45.0	PT	Percent		40.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2011	M	Male		45.0	PT	Percent		41.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2012	M	Male		47.0	PT	Percent		42.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2013	M	Male		46.0	PT	Percent		41.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2014	M	Male		46.0	PT	Percent		41.0		51.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2015	M	Male		60.0	PT	Percent		54.0		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2016	M	Male		56.00000000000001	PT	Percent		50.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2017	M	Male		44.0	PT	Percent		39.0		49.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2018	M	Male		29.0	PT	Percent		26.0		33.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2019	M	Male		53.0	PT	Percent		47.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	862	Venezuela (Bolivarian Republic of)	VEN	-66.15642084	7.121324748	Latin America and the Caribbean	2020	M	Male		69.0	PT	Percent		61.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2005	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2006	M	Male		4.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2007	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2008	M	Male		13.0	PT	Percent		12.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2009	M	Male		18.0	PT	Percent		16.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2010	M	Male		22.0	PT	Percent		20.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2011	M	Male		26.0	PT	Percent		23.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2012	M	Male		30.0	PT	Percent		27.0		32.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2013	M	Male		34.0	PT	Percent		30.0		37.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2014	M	Male		37.0	PT	Percent		33.0		41.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2015	M	Male		44.0	PT	Percent		39.0		47.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2016	M	Male		48.0	PT	Percent		43.0		52.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2017	M	Male		55.00000000000001	PT	Percent		50.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2018	M	Male		57.99999999999999	PT	Percent		53.0		63.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2019	M	Male		62.0	PT	Percent		56.00000000000001		68.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	704	Viet Nam	VNM	105.802499	10.09643079	Eastern and South-Eastern Asia	2020	M	Male		66.0	PT	Percent		60.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2004	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2005	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2006	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2007	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2008	M	Male		5.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2009	M	Male		6.0	PT	Percent		6.0		7.000000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2010	M	Male		10.0	PT	Percent		9.0		11.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2011	M	Male		11.0	PT	Percent		10.0		12.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2012	M	Male		12.0	PT	Percent		11.0		13.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2013	M	Male		14.000000000000002	PT	Percent		13.0		15.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2014	M	Male		18.0	PT	Percent		16.0		19.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2015	M	Male		19.0	PT	Percent		17.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2016	M	Male		22.0	PT	Percent		20.0		23.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2017	M	Male		23.0	PT	Percent		21.0		25.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2018	M	Male		25.0	PT	Percent		23.0		27.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2019	M	Male		27.0	PT	Percent		25.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	887	Yemen	YEM	45.22389143	15.22242099	Northern Africa and Western Asia	2020	M	Male		28.000000000000004	PT	Percent		26.0		30.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2003	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2004	M	Male		3.0	PT	Percent		3.0		4.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2005	M	Male		6.0	PT	Percent		5.0		6.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2006	M	Male		9.0	PT	Percent		8.0		10.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2007	M	Male		17.0	PT	Percent		16.0		18.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2008	M	Male		22.0	PT	Percent		21.0		24.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2009	M	Male		28.000000000000004	PT	Percent		26.0		31.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2010	M	Male		33.0	PT	Percent		31.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2011	M	Male		39.0	PT	Percent		37.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2012	M	Male		45.0	PT	Percent		43.0		50.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2013	M	Male		50.0	PT	Percent		47.0		55.00000000000001	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2014	M	Male		53.0	PT	Percent		50.0		57.99999999999999	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2015	M	Male		59.0	PT	Percent		56.00000000000001		65.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2016	M	Male		61.0	PT	Percent		56.99999999999999		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2017	M	Male		61.0	PT	Percent		57.99999999999999		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2018	M	Male		68.0	PT	Percent		64.0		75.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2019	M	Male		73.0	PT	Percent		69.0		81.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	894	Zambia	ZMB	27.850329	-14.59701056	Sub-Saharan Africa	2020	M	Male		80.0	PT	Percent		75.0		90.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1990	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1991	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1992	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1993	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1994	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1995	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1996	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1997	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1998	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	1999	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2000	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2001	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2002	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2003	M	Male	<	1.0	PT	Percent	<	1.0	<	1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2004	M	Male		1.0	PT	Percent		1.0		1.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2005	M	Male		2.0	PT	Percent		2.0		2.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2006	M	Male		5.0	PT	Percent		4.0		5.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2007	M	Male		8.0	PT	Percent		7.000000000000001		9.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2008	M	Male		13.0	PT	Percent		12.0		14.000000000000002	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2009	M	Male		18.0	PT	Percent		17.0		20.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2010	M	Male		27.0	PT	Percent		24.0		29.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2011	M	Male		33.0	PT	Percent		30.0		36.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2012	M	Male		39.0	PT	Percent		35.0		43.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2013	M	Male		53.0	PT	Percent		48.0		59.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2014	M	Male		55.00000000000001	PT	Percent		50.0		60.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2015	M	Male		61.0	PT	Percent		55.00000000000001		67.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2016	M	Male		65.0	PT	Percent		59.0		72.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2017	M	Male		76.0	PT	Percent		69.0		84.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2018	M	Male		70.0	PT	Percent		63.0		77.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2019	M	Male		86.0	PT	Percent		79.0		95.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	False
III.9	I121f0e02	Access to anti-retroviral drug, by sex	S121f0e02	Access to anti-retroviral drug, by sex	716	Zimbabwe	ZWE	29.86909584	-19.00075492	Sub-Saharan Africa	2020	M	Male		92.0	PT	Percent		84.0		100.0	E	Estimated	G	Global	2021	6700				SEX	M	Male	True
